<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8790">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805389</url>
  </required_header>
  <id_info>
    <org_study_id>112115</org_study_id>
    <nct_id>NCT00805389</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine</brief_title>
  <official_title>Comparison of the Immunogenicity and Safety of Various Investigational and Licensed Formulations of Hepatitis B Surface Antigen (HBsAg) Vaccines.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Belgium: Agence Fédérale des Médicaments et des Produits de la Santé</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Observer-blind study is to compare different Adjuvant Systems with the same,
      well-known antigen (HBsAg) already used in the GSK marketed vaccines against Hepatitis B
      (Engerix-BTM and FendrixTM), in order to better understand the immune response induced by
      each of the Adjuvant System.

      This Protocol Posting has been updated following Protocol amendment 6, October 2009. The
      section impacted is Eligibility Criteria
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells .</measure>
    <time_frame>At Days 0, 14, 30, 44 and 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD40L), Interleukin (IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs). Results for the Day 44 time point are the primary results among the outcome measure results presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells.</measure>
    <time_frame>At Days 0, 14, 30, 44, and 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD40L), Interleukin (IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells .</measure>
    <time_frame>At Days 0, 180 and 360</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells.</measure>
    <time_frame>At Days 0, 180 and 360</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells.</measure>
    <time_frame>At Days 0, 360 and 374</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells</measure>
    <time_frame>At Days 0, 360 and 374</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells</measure>
    <time_frame>At Days 0, 14, 30, 33, 37, 44 and 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), and Tumor Necrosis Factor-alpha (TNF-a) was measured by Intracellular Cytokine Staining (ICS), using whole blood. This analysis was performed solely on eligible subjects enrolled at the Centre for Vaccinology (CEVAC) in Ghent, Belgium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells</measure>
    <time_frame>At Days 0, 14, 30, 44, 60 and 180</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), and Tumor Necrosis Factor-alpha (TNF-a) was measured by Intracellular Cytokine Staining (ICS), using whole blood. This analysis was performed solely on eligible subjects enrolled at the Centre for Vaccinology (CEVAC) in Ghent, Belgium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile</measure>
    <time_frame>At Days 0, 14, 30, 44 and 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-specific CD4+ T cells (per million cells) expressing Th1 and/or Th2 cytokine profile was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile</measure>
    <time_frame>At Days 0 and 180</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-specific CD4+ T cells (per million cells) expressing Th1 and/or Th2 cytokine profile was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile</measure>
    <time_frame>At Days 0, 14, 30, 44, 60, 180</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-specific CD8+ T cells (per million cells) expressing Th1 and/or Th2 cytokine profile was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs). Since T helper cells are all CD4 T cell, no Th1/ Th2 cytokine profile was performed for CD8 T cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)</measure>
    <time_frame>At Days 0, 30, 44, and 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-HBs antibody concentrations in serum were measured by CLIA Assay. Concentrations were presented as geometric mean concentrations, in milli-International Units per milliliter (mIU/mL). Analysis was initially planned to be performed by Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSB Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated CLIA assay. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)</measure>
    <time_frame>At Days 0, 180 and 360</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-HBs antibody concentrations in serum were measured by CLIA Assay. Concentrations were presented as geometric mean concentrations, in milli-International Units per milliliter (mIU/mL). Analysis was initially planned to be performed by Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSB Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated CLIA assay. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)</measure>
    <time_frame>At Days 0, 374 and 390</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-HBs antibody concentrations in serum were measured by CLIA Assay. Concentrations were presented as geometric mean concentrations, in milli-International Units per milliliter (mIU/mL). Analysis was initially planned to be performed by Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSB Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated CLIA assay. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Memory B Cells</measure>
    <time_frame>At Days 0, 30, 37, 44 and 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-specific memory B-cells (HB mem-B cells), per million cells - expressed through tabulation of interquartile range data - was measured by B-cell Enzyme-Linked Immunosorbent Spot (ELISPOT) using Peripheral Blood Mononuclear Cells (PBMCs). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hepatitis B (HB)-Specific Memory B Cells</measure>
    <time_frame>At Days 180 and 360</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of HB-specific memory B-cells (HB mem-B cells), per million cells - expressed through tabulation of interquartile range data - was measured by B-cell Enzyme-Linked Immunosorbent Spot (ELISPOT) using Peripheral Blood Mononuclear Cells (PBMCs). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of the Interferon-gamma (IFN-g), Interleukin (IL)-1beta, IL-5, IL-6, IL-10, Tumor Necrosis Factor-alpha, IFN-g-inducible Protein-10 and Monocyte Chemotactic Protein-1 Cytokines in Serum</measure>
    <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30,30+ (Day 30 + 3 to 6 hours), 31, 33 and 37.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations of IFN-g, IL-1 beta (IL-1B), IL-5, IL-6, IL-10, Tumor Necrosis Factor-alpha (TNF-a), IFN-g-inducible protein-10 (IP-10) and monocyte chemotactic protein (MCP)-1 Concentrations of the IFN-g, IL-1B, IL-5, IL-6, IL-10, TNF-a, IP-10 and MCP-1 cytokines in serum were measured by Cytokine bead assay (CBA) and expressed in picograms per milliliter (pg/mL). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Levels of White Blood Cells (WBC) and Creatine Phosphokinases (CPK)</measure>
    <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30, 30+ (Day 30 + 3 to 6 hours), 31, 33, 37 and 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of levels of CPK and WBC was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result - lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Levels of C-reactive Protein (CRP)</measure>
    <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30, 30+ (Day 30 + 3 to 6 hours), 31, 33 and 37.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of levels of CRP was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result - lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Levels of White Blood Cells (WBC) and of Creatine Phosphokinases (CPK)</measure>
    <time_frame>At Days 0, 30, 37 and 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of levels of CPK and WBC was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result - lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Levels of C-reactive Protein (CRP)</measure>
    <time_frame>At Days 0, 30 and 37.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of levels of CRP was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result - lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils</measure>
    <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30, 30+ (Day 30 + 3 to 6 hours), 31, 33, 37 and 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Levels of white blood cells (WBC) as absolute counts, neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS) and basophils (BAS) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. This outcome measure presents the raw data collected in percent (%), expressed in IH Center normalized levels based on raw data in % (IH normalized %), and concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils</measure>
    <time_frame>At Days 0, 30, 37 and 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Levels of white blood cells (WBC) as absolute counts, neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS) and basophils (BAS) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. This outcome measure presents the raw data collected in percent (%), expressed in IH Center normalized levels based on raw data in % (IH normalized %), and concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Levels of Red Blood Cells and Platelets</measure>
    <time_frame>At Days 0, 30, 37 and 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of levels of red blood cells (RBC) and platelets (PLA) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result - lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure presents the raw data collected in absolute count, expressed in IH Center normalized levels based on absolute count data (IH normalized abs. count).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Levels of Haemoglobin, Alanine Aminotransferase and Aspartate Aminotransferase</measure>
    <time_frame>At Days 0, 30, 37 and 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of levels of haemoglobin (Hgb), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result - lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure presents the raw data collected in absolute count, expressed in IH Center normalized levels based on absolute count data (IH normalized abs. count).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Levels of Serum Creatinine, Urea and Lactate Dehydrogenase</measure>
    <time_frame>At Days 0, 30, 37 and 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of levels of serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result - lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure presents the raw data collected in absolute count, expressed in IH Center normalized levels based on absolute count data (IH normalized abs. count).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</measure>
    <time_frame>At Day 0 and up to Day 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 0 baseline versus their status post vaccination (Day 60). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</measure>
    <time_frame>At Day 0 and up to Day 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 0 baseline versus their status post vaccination (Day 60). This outcome measure concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</measure>
    <time_frame>Post vaccination (up to Day 360)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 0 baseline versus their status post vaccination (Day 180 or 360). Day 180 or 360 results were chosen based on assessment of grading of the abnormality observed, with results for higher grading being tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</measure>
    <time_frame>At Days 360 and 390.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 360 baseline versus their status post vaccination (Day 390). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase</measure>
    <time_frame>At Day 0 and up to Day 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of red blood cells (RBC), platelets (PLA), haemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) at the Day 0 baseline versus their status post vaccination (Day 60).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase</measure>
    <time_frame>post vaccination (up to Day 360).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of red blood cells (RBC), platelets (PLA), haemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) at the Day 0 baseline versus their status post vaccination (Day 180 or 360). Day 180 or 360 results were chosen based on assessment of grading of the abnormality observed, with results for higher grading being tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase</measure>
    <time_frame>At Days 360 and 390.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of red blood cells (RBC), platelets (PLA), haemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) at the Day 360 baseline versus their status post vaccination (Day 390). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms Following Primary Vaccination.</measure>
    <time_frame>Within the 14-day (Days 0-13) follow up period following primary vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccines.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed were pain, redness and swelling. All solicited local symptoms were considered as related to study vaccination. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling above (&gt;) 50 millimeters (mm). Occurrence of a solicited local symptoms collected post-vaccination was a priori considered as related to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms Following Primary Vaccination.</measure>
    <time_frame>Within the 14-day (Days 0-13) follow up period following primary vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed were Fatigue, Fever - oral temperature equal to or above (&gt;=) 37.5 degrees Celsius (°C) -, Gastrointestinal symptoms (Gastr.), Headache, Malaise and Myalgia. Any = occurrence of a general symptom regardless of its intensity grade or relationship to vaccination. Related = occurrence of a general symptom assessed by the investigator to be causally related to vaccination. Grade 3 fever = oral temperature above (&gt;) 39.0 °C. Grade 3 for Gastr., Headache, Malaise and Myalgia = occurrence of the specified solicited general symptom which prevented normal activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms Following Booster Vaccination.</measure>
    <time_frame>Within the 7-day (Days 0-6) follow up period following booster vaccination with HBsAg antigens</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed were pain, redness and swelling. All solicited local symptoms were considered as related to study vaccination. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling above (&gt;) 50 millimeters (mm). Occurrence of a solicited local symptoms collected post-vaccination was a priori considered as related to vaccination. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms Following Booster Vaccination.</measure>
    <time_frame>Within the 7-day (Days 0-6) follow up period following booster vaccination with HBsAg antigens</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed were Fatigue, Fever - oral temperature equal to or above (&gt;=) 37.5 degrees Celsius (°C) -, Gastrointestinal symptoms (Gastr.), Headache, Malaise and Myalgia. Any = occurrence of a general symptom regardless of its intensity grade or relationship to vaccination. Related = occurrence of a general symptom assessed by the investigator to be causally related to vaccination. Grade 3 fever = oral temperature above (&gt;) 39.0 °C. Grade 3 for Gastr., Headache, Malaise and Myalgia = occurrence of the specified solicited general symptom which prevented normal activity. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and/or Related Unsolicited Adverse Events (AEs) Following Primary Vaccination</measure>
    <time_frame>Within the 31-day (Days 0-30) follow up period following primary vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination. Grade 3 = occurrence of an AE that prevented normal activity. Related = occurrence of an AE assessed by the investigators as causally related to the study vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and/or Related Unsolicited Adverse Events (AEs) Following Booster Vaccination</measure>
    <time_frame>Within the 31-day (Days 0-30) follow up period following booster vaccination with HBsAg antigens</time_frame>
    <safety_issue>No</safety_issue>
    <description>An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination. Grade 3 = occurrence of an AE that prevented normal activity. Related = occurrence of an AE assessed by the investigators as causally related to the study vaccine. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Adverse Events of Specific Interest (AESIs)</measure>
    <time_frame>During the entire study period, from Day 0 to study end, at Day 360 for subjects not in Subsets 1 &amp; 2 and at Day 390 for subjects in Subsets 1 &amp; 2.</time_frame>
    <safety_issue>No</safety_issue>
    <description>AESIs included Autoimmune Disease (AID), neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, and other autoimmune/inflammatory events. Any AESI(s) = occurrence of any AESI(s) in a subject regardless of assessment of relationship to study vaccination. Related AESI(s) = Occurrence of AESI(s) in a subject assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Serious Adverse Events (SAEs) and SAEs Related to Study Vaccination</measure>
    <time_frame>During the entire study period, from Day 0 to study end, at Day 360 for subjects not in Subsets 1 &amp; 2 and at Day 390 for subjects in Subsets 1 &amp; 2.</time_frame>
    <safety_issue>No</safety_issue>
    <description>A SAE was defined as a medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any SAE(s) = occurrence of SAE(s) in a subject regardless of assessment of relationship to study vaccination. Related SAE(s) = occurrence of occurrence of SAE(s) in a subject assessed by the investigators as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene Expression Signature Related to the Immune Response to the GSK223192A, Fendrix™ and Engerix-B™ Vaccines.</measure>
    <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30, 30+ (Day 30 + 3 to 6 hours), 31, 33 and 37.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gene expression signature related to the immune response to the GSK223192A, Fendrix™ and Engerix-B™ vaccines will be measured by microarray/Polymerase Chain Reaction (PCR) array/quantitative PCR, using whole blood. This outcome will be assessed in the first 140 subjects in Subsets 1 and 2 recruited at the Immune Health (IH) Centre in La Louvière, Belgium. Results for this outcome measure will be posted when available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</measure>
    <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Tumor Necrosis Factor (TNF), Tumor Necrosis Factor Receptor Superfamily (TNFRSF9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</measure>
    <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Fas associated factor 1 (FAF1), Signal Transducer And Activator Of Transcription 1(STAT1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</measure>
    <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Interferon Regulatory Factor 1 (IRF1), MX Dynamin-Like GTPase 1(MX1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</measure>
    <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Interleukin-12A (IL-12A), Marker Of Proliferation Ki-67 (MKI67).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</measure>
    <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Chemokine Ligand 10 (CXCL10), Interleukin-1B (IL-1B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</measure>
    <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Prostaglandin-Endoperoxide Synthase 2 (PTGS2), Dual Specificity Phosphatase 1 (DUSP1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</measure>
    <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Nuclear Factor Of Activated T-Cells, Cytoplasmic, Calcineurin-Dependent 2 (NFATC2) and Interferon-gamma (IFN-γ).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">713</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>GSK223192A 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK223192A 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK223192A 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fendrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix-B Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B™</intervention_name>
    <description>2 doses intramuscular injections</description>
    <arm_group_label>Engerix-B Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fendrix™</intervention_name>
    <description>2 doses intramuscular injections</description>
    <arm_group_label>Fendrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Hepatitis B vaccines (GSK223192A)</intervention_name>
    <description>2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group</description>
    <arm_group_label>GSK223192A 3 Group</arm_group_label>
    <arm_group_label>GSK223192A 1 Group</arm_group_label>
    <arm_group_label>GSK223192A 2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBsAg (Booster injection)</intervention_name>
    <description>Single dose intramuscular injection</description>
    <arm_group_label>GSK223192A 3 Group</arm_group_label>
    <arm_group_label>GSK223192A 1 Group</arm_group_label>
    <arm_group_label>GSK223192A 2 Group</arm_group_label>
    <arm_group_label>Fendrix Group</arm_group_label>
    <arm_group_label>Engerix-B Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must satisfy the following criteria at study entry :

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol.

          -  A male or female between, and including, 18 and 45 years at the time of the first
             vaccination.

          -  Written informed consent obtained from the subject.

          -  Healthy subjects as established by medical history, clinical examination and clinical
             laboratory assessment before entering into the study.

          -  If the subject is female, she must be of non-childbearing potential, or if she is of
             childbearing potential, she must practice adequate contraception for 30 days prior to
             vaccination, have a negative pregnancy test and continue such precautions for 2
             months after completion of the vaccination series.

        Exclusion criteria:

        The following criteria should be checked at the time of study entry. If any apply, the
        subject must not be included in the study:

          -  Previous vaccination against Hepatitis B.

          -  Positive for anti-HBs antibodies, antiHBc antibodies, HBsAg, HCV antibodies and/or
             HIV.

          -  Any previous administration of specific adjuvant components.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period or participation to another pharmaceutical/vaccine study.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Planned administration/ administration of a vaccine not foreseen by the study
             protocol within 30 days of the first dose of vaccine with the exception of the
             influenza vaccine (pandemic or seasonal) which can be administered &gt; 21 days
             preceding or &gt; 21 days following each primary vaccine dose (Doses 1 and 2) AND &gt; 7
             days preceding or &gt; 7 days following the booster dose.

          -  Administration of immunoglobulins and/or any blood products within the last 3 months.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s).

          -  Current serious neurologic or mental disease.

          -  Any past or current malignancies and lymphoproliferative disorders.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal
             functional abnormality, autoimmune disease or anemia, as determined by physical
             examination or laboratory screening tests at the discretion of the investigator.

          -  Acute disease at the time of enrolment.

          -  Pregnant or lactating female.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Other conditions that the principal investigator judges may interfere with study
             findings.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haag</city>
        <state>Bayern</state>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 29, 2016</lastchanged_date>
  <firstreceived_date>December 5, 2008</firstreceived_date>
  <firstreceived_results_date>December 19, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvant Systems</keyword>
  <keyword>Hepatitis B</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Approximately 75 subjects in each group, approximately 23 and 52 subjects/group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I and II subtypes [Subset 1 and 2, respectively], received a booster dose of HBsAg at Day 360.</recruitment_details>
      <pre_assignment_details>Study duration was of 390 days for subjects in Subsets 1 and 2 (subjects identified with a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) vaccinated with an additional dose of Hepatitis B surface antigens (HBsAg)) and of 360 days for subjects not receiving this dose of HBsAg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK223192A 1 Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>GSK223192A 2 Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>GSK223192A 3 Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>Fendrix Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="P5">
          <title>Engerix-B Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="141"/>
                <participants group_id="P4" count="145"/>
                <participants group_id="P5" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="129"/>
                <participants group_id="P4" count="128"/>
                <participants group_id="P5" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK223192A 1 Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>GSK223192A 2 Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>GSK223192A 3 Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Fendrix Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Engerix-B Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="143"/>
                <measurement group_id="B2" value="142"/>
                <measurement group_id="B3" value="141"/>
                <measurement group_id="B4" value="145"/>
                <measurement group_id="B5" value="142"/>
                <measurement group_id="B6" value="713"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34.7" spread="6.94"/>
                <measurement group_id="B2" value="33.7" spread="7.28"/>
                <measurement group_id="B3" value="32.9" spread="7.58"/>
                <measurement group_id="B4" value="33.5" spread="7.41"/>
                <measurement group_id="B5" value="32.9" spread="7.50"/>
                <measurement group_id="B6" value="33.5" spread="7.34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="66"/>
                <measurement group_id="B2" value="66"/>
                <measurement group_id="B3" value="64"/>
                <measurement group_id="B4" value="66"/>
                <measurement group_id="B5" value="65"/>
                <measurement group_id="B6" value="327"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="77"/>
                <measurement group_id="B2" value="76"/>
                <measurement group_id="B3" value="77"/>
                <measurement group_id="B4" value="79"/>
                <measurement group_id="B5" value="77"/>
                <measurement group_id="B6" value="386"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells .</title>
        <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD40L), Interleukin (IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs). Results for the Day 44 time point are the primary results among the outcome measure results presented.</description>
        <time_frame>At Days 0, 14, 30, 44 and 60</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analyses were performed on the According-to-Protocol cohort for adaptive immunogenicity up to Day 60, which included all evaluable subjects who complied with the vaccination schedule and for whom T cell, antibody and memory B cell response data were available for at least one amongst the Day 0, 14, 30, 44, or 60 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="112"/>
                  <measurement group_id="O3" value="109"/>
                  <measurement group_id="O4" value="112"/>
                  <measurement group_id="O5" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells .</title>
            <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD40L), Interleukin (IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs). Results for the Day 44 time point are the primary results among the outcome measure results presented.</description>
            <units>HB-CD4+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD4+, at Day 0 (N=111,110,107,109,106)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="228" lower_limit="163" upper_limit="332"/>
                  <measurement group_id="O2" value="230" lower_limit="166" upper_limit="326"/>
                  <measurement group_id="O3" value="234" lower_limit="171" upper_limit="312"/>
                  <measurement group_id="O4" value="234" lower_limit="172" upper_limit="362"/>
                  <measurement group_id="O5" value="235" lower_limit="176" upper_limit="353"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 14 (N=114,110,106,112,107)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="408" lower_limit="225" upper_limit="656"/>
                  <measurement group_id="O2" value="447" lower_limit="248" upper_limit="752"/>
                  <measurement group_id="O3" value="460" lower_limit="309" upper_limit="819"/>
                  <measurement group_id="O4" value="289" lower_limit="208" upper_limit="434"/>
                  <measurement group_id="O5" value="245" lower_limit="173" upper_limit="412"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 30 (N=108,107,109,109,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="277" lower_limit="190" upper_limit="430"/>
                  <measurement group_id="O2" value="333" lower_limit="233" upper_limit="482"/>
                  <measurement group_id="O3" value="314" lower_limit="249" upper_limit="496"/>
                  <measurement group_id="O4" value="255" lower_limit="189" upper_limit="362"/>
                  <measurement group_id="O5" value="249" lower_limit="178" upper_limit="376"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 44 (N=112,109,103,108,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1345" lower_limit="626" upper_limit="3100"/>
                  <measurement group_id="O2" value="1257" lower_limit="540" upper_limit="2168"/>
                  <measurement group_id="O3" value="647" lower_limit="436" upper_limit="1284"/>
                  <measurement group_id="O4" value="391" lower_limit="242" upper_limit="557"/>
                  <measurement group_id="O5" value="299" lower_limit="202" upper_limit="486"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 60 (N=108,112,108,112,104)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="965" lower_limit="560" upper_limit="1925"/>
                  <measurement group_id="O2" value="958" lower_limit="450" upper_limit="1777"/>
                  <measurement group_id="O3" value="587" lower_limit="360" upper_limit="1031"/>
                  <measurement group_id="O4" value="393" lower_limit="250" upper_limit="582"/>
                  <measurement group_id="O5" value="308" lower_limit="201" upper_limit="555"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells.</title>
        <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD40L), Interleukin (IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
        <time_frame>At Days 0, 14, 30, 44, and 60</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for adaptive immunogenicity to Day 60, which included all evaluable subjects for whom T cell, antibody and memory B cell response data were available for at least one amongst the Day 0, 14, 30, 44, or 60 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="112"/>
                  <measurement group_id="O3" value="107"/>
                  <measurement group_id="O4" value="109"/>
                  <measurement group_id="O5" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells.</title>
            <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD40L), Interleukin (IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
            <units>HB-CD8+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD8+, at Day 0 (N=107,108,105,104,104)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="176" lower_limit="107" upper_limit="286"/>
                  <measurement group_id="O2" value="174" lower_limit="112" upper_limit="312"/>
                  <measurement group_id="O3" value="172" lower_limit="123" upper_limit="236"/>
                  <measurement group_id="O4" value="201" lower_limit="109" upper_limit="300"/>
                  <measurement group_id="O5" value="184" lower_limit="108" upper_limit="236"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD8+, at Day 14 (N=112,110,104,108,105)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="174" lower_limit="121" upper_limit="290"/>
                  <measurement group_id="O2" value="160" lower_limit="106" upper_limit="273"/>
                  <measurement group_id="O3" value="174" lower_limit="121" upper_limit="234"/>
                  <measurement group_id="O4" value="193" lower_limit="129" upper_limit="296"/>
                  <measurement group_id="O5" value="177" lower_limit="129" upper_limit="274"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD8+, at Day 30 (N=105,103,107,107,100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="185" lower_limit="109" upper_limit="276"/>
                  <measurement group_id="O2" value="173" lower_limit="118" upper_limit="255"/>
                  <measurement group_id="O3" value="160" lower_limit="113" upper_limit="248"/>
                  <measurement group_id="O4" value="191" lower_limit="132" upper_limit="254"/>
                  <measurement group_id="O5" value="173" lower_limit="133" upper_limit="259"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD8+, at Day 44 (N=107,106,102,105,98)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="212" lower_limit="129" upper_limit="300"/>
                  <measurement group_id="O2" value="213" lower_limit="148" upper_limit="338"/>
                  <measurement group_id="O3" value="177" lower_limit="116" upper_limit="272"/>
                  <measurement group_id="O4" value="157" lower_limit="106" upper_limit="274"/>
                  <measurement group_id="O5" value="169" lower_limit="118" upper_limit="246"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD8+, at Day 60 (N=108,112,107,109,104)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="209" lower_limit="129" upper_limit="308"/>
                  <measurement group_id="O2" value="228" lower_limit="144" upper_limit="339"/>
                  <measurement group_id="O3" value="171" lower_limit="123" upper_limit="281"/>
                  <measurement group_id="O4" value="184" lower_limit="115" upper_limit="298"/>
                  <measurement group_id="O5" value="166" lower_limit="124" upper_limit="266"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells .</title>
        <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
        <time_frame>At Days 0, 180 and 360</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for persistence which included all subjects from the ATP cohort for adaptive immunogenicity up to Day 60 for whom adaptive immunogenicity data were available for at least one post-vaccination time point (Day 180 or Day 360).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                  <measurement group_id="O2" value="107"/>
                  <measurement group_id="O3" value="101"/>
                  <measurement group_id="O4" value="106"/>
                  <measurement group_id="O5" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells .</title>
            <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
            <units>HB-CD4+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD4+, at Day 0 (N=106,102,98,99,97)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="230" lower_limit="163" upper_limit="333"/>
                  <measurement group_id="O2" value="231" lower_limit="166" upper_limit="331"/>
                  <measurement group_id="O3" value="248" lower_limit="179" upper_limit="313"/>
                  <measurement group_id="O4" value="223" lower_limit="171" upper_limit="348"/>
                  <measurement group_id="O5" value="240" lower_limit="172" upper_limit="347"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 180 (N=104,107,97,106,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1090" lower_limit="573" upper_limit="1827"/>
                  <measurement group_id="O2" value="954" lower_limit="508" upper_limit="1504"/>
                  <measurement group_id="O3" value="546" lower_limit="382" upper_limit="911"/>
                  <measurement group_id="O4" value="360" lower_limit="259" upper_limit="666"/>
                  <measurement group_id="O5" value="334" lower_limit="256" upper_limit="493"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 360 (N=108,105,101,100,95)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="960" lower_limit="564" upper_limit="1566"/>
                  <measurement group_id="O2" value="829" lower_limit="388" upper_limit="1509"/>
                  <measurement group_id="O3" value="564" lower_limit="340" upper_limit="887"/>
                  <measurement group_id="O4" value="388" lower_limit="217" upper_limit="627"/>
                  <measurement group_id="O5" value="350" lower_limit="246" upper_limit="499"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells.</title>
        <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
        <time_frame>At Days 0, 180 and 360</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for persistence which included all subjects from the ATP cohort for adaptive immunogenicity up to Day 60 for whom adaptive immunogenicity data were available for at least one post-vaccination time point (Day 180 or Day 360).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                  <measurement group_id="O2" value="107"/>
                  <measurement group_id="O3" value="99"/>
                  <measurement group_id="O4" value="105"/>
                  <measurement group_id="O5" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells.</title>
            <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
            <units>HB-CD8+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD8+, at Day 0 (N=102,100,96,96,95)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="175" lower_limit="107" upper_limit="284"/>
                  <measurement group_id="O2" value="169" lower_limit="110" upper_limit="312"/>
                  <measurement group_id="O3" value="176" lower_limit="125" upper_limit="261"/>
                  <measurement group_id="O4" value="191" lower_limit="107" upper_limit="286"/>
                  <measurement group_id="O5" value="184" lower_limit="107" upper_limit="237"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD8+, at Day 180 (N=104,107,96,105,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="120" lower_limit="81" upper_limit="170"/>
                  <measurement group_id="O2" value="124" lower_limit="81" upper_limit="187"/>
                  <measurement group_id="O3" value="92" lower_limit="57" upper_limit="133"/>
                  <measurement group_id="O4" value="102" lower_limit="57" upper_limit="153"/>
                  <measurement group_id="O5" value="110" lower_limit="64" upper_limit="171"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD8+, at Day 360 (N=108,104,99,98,94)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="114" lower_limit="57" upper_limit="163"/>
                  <measurement group_id="O2" value="115" lower_limit="57" upper_limit="163"/>
                  <measurement group_id="O3" value="112" lower_limit="78" upper_limit="160"/>
                  <measurement group_id="O4" value="104" lower_limit="57" upper_limit="154"/>
                  <measurement group_id="O5" value="90" lower_limit="57" upper_limit="159"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells.</title>
        <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
        <time_frame>At Days 0, 360 and 374</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Booster According-to-Protocol (ATP) cohort for immunogenicity which included all subjects from subsets 1 and 2 who received a booster vaccination at Day 360 for whom adaptive immunogenicity data were available for at least one post-booster time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="52"/>
                  <measurement group_id="O5" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells.</title>
            <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
            <units>HB-CD4+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD4+, at Day 0 (N=54,51,53,52,48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="228" lower_limit="175" upper_limit="346"/>
                  <measurement group_id="O2" value="233" lower_limit="172" upper_limit="307"/>
                  <measurement group_id="O3" value="254" lower_limit="177" upper_limit="347"/>
                  <measurement group_id="O4" value="234" lower_limit="183" upper_limit="293"/>
                  <measurement group_id="O5" value="266" lower_limit="194" upper_limit="362"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 360 (N=54,51,53,52,48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1029" lower_limit="601" upper_limit="1781"/>
                  <measurement group_id="O2" value="770" lower_limit="388" upper_limit="1511"/>
                  <measurement group_id="O3" value="538" lower_limit="301" upper_limit="974"/>
                  <measurement group_id="O4" value="300" lower_limit="199" upper_limit="590"/>
                  <measurement group_id="O5" value="360" lower_limit="273" upper_limit="506"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 374 (N=50,48,49,52,48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1006" lower_limit="725" upper_limit="1907"/>
                  <measurement group_id="O2" value="1037" lower_limit="580" upper_limit="1882"/>
                  <measurement group_id="O3" value="688" lower_limit="456" upper_limit="1129"/>
                  <measurement group_id="O4" value="401" lower_limit="250" upper_limit="750"/>
                  <measurement group_id="O5" value="353" lower_limit="271" upper_limit="599"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells</title>
        <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
        <time_frame>At Days 0, 360 and 374</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Booster According-to-Protocol (ATP) cohort for immunogenicity which included all subjects from subsets 1 and 2 who received a booster vaccination at Day 360 for whom adaptive immunogenicity data were available for at least one post-booster time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="51"/>
                  <measurement group_id="O4" value="52"/>
                  <measurement group_id="O5" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells</title>
            <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), IL-13 and IL-17 was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
            <units>HB-CD8+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD8+, at Day 0 (N=51,45,49,46,42)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="187" lower_limit="111" upper_limit="304"/>
                  <measurement group_id="O2" value="161" lower_limit="100" upper_limit="256"/>
                  <measurement group_id="O3" value="196" lower_limit="138" upper_limit="271"/>
                  <measurement group_id="O4" value="244" lower_limit="120" upper_limit="316"/>
                  <measurement group_id="O5" value="168" lower_limit="125" upper_limit="234"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD8+, at Day 360 (N=54,51,51,50,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="109" lower_limit="57" upper_limit="151"/>
                  <measurement group_id="O2" value="118" lower_limit="57" upper_limit="161"/>
                  <measurement group_id="O3" value="121" lower_limit="77" upper_limit="183"/>
                  <measurement group_id="O4" value="99" lower_limit="57" upper_limit="130"/>
                  <measurement group_id="O5" value="90" lower_limit="57" upper_limit="169"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD8+, at Day 374 (N=50,48,49,52,48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107" lower_limit="57" upper_limit="133"/>
                  <measurement group_id="O2" value="111" lower_limit="57" upper_limit="166"/>
                  <measurement group_id="O3" value="122" lower_limit="57" upper_limit="174"/>
                  <measurement group_id="O4" value="121" lower_limit="75" upper_limit="185"/>
                  <measurement group_id="O5" value="111" lower_limit="85" upper_limit="212"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells</title>
        <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), and Tumor Necrosis Factor-alpha (TNF-a) was measured by Intracellular Cytokine Staining (ICS), using whole blood. This analysis was performed solely on eligible subjects enrolled at the Centre for Vaccinology (CEVAC) in Ghent, Belgium.</description>
        <time_frame>At Days 0, 14, 30, 33, 37, 44 and 60</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for adaptive immunogenicity to Day 60, which included all evaluable subjects for whom T cell, antibody and memory B cell response data were available for at least one amongst the Day 0, 14, 30, 44, or 60 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="15"/>
                  <measurement group_id="O4" value="19"/>
                  <measurement group_id="O5" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells</title>
            <description>The number of HB-CD4+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), and Tumor Necrosis Factor-alpha (TNF-a) was measured by Intracellular Cytokine Staining (ICS), using whole blood. This analysis was performed solely on eligible subjects enrolled at the Centre for Vaccinology (CEVAC) in Ghent, Belgium.</description>
            <units>HB-CD4+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD4+, at Day 0 (N=13,11,13,16,12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68" lower_limit="11" upper_limit="104"/>
                  <measurement group_id="O2" value="98" lower_limit="11" upper_limit="159"/>
                  <measurement group_id="O3" value="25" lower_limit="11" upper_limit="144"/>
                  <measurement group_id="O4" value="48" lower_limit="11" upper_limit="106"/>
                  <measurement group_id="O5" value="31" lower_limit="11" upper_limit="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 14 (N=16,14,10,19,11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="425" lower_limit="199" upper_limit="687"/>
                  <measurement group_id="O2" value="498" lower_limit="184" upper_limit="1204"/>
                  <measurement group_id="O3" value="149" lower_limit="71" upper_limit="503"/>
                  <measurement group_id="O4" value="75" lower_limit="11" upper_limit="125"/>
                  <measurement group_id="O5" value="85" lower_limit="46" upper_limit="139"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 30 (N=15,14,13,17,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="313" lower_limit="161" upper_limit="424"/>
                  <measurement group_id="O2" value="314" lower_limit="170" upper_limit="562"/>
                  <measurement group_id="O3" value="243" lower_limit="87" upper_limit="344"/>
                  <measurement group_id="O4" value="67" lower_limit="20" upper_limit="102"/>
                  <measurement group_id="O5" value="110" lower_limit="47" upper_limit="172"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 33 (N=16,12,13,15,13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="114" lower_limit="80" upper_limit="242"/>
                  <measurement group_id="O2" value="270" lower_limit="160" upper_limit="445"/>
                  <measurement group_id="O3" value="110" lower_limit="54" upper_limit="188"/>
                  <measurement group_id="O4" value="63" lower_limit="14" upper_limit="91"/>
                  <measurement group_id="O5" value="126" lower_limit="37" upper_limit="166"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 37 (N=17,13,14,19,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="844" lower_limit="598" upper_limit="1679"/>
                  <measurement group_id="O2" value="869" lower_limit="473" upper_limit="3559"/>
                  <measurement group_id="O3" value="486" lower_limit="223" upper_limit="1740"/>
                  <measurement group_id="O4" value="67" lower_limit="32" upper_limit="178"/>
                  <measurement group_id="O5" value="174" lower_limit="119" upper_limit="271"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 44 (N=14,13,14,17,12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2021" lower_limit="1187" upper_limit="3686"/>
                  <measurement group_id="O2" value="2890" lower_limit="1232" upper_limit="4337"/>
                  <measurement group_id="O3" value="1253" lower_limit="647" upper_limit="2197"/>
                  <measurement group_id="O4" value="271" lower_limit="95" upper_limit="515"/>
                  <measurement group_id="O5" value="265" lower_limit="127" upper_limit="716"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 60 (N=11,12,15,16,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1291" lower_limit="396" upper_limit="2265"/>
                  <measurement group_id="O2" value="1477" lower_limit="763" upper_limit="3920"/>
                  <measurement group_id="O3" value="768" lower_limit="317" upper_limit="1458"/>
                  <measurement group_id="O4" value="200" lower_limit="110" upper_limit="459"/>
                  <measurement group_id="O5" value="247" lower_limit="107" upper_limit="398"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells</title>
        <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), and Tumor Necrosis Factor-alpha (TNF-a) was measured by Intracellular Cytokine Staining (ICS), using whole blood. This analysis was performed solely on eligible subjects enrolled at the Centre for Vaccinology (CEVAC) in Ghent, Belgium.</description>
        <time_frame>At Days 0, 14, 30, 44, 60 and 180</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for adaptive immunogenicity to Day 60, which included all evaluable subjects for whom T cell, antibody and memory B cell response data were available for at least one amongst the Day 0, 14, 30, 44, or 60 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="15"/>
                  <measurement group_id="O5" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells</title>
            <description>The number of HB-CD8+ T cells (per million cells) producing 2 or more markers amongst Cluster Differentiation 40 Ligand (CD-40L), Interleukin(IL)-2, Interferon-gamma (IFN-g), and Tumor Necrosis Factor-alpha (TNF-a) was measured by Intracellular Cytokine Staining (ICS), using whole blood. This analysis was performed solely on eligible subjects enrolled at the Centre for Vaccinology (CEVAC) in Ghent, Belgium.</description>
            <units>HB-CD8+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD4+, at Day 0 (N=13,10,13,14,11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11" lower_limit="11" upper_limit="11"/>
                  <measurement group_id="O2" value="11" lower_limit="11" upper_limit="64"/>
                  <measurement group_id="O3" value="11" lower_limit="11" upper_limit="11"/>
                  <measurement group_id="O4" value="11" lower_limit="11" upper_limit="40"/>
                  <measurement group_id="O5" value="11" lower_limit="11" upper_limit="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 14 (N=13,10,10,15,11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12" lower_limit="11" upper_limit="91"/>
                  <measurement group_id="O2" value="11" lower_limit="11" upper_limit="123"/>
                  <measurement group_id="O3" value="11" lower_limit="11" upper_limit="67"/>
                  <measurement group_id="O4" value="11" lower_limit="11" upper_limit="121"/>
                  <measurement group_id="O5" value="11" lower_limit="11" upper_limit="205"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 30 (N=14,12,13,15,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64" lower_limit="11" upper_limit="100"/>
                  <measurement group_id="O2" value="11" lower_limit="11" upper_limit="11"/>
                  <measurement group_id="O3" value="11" lower_limit="11" upper_limit="68"/>
                  <measurement group_id="O4" value="11" lower_limit="11" upper_limit="52"/>
                  <measurement group_id="O5" value="11" lower_limit="11" upper_limit="92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 33 (N=16,12,10,12,13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11" lower_limit="11" upper_limit="106"/>
                  <measurement group_id="O2" value="11" lower_limit="11" upper_limit="68"/>
                  <measurement group_id="O3" value="41" lower_limit="11" upper_limit="82"/>
                  <measurement group_id="O4" value="11" lower_limit="11" upper_limit="11"/>
                  <measurement group_id="O5" value="11" lower_limit="11" upper_limit="68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 37 (N=16,13,14,15,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11" lower_limit="11" upper_limit="108"/>
                  <measurement group_id="O2" value="103" lower_limit="11" upper_limit="207"/>
                  <measurement group_id="O3" value="11" lower_limit="11" upper_limit="84"/>
                  <measurement group_id="O4" value="11" lower_limit="11" upper_limit="11"/>
                  <measurement group_id="O5" value="42" lower_limit="11" upper_limit="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 44 (N=13,13,13,14,11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11" lower_limit="11" upper_limit="97"/>
                  <measurement group_id="O2" value="99" lower_limit="11" upper_limit="184"/>
                  <measurement group_id="O3" value="11" lower_limit="11" upper_limit="130"/>
                  <measurement group_id="O4" value="11" lower_limit="11" upper_limit="89"/>
                  <measurement group_id="O5" value="11" lower_limit="11" upper_limit="178"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, at Day 60 (N=11,9,16,13,13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37" lower_limit="11" upper_limit="109"/>
                  <measurement group_id="O2" value="102" lower_limit="11" upper_limit="229"/>
                  <measurement group_id="O3" value="11" lower_limit="11" upper_limit="73"/>
                  <measurement group_id="O4" value="11" lower_limit="11" upper_limit="64"/>
                  <measurement group_id="O5" value="11" lower_limit="11" upper_limit="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile</title>
        <description>The number of HB-specific CD4+ T cells (per million cells) expressing Th1 and/or Th2 cytokine profile was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
        <time_frame>At Days 0, 14, 30, 44 and 60</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for adaptive immunogenicity to Day 60, which included all evaluable subjects for whom T cell, antibody and memory B cell response data were available for at least one amongst the Day 0, 14, 30, 44, or 60 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="112"/>
                  <measurement group_id="O3" value="109"/>
                  <measurement group_id="O4" value="112"/>
                  <measurement group_id="O5" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile</title>
            <description>The number of HB-specific CD4+ T cells (per million cells) expressing Th1 and/or Th2 cytokine profile was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
            <units>HB-CD4+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD4+, Th1, at Day 0 (N=111,110,107,109,106)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65" lower_limit="38" upper_limit="113"/>
                  <measurement group_id="O2" value="62" lower_limit="40" upper_limit="111"/>
                  <measurement group_id="O3" value="53" lower_limit="29" upper_limit="101"/>
                  <measurement group_id="O4" value="70" lower_limit="41" upper_limit="117"/>
                  <measurement group_id="O5" value="67" lower_limit="38" upper_limit="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th1, at Day 14 (N=114,110,106,112,107)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64" lower_limit="40" upper_limit="103"/>
                  <measurement group_id="O2" value="75" lower_limit="44" upper_limit="124"/>
                  <measurement group_id="O3" value="68" lower_limit="40" upper_limit="102"/>
                  <measurement group_id="O4" value="81" lower_limit="48" upper_limit="132"/>
                  <measurement group_id="O5" value="66" lower_limit="38" upper_limit="102"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th1, at Day 30 (N=108,107,109,109,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61" lower_limit="36" upper_limit="91"/>
                  <measurement group_id="O2" value="66" lower_limit="42" upper_limit="109"/>
                  <measurement group_id="O3" value="75" lower_limit="45" upper_limit="120"/>
                  <measurement group_id="O4" value="64" lower_limit="35" upper_limit="113"/>
                  <measurement group_id="O5" value="72" lower_limit="40" upper_limit="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th1, at Day 44 (N=112,109,103,108,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="155" lower_limit="78" upper_limit="382"/>
                  <measurement group_id="O2" value="174" lower_limit="72" upper_limit="354"/>
                  <measurement group_id="O3" value="95" lower_limit="46" upper_limit="184"/>
                  <measurement group_id="O4" value="74" lower_limit="46" upper_limit="140"/>
                  <measurement group_id="O5" value="64" lower_limit="40" upper_limit="115"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th1, at Day 60 (N=108,112,108,112,104)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="119" lower_limit="63" upper_limit="244"/>
                  <measurement group_id="O2" value="141" lower_limit="71" upper_limit="270"/>
                  <measurement group_id="O3" value="90" lower_limit="53" upper_limit="146"/>
                  <measurement group_id="O4" value="94" lower_limit="52" upper_limit="144"/>
                  <measurement group_id="O5" value="61" lower_limit="40" upper_limit="129"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th2, at Day 0 (N=111,110,107,109,106)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50" lower_limit="26" upper_limit="95"/>
                  <measurement group_id="O2" value="63" lower_limit="35" upper_limit="119"/>
                  <measurement group_id="O3" value="55" lower_limit="17" upper_limit="102"/>
                  <measurement group_id="O4" value="53" lower_limit="27" upper_limit="118"/>
                  <measurement group_id="O5" value="52" lower_limit="28" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th2, at Day 14 (N=114,110,106,112,107)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52" lower_limit="28" upper_limit="99"/>
                  <measurement group_id="O2" value="58" lower_limit="29" upper_limit="124"/>
                  <measurement group_id="O3" value="60" lower_limit="28" upper_limit="105"/>
                  <measurement group_id="O4" value="42" lower_limit="21" upper_limit="90"/>
                  <measurement group_id="O5" value="57" lower_limit="28" upper_limit="125"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th2, at Day 30 (N=108,107,109,109,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39" lower_limit="16" upper_limit="91"/>
                  <measurement group_id="O2" value="52" lower_limit="28" upper_limit="96"/>
                  <measurement group_id="O3" value="56" lower_limit="25" upper_limit="100"/>
                  <measurement group_id="O4" value="45" lower_limit="25" upper_limit="95"/>
                  <measurement group_id="O5" value="47" lower_limit="28" upper_limit="92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th2, at Day 44 (N=112,109,103,108,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85" lower_limit="33" upper_limit="133"/>
                  <measurement group_id="O2" value="77" lower_limit="34" upper_limit="158"/>
                  <measurement group_id="O3" value="87" lower_limit="37" upper_limit="155"/>
                  <measurement group_id="O4" value="55" lower_limit="29" upper_limit="109"/>
                  <measurement group_id="O5" value="74" lower_limit="29" upper_limit="141"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th2, at Day 60 (N=108,112,108,112,104)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78" lower_limit="41" upper_limit="125"/>
                  <measurement group_id="O2" value="58" lower_limit="29" upper_limit="127"/>
                  <measurement group_id="O3" value="71" lower_limit="38" upper_limit="127"/>
                  <measurement group_id="O4" value="53" lower_limit="29" upper_limit="123"/>
                  <measurement group_id="O5" value="59" lower_limit="28" upper_limit="153"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile</title>
        <description>The number of HB-specific CD4+ T cells (per million cells) expressing Th1 and/or Th2 cytokine profile was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
        <time_frame>At Days 0 and 180</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for persistence which included all subjects from the ATP cohort for adaptive immunogenicity up to Day 60 for whom adaptive immunogenicity data were available for at least one post-vaccination time point (Day 180 or Day 360).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="107"/>
                  <measurement group_id="O3" value="97"/>
                  <measurement group_id="O4" value="106"/>
                  <measurement group_id="O5" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile</title>
            <description>The number of HB-specific CD4+ T cells (per million cells) expressing Th1 and/or Th2 cytokine profile was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs).</description>
            <units>HB-CD4+ T cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-CD4+, Th1, at Day 0 (N=106,102,98,99,97)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66" lower_limit="40" upper_limit="106"/>
                  <measurement group_id="O2" value="63" lower_limit="44" upper_limit="123"/>
                  <measurement group_id="O3" value="53" lower_limit="29" upper_limit="101"/>
                  <measurement group_id="O4" value="65" lower_limit="41" upper_limit="114"/>
                  <measurement group_id="O5" value="64" lower_limit="38" upper_limit="117"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th1, at Day 180 (N=104,107,97,106,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129" lower_limit="71" upper_limit="215"/>
                  <measurement group_id="O2" value="137" lower_limit="73" upper_limit="244"/>
                  <measurement group_id="O3" value="76" lower_limit="49" upper_limit="129"/>
                  <measurement group_id="O4" value="68" lower_limit="40" upper_limit="122"/>
                  <measurement group_id="O5" value="70" lower_limit="40" upper_limit="108"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th2, at Day 0 (N=106,102,98,99,97)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51" lower_limit="27" upper_limit="95"/>
                  <measurement group_id="O2" value="64" lower_limit="35" upper_limit="119"/>
                  <measurement group_id="O3" value="57" lower_limit="25" upper_limit="105"/>
                  <measurement group_id="O4" value="50" lower_limit="27" upper_limit="102"/>
                  <measurement group_id="O5" value="48" lower_limit="28" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-CD4+, Th2, at Day 180 (N=104,107,97,106,101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54" lower_limit="20" upper_limit="106"/>
                  <measurement group_id="O2" value="63" lower_limit="28" upper_limit="106"/>
                  <measurement group_id="O3" value="46" lower_limit="20" upper_limit="85"/>
                  <measurement group_id="O4" value="54" lower_limit="31" upper_limit="101"/>
                  <measurement group_id="O5" value="49" lower_limit="16" upper_limit="96"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile</title>
        <description>The number of HB-specific CD8+ T cells (per million cells) expressing Th1 and/or Th2 cytokine profile was measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs). Since T helper cells are all CD4 T cell, no Th1/ Th2 cytokine profile was performed for CD8 T cells.</description>
        <time_frame>At Days 0, 14, 30, 44, 60, 180</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2050</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)</title>
        <description>Anti-HBs antibody concentrations in serum were measured by CLIA Assay. Concentrations were presented as geometric mean concentrations, in milli-International Units per milliliter (mIU/mL). Analysis was initially planned to be performed by Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSB Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated CLIA assay. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 0, 30, 44, and 60</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for adaptive immunogenicity to Day 60, which included all evaluable subjects for whom T cell, antibody and memory B cell response data were available for at least one amongst the Day 0, 14, 30, 44, or 60 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="58"/>
                  <measurement group_id="O4" value="62"/>
                  <measurement group_id="O5" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)</title>
            <description>Anti-HBs antibody concentrations in serum were measured by CLIA Assay. Concentrations were presented as geometric mean concentrations, in milli-International Units per milliliter (mIU/mL). Analysis was initially planned to be performed by Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSB Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated CLIA assay. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>mIU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti HBs, Day 0 (N=59;57;58;62;57)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.1" lower_limit="3.1" upper_limit="3.2"/>
                  <measurement group_id="O2" value="NA">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O3" value="3.3" lower_limit="3.1" upper_limit="3.6"/>
                  <measurement group_id="O4" value="NA">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O5" value="NA">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti HBs, Day 30 (N=59;57;58;60;55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108.0" lower_limit="65.0" upper_limit="179.6"/>
                  <measurement group_id="O2" value="59.6" lower_limit="31.9" upper_limit="111.5"/>
                  <measurement group_id="O3" value="66.3" lower_limit="35.7" upper_limit="123.0"/>
                  <measurement group_id="O4" value="6.1" lower_limit="4.2" upper_limit="9.1"/>
                  <measurement group_id="O5" value="3.5" lower_limit="2.9" upper_limit="4.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti HBs, Day 44 (N=59;56;57;60;53)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11986.2" lower_limit="8676.4" upper_limit="16558.7"/>
                  <measurement group_id="O2" value="7942.6" lower_limit="5288.7" upper_limit="11928.2"/>
                  <measurement group_id="O3" value="5525.4" lower_limit="3639.3" upper_limit="8389.2"/>
                  <measurement group_id="O4" value="220.2" lower_limit="126.5" upper_limit="383.3"/>
                  <measurement group_id="O5" value="19.2" lower_limit="11.1" upper_limit="33.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti HBs, Day 60 (N=59;57;58;59;55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7454.3" lower_limit="5603.6" upper_limit="9916.2"/>
                  <measurement group_id="O2" value="5030.9" lower_limit="3396.4" upper_limit="7452.1"/>
                  <measurement group_id="O3" value="4194.3" lower_limit="2805.4" upper_limit="6270.8"/>
                  <measurement group_id="O4" value="251.9" lower_limit="150.6" upper_limit="421.5"/>
                  <measurement group_id="O5" value="21.5" lower_limit="12.7" upper_limit="36.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)</title>
        <description>Anti-HBs antibody concentrations in serum were measured by CLIA Assay. Concentrations were presented as geometric mean concentrations, in milli-International Units per milliliter (mIU/mL). Analysis was initially planned to be performed by Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSB Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated CLIA assay. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 0, 180 and 360</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for persistence which included all subjects from the ATP cohort for adaptive immunogenicity up to Day 60 for whom adaptive immunogenicity data were available for at least one post-vaccination time point (Day 180 or Day 360).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="54"/>
                  <measurement group_id="O3" value="55"/>
                  <measurement group_id="O4" value="56"/>
                  <measurement group_id="O5" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)</title>
            <description>Anti-HBs antibody concentrations in serum were measured by CLIA Assay. Concentrations were presented as geometric mean concentrations, in milli-International Units per milliliter (mIU/mL). Analysis was initially planned to be performed by Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSB Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated CLIA assay. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>mIU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti HBs, Day 0 (N=58;54;55;56;54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA" upper_limit="3.2">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O2" value="NA">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O3" value="3.3" upper_limit="3.6">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O4" value="NA">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O5" value="NA">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti HBs, Day 180 (N=57;54;55;55;53)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3840.7" lower_limit="2953.4" upper_limit="4994.6"/>
                  <measurement group_id="O2" value="2657.5" lower_limit="1972.1" upper_limit="3581.0"/>
                  <measurement group_id="O3" value="3330.2" lower_limit="2502.2" upper_limit="4432.1"/>
                  <measurement group_id="O4" value="254.5" lower_limit="169.9" upper_limit="381.2"/>
                  <measurement group_id="O5" value="39.0" lower_limit="23.3" upper_limit="65.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti HBs, Day 360 (N=58;53;54;54;51)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2150.7" lower_limit="1602.7" upper_limit="2885.9"/>
                  <measurement group_id="O2" value="1650.6" lower_limit="1159.7" upper_limit="2349.4"/>
                  <measurement group_id="O3" value="2122.5" lower_limit="1542.3" upper_limit="2921.1"/>
                  <measurement group_id="O4" value="94.5" lower_limit="59.6" upper_limit="149.8"/>
                  <measurement group_id="O5" value="19.8" lower_limit="12.5" upper_limit="31.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)</title>
        <description>Anti-HBs antibody concentrations in serum were measured by CLIA Assay. Concentrations were presented as geometric mean concentrations, in milli-International Units per milliliter (mIU/mL). Analysis was initially planned to be performed by Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSB Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated CLIA assay. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 0, 374 and 390</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Booster According-to-Protocol (ATP) cohort for immunogenicity which included all subjects from subsets 1 and 2 who received a booster vaccination at Day 360 for whom adaptive immunogenicity data were available for at least one post-booster time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="52"/>
                  <measurement group_id="O3" value="54"/>
                  <measurement group_id="O4" value="54"/>
                  <measurement group_id="O5" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)</title>
            <description>Anti-HBs antibody concentrations in serum were measured by CLIA Assay. Concentrations were presented as geometric mean concentrations, in milli-International Units per milliliter (mIU/mL). Analysis was initially planned to be performed by Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSB Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated CLIA assay. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>mIU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti HBs, Day 0 (N=55;52;54;54;50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA" upper_limit="3.2">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O2" value="NA">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O3" value="3.3" upper_limit="3.6">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O4" value="NA">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                  <measurement group_id="O5" value="NA">Concentration value was not computed as falling below the cut-off value for the assay.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti HBs, Day 374 (N=52;50;53;54;50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51509.0" lower_limit="35731.5" upper_limit="74253.1"/>
                  <measurement group_id="O2" value="31985.9" lower_limit="22628.6" upper_limit="45212.7"/>
                  <measurement group_id="O3" value="27135.3" lower_limit="19376.8" upper_limit="38000.5"/>
                  <measurement group_id="O4" value="3788.4" lower_limit="2047.8" upper_limit="7008.6"/>
                  <measurement group_id="O5" value="341.3" lower_limit="143.7" upper_limit="810.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti HBs, Day 390 (N=52;48;53;51;50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43674.6" lower_limit="29975.7" upper_limit="63633.8"/>
                  <measurement group_id="O2" value="27035.7" lower_limit="18737.0" upper_limit="39009.7"/>
                  <measurement group_id="O3" value="25105.7" lower_limit="17730.1" upper_limit="35549.4"/>
                  <measurement group_id="O4" value="3352.2" lower_limit="1756.0" upper_limit="6399.1"/>
                  <measurement group_id="O5" value="351.1" lower_limit="147.0" upper_limit="838.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Memory B Cells</title>
        <description>The number of HB-specific memory B-cells (HB mem-B cells), per million cells – expressed through tabulation of interquartile range data – was measured by B-cell Enzyme-Linked Immunosorbent Spot (ELISPOT) using Peripheral Blood Mononuclear Cells (PBMCs). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 0, 30, 37, 44 and 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for adaptive immunogenicity to Day 60, which included all evaluable subjects for whom T cell, antibody and memory B cell response data were available for at least one amongst the Day 0, 14, 30, 44, or 60 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="53"/>
                  <measurement group_id="O3" value="55"/>
                  <measurement group_id="O4" value="54"/>
                  <measurement group_id="O5" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Memory B Cells</title>
            <description>The number of HB-specific memory B-cells (HB mem-B cells), per million cells – expressed through tabulation of interquartile range data – was measured by B-cell Enzyme-Linked Immunosorbent Spot (ELISPOT) using Peripheral Blood Mononuclear Cells (PBMCs). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>HB mem-B cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-mem B cells, at Day 0 (N=50,51,53,53,51)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14" lower_limit="1" upper_limit="64"/>
                  <measurement group_id="O2" value="1" lower_limit="1" upper_limit="44"/>
                  <measurement group_id="O3" value="1" lower_limit="1" upper_limit="39"/>
                  <measurement group_id="O4" value="1" lower_limit="1" upper_limit="38"/>
                  <measurement group_id="O5" value="1" lower_limit="1" upper_limit="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-mem B cells, at Day 30 (N=54,51,55,53,52)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="296" lower_limit="38" upper_limit="1161"/>
                  <measurement group_id="O2" value="186" lower_limit="35" upper_limit="776"/>
                  <measurement group_id="O3" value="265" lower_limit="48" upper_limit="759"/>
                  <measurement group_id="O4" value="28" lower_limit="1" upper_limit="86"/>
                  <measurement group_id="O5" value="1" lower_limit="1" upper_limit="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-mem B cells, at Day 37 (N=52,53,48,53,52)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3817" lower_limit="1440" upper_limit="9196"/>
                  <measurement group_id="O2" value="3577" lower_limit="1486" upper_limit="9753"/>
                  <measurement group_id="O3" value="2597" lower_limit="1028" upper_limit="8770"/>
                  <measurement group_id="O4" value="71" lower_limit="1" upper_limit="167"/>
                  <measurement group_id="O5" value="19" lower_limit="1" upper_limit="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-mem B cells, at Day 44 (N=54,52,50,51,48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4656" lower_limit="1430" upper_limit="7808"/>
                  <measurement group_id="O2" value="4808" lower_limit="1845" upper_limit="11274"/>
                  <measurement group_id="O3" value="2498" lower_limit="672" upper_limit="7782"/>
                  <measurement group_id="O4" value="51" lower_limit="1" upper_limit="299"/>
                  <measurement group_id="O5" value="28" lower_limit="1" upper_limit="114"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-mem B cells, at Day 60 (N=52,51,54,53,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3742" lower_limit="835" upper_limit="7997"/>
                  <measurement group_id="O2" value="3383" lower_limit="1467" upper_limit="8145"/>
                  <measurement group_id="O3" value="1806" lower_limit="599" upper_limit="5833"/>
                  <measurement group_id="O4" value="47" lower_limit="1" upper_limit="152"/>
                  <measurement group_id="O5" value="44" lower_limit="1" upper_limit="161"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hepatitis B (HB)-Specific Memory B Cells</title>
        <description>The number of HB-specific memory B-cells (HB mem-B cells), per million cells – expressed through tabulation of interquartile range data – was measured by B-cell Enzyme-Linked Immunosorbent Spot (ELISPOT) using Peripheral Blood Mononuclear Cells (PBMCs). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 180 and 360</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for persistence which included all subjects from the ATP cohort for adaptive immunogenicity up to Day 60 for whom adaptive immunogenicity data were available for at least one post-vaccination time point (Day 180 or Day 360).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="52"/>
                  <measurement group_id="O3" value="52"/>
                  <measurement group_id="O4" value="51"/>
                  <measurement group_id="O5" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hepatitis B (HB)-Specific Memory B Cells</title>
            <description>The number of HB-specific memory B-cells (HB mem-B cells), per million cells – expressed through tabulation of interquartile range data – was measured by B-cell Enzyme-Linked Immunosorbent Spot (ELISPOT) using Peripheral Blood Mononuclear Cells (PBMCs). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>HB mem-B cells (per million cells)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>HB-mem B cells, at Day 180 (N=49,48,49,45,50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1454" lower_limit="395" upper_limit="2486"/>
                  <measurement group_id="O2" value="1013" lower_limit="227" upper_limit="2164"/>
                  <measurement group_id="O3" value="1410" lower_limit="567" upper_limit="2671"/>
                  <measurement group_id="O4" value="24" lower_limit="1" upper_limit="128"/>
                  <measurement group_id="O5" value="1" lower_limit="1" upper_limit="67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB-mem B cells, at Day 360 (N=52,46,50,49,49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1070" lower_limit="747" upper_limit="2616"/>
                  <measurement group_id="O2" value="1437" lower_limit="306" upper_limit="2770"/>
                  <measurement group_id="O3" value="1473" lower_limit="463" upper_limit="2430"/>
                  <measurement group_id="O4" value="66" lower_limit="1" upper_limit="255"/>
                  <measurement group_id="O5" value="21" lower_limit="1" upper_limit="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of the Interferon-gamma (IFN-g), Interleukin (IL)-1beta, IL-5, IL-6, IL-10, Tumor Necrosis Factor-alpha, IFN-g-inducible Protein-10 and Monocyte Chemotactic Protein-1 Cytokines in Serum</title>
        <description>Concentrations of IFN-g, IL-1 beta (IL-1B), IL-5, IL-6, IL-10, Tumor Necrosis Factor-alpha (TNF-a), IFN-g-inducible protein-10 (IP-10) and monocyte chemotactic protein (MCP)-1 Concentrations of the IFN-g, IL-1B, IL-5, IL-6, IL-10, TNF-a, IP-10 and MCP-1 cytokines in serum were measured by Cytokine bead assay (CBA) and expressed in picograms per milliliter (pg/mL). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30,30+ (Day 30 + 3 to 6 hours), 31, 33 and 37.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for innate immunogenicity to Day 60, which included all evaluable subjects with immunogenicity and innate response (=early immune response [i.e. cytokines in serum, gene expression signature, white blood cells counts]) results available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="61"/>
                  <measurement group_id="O4" value="61"/>
                  <measurement group_id="O5" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentrations of the Interferon-gamma (IFN-g), Interleukin (IL)-1beta, IL-5, IL-6, IL-10, Tumor Necrosis Factor-alpha, IFN-g-inducible Protein-10 and Monocyte Chemotactic Protein-1 Cytokines in Serum</title>
            <description>Concentrations of IFN-g, IL-1 beta (IL-1B), IL-5, IL-6, IL-10, Tumor Necrosis Factor-alpha (TNF-a), IFN-g-inducible protein-10 (IP-10) and monocyte chemotactic protein (MCP)-1 Concentrations of the IFN-g, IL-1B, IL-5, IL-6, IL-10, TNF-a, IP-10 and MCP-1 cytokines in serum were measured by Cytokine bead assay (CBA) and expressed in picograms per milliliter (pg/mL). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>pg/mL</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>IFN-g; Day 0 (N=59,57,59,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O2" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O3" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O4" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O5" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-g; Day 0+ (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O2" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O3" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O4" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O5" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-g; Day 1 (N=58,57,58,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O2" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O3" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O4" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O5" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-g; Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O2" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O3" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O4" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O5" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-g; Day 30+ (N=59,57,57,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O2" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O3" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O4" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O5" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-g; Day 31 (N=58,57,56,57,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.568" lower_limit="3.704" upper_limit="57.695"/>
                  <measurement group_id="O2" value="3.704" lower_limit="3.704" upper_limit="21.747"/>
                  <measurement group_id="O3" value="3.704" lower_limit="3.704" upper_limit="5.575"/>
                  <measurement group_id="O4" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O5" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-g; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O2" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O3" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O4" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O5" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-g; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O2" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O3" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O4" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                  <measurement group_id="O5" value="3.704" lower_limit="3.704" upper_limit="3.704"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B; Day 0 (N=59,57,59,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.837"/>
                  <measurement group_id="O2" value="1.379" lower_limit="0.411" upper_limit="3.046"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.937"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="2.516"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="2.06"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B; Day 0+ (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.636" lower_limit="0.411" upper_limit="2.087"/>
                  <measurement group_id="O2" value="1.873" lower_limit="0.411" upper_limit="2.742"/>
                  <measurement group_id="O3" value="0.856" lower_limit="0.411" upper_limit="2.535"/>
                  <measurement group_id="O4" value="0.947" lower_limit="0.411" upper_limit="2.394"/>
                  <measurement group_id="O5" value="1.146" lower_limit="0.411" upper_limit="2.674"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B; Day 1 (N=58,57,58,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.024" lower_limit="0.852" upper_limit="3.406"/>
                  <measurement group_id="O2" value="2.237" lower_limit="1.302" upper_limit="4.214"/>
                  <measurement group_id="O3" value="1.912" lower_limit="0.411" upper_limit="3.07"/>
                  <measurement group_id="O4" value="1.628" lower_limit="0.856" upper_limit="2.449"/>
                  <measurement group_id="O5" value="1.885" lower_limit="1.094" upper_limit="3.819"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B; Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.232" lower_limit="0.411" upper_limit="2.385"/>
                  <measurement group_id="O2" value="0.879" lower_limit="0.411" upper_limit="2.26"/>
                  <measurement group_id="O3" value="1.017" lower_limit="0.411" upper_limit="2.631"/>
                  <measurement group_id="O4" value="0.925" lower_limit="0.411" upper_limit="2.516"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="2.326"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B; Day 30+ (N=59,57,57,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.292" lower_limit="0.411" upper_limit="2.333"/>
                  <measurement group_id="O2" value="1.099" lower_limit="0.411" upper_limit="2.28"/>
                  <measurement group_id="O3" value="0.856" lower_limit="0.411" upper_limit="2.332"/>
                  <measurement group_id="O4" value="1.214" lower_limit="0.411" upper_limit="1.981"/>
                  <measurement group_id="O5" value="1.349" lower_limit="0.411" upper_limit="2.384"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B; Day 31 (N=58,57,56,57,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.991" lower_limit="0.411" upper_limit="2.577"/>
                  <measurement group_id="O2" value="1.263" lower_limit="0.411" upper_limit="2.528"/>
                  <measurement group_id="O3" value="1.117" lower_limit="0.411" upper_limit="3.164"/>
                  <measurement group_id="O4" value="1.159" lower_limit="0.411" upper_limit="2.581"/>
                  <measurement group_id="O5" value="1.135" lower_limit="0.411" upper_limit="2.775"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.432"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="1.886"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="2.182"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="1.77"/>
                  <measurement group_id="O5" value="0.86" lower_limit="0.411" upper_limit="1.88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.585"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="2.41"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.506"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="2.122"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="2.764"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-10; Day 0 (N=59,57,59,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="0.411"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="1.051"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.13"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="0.411"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="0.411"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-10; Day 0+ (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.597"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="1.516"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.31"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="0.904"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="1.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-10; Day 1 (N=58,57,58,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.977" lower_limit="0.411" upper_limit="2.135"/>
                  <measurement group_id="O2" value="1.08" lower_limit="0.411" upper_limit="2.323"/>
                  <measurement group_id="O3" value="1.055" lower_limit="0.411" upper_limit="2.518"/>
                  <measurement group_id="O4" value="0.893" lower_limit="0.411" upper_limit="1.813"/>
                  <measurement group_id="O5" value="0.916" lower_limit="0.411" upper_limit="2.593"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-10; Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.409"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="1.165"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.799"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="1.289"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="0.967"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-10; Day 30+ (N=59,57,57,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.113"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="1.027"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.082"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="0.867"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="0.908"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-10; Day 31 (N=58,57,56,57,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.705" lower_limit="0.411" upper_limit="2.233"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="1.961"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="2.046"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="1.392"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="1.303"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-10; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="0.411"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="1.165"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.208"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="0.989"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="0.411"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-10; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="0.844"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="0.906"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="0.984"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="1.425"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="1.052"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-5; Day 0 (N=59,57,59,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.662"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="2.413"/>
                  <measurement group_id="O3" value="0.905" lower_limit="0.411" upper_limit="1.677"/>
                  <measurement group_id="O4" value="0.867" lower_limit="0.411" upper_limit="1.917"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="1.619"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-5; Day 0+ (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.161" lower_limit="0.411" upper_limit="2.094"/>
                  <measurement group_id="O2" value="1.37" lower_limit="0.411" upper_limit="2.089"/>
                  <measurement group_id="O3" value="0.905" lower_limit="0.411" upper_limit="2.017"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="1.77"/>
                  <measurement group_id="O5" value="1.092" lower_limit="0.411" upper_limit="2.105"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-5; Day 1 (N=58,57,58,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.004" lower_limit="0.932" upper_limit="2.758"/>
                  <measurement group_id="O2" value="2.089" lower_limit="1.092" upper_limit="3.095"/>
                  <measurement group_id="O3" value="1.83" lower_limit="0.411" upper_limit="3.049"/>
                  <measurement group_id="O4" value="1.77" lower_limit="1.023" upper_limit="2.73"/>
                  <measurement group_id="O5" value="1.942" lower_limit="1.23" upper_limit="3.143"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-5; Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.202" lower_limit="0.411" upper_limit="1.972"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="1.663"/>
                  <measurement group_id="O3" value="1.011" lower_limit="0.411" upper_limit="2.733"/>
                  <measurement group_id="O4" value="0.89" lower_limit="0.411" upper_limit="2.403"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="2.381"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-5; Day 30+ (N=59,57,57,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.884" lower_limit="0.411" upper_limit="2.024"/>
                  <measurement group_id="O2" value="0.916" lower_limit="0.411" upper_limit="2.028"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="2.15"/>
                  <measurement group_id="O4" value="0.992" lower_limit="0.411" upper_limit="1.89"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="2.273"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-5; Day 31 (N=58,57,56,57,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.119" lower_limit="0.411" upper_limit="2.719"/>
                  <measurement group_id="O2" value="0.951" lower_limit="0.411" upper_limit="2.664"/>
                  <measurement group_id="O3" value="1.289" lower_limit="0.411" upper_limit="2.901"/>
                  <measurement group_id="O4" value="1.113" lower_limit="0.411" upper_limit="2.367"/>
                  <measurement group_id="O5" value="0.99" lower_limit="0.411" upper_limit="2.501"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-5; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.599"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="2.134"/>
                  <measurement group_id="O3" value="1.192" lower_limit="0.411" upper_limit="2.948"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="2.047"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="2.221"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-5; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.509"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.411" upper_limit="2.015"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.43"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="2.262"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="2.661"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-6; Day 0 (N=59,57,59,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.291" lower_limit="0.411" upper_limit="1.984"/>
                  <measurement group_id="O2" value="1.19" lower_limit="0.411" upper_limit="2.783"/>
                  <measurement group_id="O3" value="1.291" lower_limit="0.411" upper_limit="1.946"/>
                  <measurement group_id="O4" value="1.26" lower_limit="0.411" upper_limit="2.176"/>
                  <measurement group_id="O5" value="1.055" lower_limit="0.411" upper_limit="1.768"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-6; Day 0+ (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.882" lower_limit="2.018" upper_limit="4.57"/>
                  <measurement group_id="O2" value="2.523" lower_limit="1.55" upper_limit="3.977"/>
                  <measurement group_id="O3" value="1.605" lower_limit="0.411" upper_limit="2.652"/>
                  <measurement group_id="O4" value="1.579" lower_limit="1.174" upper_limit="2.278"/>
                  <measurement group_id="O5" value="1.418" lower_limit="0.411" upper_limit="2.049"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-6; Day 1 (N=58,57,58,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.07" lower_limit="2.707" upper_limit="5.621"/>
                  <measurement group_id="O2" value="2.578" lower_limit="1.748" upper_limit="3.807"/>
                  <measurement group_id="O3" value="2.223" lower_limit="1.435" upper_limit="3.637"/>
                  <measurement group_id="O4" value="2.147" lower_limit="1.658" upper_limit="3.273"/>
                  <measurement group_id="O5" value="1.739" lower_limit="1.159" upper_limit="2.819"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-6; Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.641" lower_limit="0.92" upper_limit="2.839"/>
                  <measurement group_id="O2" value="1.377" lower_limit="0.411" upper_limit="1.982"/>
                  <measurement group_id="O3" value="1.79" lower_limit="0.411" upper_limit="2.564"/>
                  <measurement group_id="O4" value="1.653" lower_limit="0.411" upper_limit="2.368"/>
                  <measurement group_id="O5" value="1.218" lower_limit="0.411" upper_limit="2.229"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-6; Day 30+ (N=59,57,57,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.195" lower_limit="2.056" upper_limit="5.288"/>
                  <measurement group_id="O2" value="2.53" lower_limit="1.589" upper_limit="3.87"/>
                  <measurement group_id="O3" value="1.664" lower_limit="1.074" upper_limit="2.223"/>
                  <measurement group_id="O4" value="1.753" lower_limit="1.273" upper_limit="2.341"/>
                  <measurement group_id="O5" value="1.394" lower_limit="0.411" upper_limit="2.272"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-6; Day 31 (N=58,57,56,57,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.459" lower_limit="5.284" upper_limit="10.345"/>
                  <measurement group_id="O2" value="4.174" lower_limit="2.925" upper_limit="7.202"/>
                  <measurement group_id="O3" value="3.457" lower_limit="1.971" upper_limit="5.488"/>
                  <measurement group_id="O4" value="2.538" lower_limit="1.521" upper_limit="4.016"/>
                  <measurement group_id="O5" value="1.567" lower_limit="0.861" upper_limit="2.316"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-6; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.644" lower_limit="1.1" upper_limit="3.287"/>
                  <measurement group_id="O2" value="1.253" lower_limit="0.411" upper_limit="2.538"/>
                  <measurement group_id="O3" value="1.435" lower_limit="0.411" upper_limit="2.405"/>
                  <measurement group_id="O4" value="1.676" lower_limit="0.937" upper_limit="2.456"/>
                  <measurement group_id="O5" value="1.389" lower_limit="0.411" upper_limit="2.001"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-6; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.003" lower_limit="0.411" upper_limit="1.982"/>
                  <measurement group_id="O2" value="0.976" lower_limit="0.411" upper_limit="1.875"/>
                  <measurement group_id="O3" value="0.95" lower_limit="0.411" upper_limit="1.938"/>
                  <measurement group_id="O4" value="1.321" lower_limit="0.411" upper_limit="1.946"/>
                  <measurement group_id="O5" value="1.158" lower_limit="0.411" upper_limit="2.17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IP-10; Day 0 (N=59,57,58,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94" lower_limit="70" upper_limit="162"/>
                  <measurement group_id="O2" value="92" lower_limit="68" upper_limit="141"/>
                  <measurement group_id="O3" value="101.5" lower_limit="62" upper_limit="136"/>
                  <measurement group_id="O4" value="102" lower_limit="64.5" upper_limit="154.5"/>
                  <measurement group_id="O5" value="91" lower_limit="61" upper_limit="136"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IP-10; Day 0+ (N=57,57,59,61,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80" lower_limit="53" upper_limit="117"/>
                  <measurement group_id="O2" value="81" lower_limit="54" upper_limit="113"/>
                  <measurement group_id="O3" value="78" lower_limit="46" upper_limit="113"/>
                  <measurement group_id="O4" value="80" lower_limit="52" upper_limit="109"/>
                  <measurement group_id="O5" value="75.5" lower_limit="55" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IP-10; Day 1 (N=58,57,58,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="147" lower_limit="99" upper_limit="252"/>
                  <measurement group_id="O2" value="111" lower_limit="71" upper_limit="154"/>
                  <measurement group_id="O3" value="92.5" lower_limit="61" upper_limit="144"/>
                  <measurement group_id="O4" value="85.5" lower_limit="71.5" upper_limit="106"/>
                  <measurement group_id="O5" value="85" lower_limit="52" upper_limit="140"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IP-10; Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="103" lower_limit="72" upper_limit="154"/>
                  <measurement group_id="O2" value="109" lower_limit="72" upper_limit="160"/>
                  <measurement group_id="O3" value="106" lower_limit="77" upper_limit="180"/>
                  <measurement group_id="O4" value="104" lower_limit="75" upper_limit="173"/>
                  <measurement group_id="O5" value="107" lower_limit="77" upper_limit="173"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IP-10; Day 30+ (N=59,57,56,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75" lower_limit="49" upper_limit="101"/>
                  <measurement group_id="O2" value="63" lower_limit="41" upper_limit="103"/>
                  <measurement group_id="O3" value="70.5" lower_limit="30.5" upper_limit="105"/>
                  <measurement group_id="O4" value="68" lower_limit="42" upper_limit="100"/>
                  <measurement group_id="O5" value="70" lower_limit="49" upper_limit="108"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IP-10; Day 31 (N=58,57,56,57,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="295" lower_limit="130" upper_limit="465"/>
                  <measurement group_id="O2" value="211" lower_limit="129" upper_limit="377"/>
                  <measurement group_id="O3" value="176.5" lower_limit="83.5" upper_limit="304"/>
                  <measurement group_id="O4" value="63" lower_limit="51" upper_limit="100"/>
                  <measurement group_id="O5" value="76" lower_limit="48" upper_limit="117"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IP-10; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="232" lower_limit="163" upper_limit="393"/>
                  <measurement group_id="O2" value="170" lower_limit="111" upper_limit="269"/>
                  <measurement group_id="O3" value="156" lower_limit="99" upper_limit="274"/>
                  <measurement group_id="O4" value="86" lower_limit="53" upper_limit="119"/>
                  <measurement group_id="O5" value="84" lower_limit="52" upper_limit="127"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IP-10; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="119" lower_limit="88" upper_limit="185"/>
                  <measurement group_id="O2" value="100.5" lower_limit="62.5" upper_limit="151.5"/>
                  <measurement group_id="O3" value="90" lower_limit="71" upper_limit="138"/>
                  <measurement group_id="O4" value="83.5" lower_limit="54" upper_limit="123"/>
                  <measurement group_id="O5" value="85" lower_limit="54" upper_limit="144"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCP-1; Day 0 (N=59,57,58,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130" lower_limit="92" upper_limit="205"/>
                  <measurement group_id="O2" value="168" lower_limit="100" upper_limit="211"/>
                  <measurement group_id="O3" value="148.5" lower_limit="104" upper_limit="194"/>
                  <measurement group_id="O4" value="143" lower_limit="93.5" upper_limit="219.5"/>
                  <measurement group_id="O5" value="120" lower_limit="83" upper_limit="182"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCP-1; Day 0+ (N=57,57,59,61,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112" lower_limit="73" upper_limit="183"/>
                  <measurement group_id="O2" value="141" lower_limit="99" upper_limit="175"/>
                  <measurement group_id="O3" value="114" lower_limit="83" upper_limit="175"/>
                  <measurement group_id="O4" value="131" lower_limit="91" upper_limit="181"/>
                  <measurement group_id="O5" value="95" lower_limit="68" upper_limit="167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCP-1; Day 1 (N=58,57,58,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144" lower_limit="97" upper_limit="198"/>
                  <measurement group_id="O2" value="139" lower_limit="88" upper_limit="208"/>
                  <measurement group_id="O3" value="111.5" lower_limit="88" upper_limit="170"/>
                  <measurement group_id="O4" value="133.5" lower_limit="92.5" upper_limit="193"/>
                  <measurement group_id="O5" value="133" lower_limit="80" upper_limit="187"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCP-1; Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151" lower_limit="70" upper_limit="245"/>
                  <measurement group_id="O2" value="179" lower_limit="111" upper_limit="233"/>
                  <measurement group_id="O3" value="164" lower_limit="119" upper_limit="213"/>
                  <measurement group_id="O4" value="165" lower_limit="109" upper_limit="275"/>
                  <measurement group_id="O5" value="161" lower_limit="94" upper_limit="227"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCP-1; Day 30+ (N=59,57,56,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="140" lower_limit="72" upper_limit="193"/>
                  <measurement group_id="O2" value="114" lower_limit="84" upper_limit="176"/>
                  <measurement group_id="O3" value="121.5" lower_limit="80.5" upper_limit="185"/>
                  <measurement group_id="O4" value="121" lower_limit="74" upper_limit="195"/>
                  <measurement group_id="O5" value="114.5" lower_limit="80" upper_limit="162"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCP-1; Day 31 (N=58,57,56,57,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="171" lower_limit="112" upper_limit="283"/>
                  <measurement group_id="O2" value="155" lower_limit="82" upper_limit="248"/>
                  <measurement group_id="O3" value="114.5" lower_limit="91.5" upper_limit="186.5"/>
                  <measurement group_id="O4" value="120" lower_limit="68" upper_limit="161"/>
                  <measurement group_id="O5" value="105" lower_limit="61" upper_limit="175"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCP-1; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83" lower_limit="48" upper_limit="134"/>
                  <measurement group_id="O2" value="92" lower_limit="59" upper_limit="139"/>
                  <measurement group_id="O3" value="79" lower_limit="50" upper_limit="136"/>
                  <measurement group_id="O4" value="122" lower_limit="72" upper_limit="180"/>
                  <measurement group_id="O5" value="88" lower_limit="56" upper_limit="151"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MCP-1; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129" lower_limit="75" upper_limit="182"/>
                  <measurement group_id="O2" value="138.5" lower_limit="102" upper_limit="176"/>
                  <measurement group_id="O3" value="150" lower_limit="111" upper_limit="196"/>
                  <measurement group_id="O4" value="140.5" lower_limit="87" upper_limit="201"/>
                  <measurement group_id="O5" value="133" lower_limit="74" upper_limit="170"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF-a; Day 0 (N=59,57,59,60,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.348"/>
                  <measurement group_id="O2" value="1.262" lower_limit="0.411" upper_limit="2.484"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.707"/>
                  <measurement group_id="O4" value="0.651" lower_limit="0.411" upper_limit="1.893"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="1.455"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF-a; Day 0+ (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.482" lower_limit="0.411" upper_limit="2.309"/>
                  <measurement group_id="O2" value="1.641" lower_limit="0.411" upper_limit="2.276"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="2.128"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="1.889"/>
                  <measurement group_id="O5" value="0.911" lower_limit="0.411" upper_limit="2.274"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF-a; Day 1 (N=58,57,58,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.902" lower_limit="0.411" upper_limit="2.346"/>
                  <measurement group_id="O2" value="1.909" lower_limit="1.079" upper_limit="3.135"/>
                  <measurement group_id="O3" value="1.727" lower_limit="0.411" upper_limit="3.277"/>
                  <measurement group_id="O4" value="1.579" lower_limit="0.411" upper_limit="2.274"/>
                  <measurement group_id="O5" value="1.701" lower_limit="0.411" upper_limit="2.907"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF-a; Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.969" lower_limit="0.411" upper_limit="2.192"/>
                  <measurement group_id="O2" value="1.023" lower_limit="0.411" upper_limit="1.809"/>
                  <measurement group_id="O3" value="1.203" lower_limit="0.411" upper_limit="2.568"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="2.298"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="2.032"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF-a; Day 30+ (N=59,57,57,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.069" lower_limit="0.411" upper_limit="1.796"/>
                  <measurement group_id="O2" value="1.08" lower_limit="0.411" upper_limit="2.196"/>
                  <measurement group_id="O3" value="1.321" lower_limit="0.411" upper_limit="2.204"/>
                  <measurement group_id="O4" value="1.243" lower_limit="0.411" upper_limit="1.853"/>
                  <measurement group_id="O5" value="1.323" lower_limit="0.411" upper_limit="2.124"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF-a; Day 31 (N=58,57,56,57,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.881" lower_limit="0.411" upper_limit="2.507"/>
                  <measurement group_id="O2" value="1.151" lower_limit="0.411" upper_limit="2.399"/>
                  <measurement group_id="O3" value="1.081" lower_limit="0.411" upper_limit="3.366"/>
                  <measurement group_id="O4" value="1.091" lower_limit="0.411" upper_limit="2.257"/>
                  <measurement group_id="O5" value="1.375" lower_limit="0.411" upper_limit="2.249"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF-a; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.568"/>
                  <measurement group_id="O2" value="0.981" lower_limit="0.411" upper_limit="1.853"/>
                  <measurement group_id="O3" value="1.129" lower_limit="0.411" upper_limit="2.486"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="2.084"/>
                  <measurement group_id="O5" value="0.411" lower_limit="0.411" upper_limit="2.204"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF-a; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.411" lower_limit="0.411" upper_limit="1.879"/>
                  <measurement group_id="O2" value="0.934" lower_limit="0.411" upper_limit="2.158"/>
                  <measurement group_id="O3" value="0.411" lower_limit="0.411" upper_limit="1.826"/>
                  <measurement group_id="O4" value="0.411" lower_limit="0.411" upper_limit="2.483"/>
                  <measurement group_id="O5" value="0.841" lower_limit="0.411" upper_limit="2.399"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Levels of White Blood Cells (WBC) and Creatine Phosphokinases (CPK)</title>
        <description>Analysis of levels of CPK and WBC was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30, 30+ (Day 30 + 3 to 6 hours), 31, 33, 37 and 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for innate immunogenicity to Day 60, which included all evaluable subjects with immunogenicity and innate response (=early immune response [i.e. cytokines in serum, gene expression signature, white blood cells counts]) results available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="59"/>
                  <measurement group_id="O4" value="61"/>
                  <measurement group_id="O5" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Normalized Levels of White Blood Cells (WBC) and Creatine Phosphokinases (CPK)</title>
            <description>Analysis of levels of CPK and WBC was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>IH Center normalized ratio</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>WBC; Day 0 (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6840" lower_limit="5520" upper_limit="7647.619"/>
                  <measurement group_id="O2" value="6090" lower_limit="5230" upper_limit="7680"/>
                  <measurement group_id="O3" value="6650" lower_limit="5130" upper_limit="8210"/>
                  <measurement group_id="O4" value="6523.81" lower_limit="5542.857" upper_limit="7350"/>
                  <measurement group_id="O5" value="6480" lower_limit="5320" upper_limit="7540"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 0+ (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7729.231" lower_limit="6340" upper_limit="9157.895"/>
                  <measurement group_id="O2" value="7670" lower_limit="6111.111" upper_limit="9368.421"/>
                  <measurement group_id="O3" value="7520" lower_limit="6460" upper_limit="9290"/>
                  <measurement group_id="O4" value="7620" lower_limit="6860" upper_limit="8421.053"/>
                  <measurement group_id="O5" value="7210" lower_limit="6300" upper_limit="9063.655"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 1 (N=58,57,58,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8265" lower_limit="7000" upper_limit="9838.095"/>
                  <measurement group_id="O2" value="7850" lower_limit="6400" upper_limit="9066.667"/>
                  <measurement group_id="O3" value="7610" lower_limit="6540" upper_limit="9530"/>
                  <measurement group_id="O4" value="8400" lower_limit="7200" upper_limit="9200"/>
                  <measurement group_id="O5" value="7130" lower_limit="5750" upper_limit="8110"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5960" lower_limit="5260" upper_limit="7866.667"/>
                  <measurement group_id="O2" value="6090" lower_limit="5230" upper_limit="7500"/>
                  <measurement group_id="O3" value="6290" lower_limit="5152.381" upper_limit="7797.342"/>
                  <measurement group_id="O4" value="6421.053" lower_limit="5570" upper_limit="7680"/>
                  <measurement group_id="O5" value="6076.923" lower_limit="5430" upper_limit="7580.952"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 30+ (N=59,57,57,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7570" lower_limit="6430" upper_limit="8838.095"/>
                  <measurement group_id="O2" value="7350" lower_limit="5894.737" upper_limit="8620"/>
                  <measurement group_id="O3" value="7120" lower_limit="5980" upper_limit="8720"/>
                  <measurement group_id="O4" value="7371.429" lower_limit="6133.333" upper_limit="8680"/>
                  <measurement group_id="O5" value="7625" lower_limit="6270" upper_limit="8520"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 31 (N=59,57,56,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8160" lower_limit="7110" upper_limit="10170"/>
                  <measurement group_id="O2" value="7533.333" lower_limit="6759.754" upper_limit="8920"/>
                  <measurement group_id="O3" value="7422.222" lower_limit="6405" upper_limit="8352.641"/>
                  <measurement group_id="O4" value="7980" lower_limit="6950" upper_limit="9090"/>
                  <measurement group_id="O5" value="6550" lower_limit="5580" upper_limit="7410"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6450" lower_limit="5010" upper_limit="7971.429"/>
                  <measurement group_id="O2" value="6080" lower_limit="4990" upper_limit="7360"/>
                  <measurement group_id="O3" value="6290" lower_limit="5650" upper_limit="7560"/>
                  <measurement group_id="O4" value="7150" lower_limit="6210" upper_limit="8130"/>
                  <measurement group_id="O5" value="6170" lower_limit="5314.286" upper_limit="8150"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6219.048" lower_limit="5520" upper_limit="7790.476"/>
                  <measurement group_id="O2" value="6464.341" lower_limit="5455" upper_limit="8130"/>
                  <measurement group_id="O3" value="6760" lower_limit="5530" upper_limit="8000"/>
                  <measurement group_id="O4" value="6740" lower_limit="5685.714" upper_limit="7560"/>
                  <measurement group_id="O5" value="6870" lower_limit="5470" upper_limit="8333.333"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 60 (N=59,57,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6400" lower_limit="5280" upper_limit="8230"/>
                  <measurement group_id="O2" value="6320" lower_limit="5466.667" upper_limit="7420"/>
                  <measurement group_id="O3" value="6090" lower_limit="5320" upper_limit="8430"/>
                  <measurement group_id="O4" value="6540" lower_limit="5257.143" upper_limit="7378.738"/>
                  <measurement group_id="O5" value="5970" lower_limit="5100" upper_limit="7980.952"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 0 (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="113" lower_limit="91" upper_limit="139.263"/>
                  <measurement group_id="O2" value="93" lower_limit="73" upper_limit="121"/>
                  <measurement group_id="O3" value="110" lower_limit="74.216" upper_limit="157.789"/>
                  <measurement group_id="O4" value="114" lower_limit="85" upper_limit="175"/>
                  <measurement group_id="O5" value="84.108" lower_limit="70" upper_limit="121.579"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 0+ (N=59,57,59,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="117" lower_limit="90" upper_limit="156"/>
                  <measurement group_id="O2" value="99.297" lower_limit="77" upper_limit="120.054"/>
                  <measurement group_id="O3" value="112" lower_limit="73.351" upper_limit="159"/>
                  <measurement group_id="O4" value="114.842" lower_limit="89.784" upper_limit="170.941"/>
                  <measurement group_id="O5" value="94" lower_limit="74" upper_limit="114.842"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 1 (N=58,57,57,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="109" lower_limit="81.135" upper_limit="136.947"/>
                  <measurement group_id="O2" value="89.784" lower_limit="73" upper_limit="115"/>
                  <measurement group_id="O3" value="104" lower_limit="76.443" upper_limit="141"/>
                  <measurement group_id="O4" value="102" lower_limit="78.541" upper_limit="163.297"/>
                  <measurement group_id="O5" value="86" lower_limit="70" upper_limit="123.514"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK, at Day 30 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123.263" lower_limit="93" upper_limit="172.444"/>
                  <measurement group_id="O2" value="90" lower_limit="72" upper_limit="114.842"/>
                  <measurement group_id="O3" value="115.73" lower_limit="73.569" upper_limit="163"/>
                  <measurement group_id="O4" value="99" lower_limit="71.653" upper_limit="158.973"/>
                  <measurement group_id="O5" value="93" lower_limit="74" upper_limit="137"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 30+ (N=59,57,57,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="120" lower_limit="96" upper_limit="174.541"/>
                  <measurement group_id="O2" value="91.772" lower_limit="75" upper_limit="118.741"/>
                  <measurement group_id="O3" value="115.73" lower_limit="74.216" upper_limit="158.108"/>
                  <measurement group_id="O4" value="106" lower_limit="78" upper_limit="144.27"/>
                  <measurement group_id="O5" value="93" lower_limit="75.081" upper_limit="143"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 31 (N=59,57,56,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="109" lower_limit="83" upper_limit="153.529"/>
                  <measurement group_id="O2" value="90" lower_limit="70.211" upper_limit="105"/>
                  <measurement group_id="O3" value="106.973" lower_limit="74.5" upper_limit="141.973"/>
                  <measurement group_id="O4" value="103.614" lower_limit="76" upper_limit="153.784"/>
                  <measurement group_id="O5" value="98" lower_limit="75.081" upper_limit="142.541"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 33 (N=59,57,57,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107" lower_limit="80.316" upper_limit="149.459"/>
                  <measurement group_id="O2" value="87" lower_limit="71.053" upper_limit="113.135"/>
                  <measurement group_id="O3" value="104" lower_limit="69" upper_limit="147"/>
                  <measurement group_id="O4" value="101" lower_limit="75.485" upper_limit="136.588"/>
                  <measurement group_id="O5" value="91.772" lower_limit="75.485" upper_limit="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 37 (N=59,56,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112.118" lower_limit="81" upper_limit="153.529"/>
                  <measurement group_id="O2" value="93.986" lower_limit="67.921" upper_limit="116.395"/>
                  <measurement group_id="O3" value="118" lower_limit="78.359" upper_limit="172.811"/>
                  <measurement group_id="O4" value="106.311" lower_limit="77" upper_limit="170.216"/>
                  <measurement group_id="O5" value="93.689" lower_limit="69" upper_limit="126"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 60 (N=59,57,57,58,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="120" lower_limit="85" upper_limit="174.632"/>
                  <measurement group_id="O2" value="85" lower_limit="70" upper_limit="108.811"/>
                  <measurement group_id="O3" value="114" lower_limit="85" upper_limit="157"/>
                  <measurement group_id="O4" value="110.647" lower_limit="79.405" upper_limit="149.765"/>
                  <measurement group_id="O5" value="96" lower_limit="76" upper_limit="131"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Levels of C-reactive Protein (CRP)</title>
        <description>Analysis of levels of CRP was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30, 30+ (Day 30 + 3 to 6 hours), 31, 33 and 37.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for innate immunogenicity to Day 60, which included all evaluable subjects with immunogenicity and innate response (=early immune response [i.e. cytokines in serum, gene expression signature, white blood cells counts]) results available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="59"/>
                  <measurement group_id="O4" value="61"/>
                  <measurement group_id="O5" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Normalized Levels of C-reactive Protein (CRP)</title>
            <description>Analysis of levels of CRP was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>IH Center normlized ratio</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>CRP; Day 0 (N=59,57,59,61,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.248" lower_limit="0.18" upper_limit="0.326"/>
                  <measurement group_id="O2" value="0.248" lower_limit="0.15" upper_limit="0.51"/>
                  <measurement group_id="O3" value="0.248" lower_limit="0.13" upper_limit="0.55"/>
                  <measurement group_id="O4" value="0.248" lower_limit="0.17" upper_limit="0.486"/>
                  <measurement group_id="O5" value="0.248" lower_limit="0.09" upper_limit="0.486"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP; Day 0+ (N=59,57,59,61,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.248" lower_limit="0.14" upper_limit="0.391"/>
                  <measurement group_id="O2" value="0.248" lower_limit="0.12" upper_limit="0.5"/>
                  <measurement group_id="O3" value="0.248" lower_limit="0.14" upper_limit="0.52"/>
                  <measurement group_id="O4" value="0.248" lower_limit="0.17" upper_limit="0.486"/>
                  <measurement group_id="O5" value="0.248" lower_limit="0.1" upper_limit="0.462"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP; Day 1 (N=58,57,58,61,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.97" lower_limit="0.795" upper_limit="3.342"/>
                  <measurement group_id="O2" value="0.962" lower_limit="0.486" upper_limit="1.661"/>
                  <measurement group_id="O3" value="0.486" lower_limit="0.25" upper_limit="0.94"/>
                  <measurement group_id="O4" value="0.462" lower_limit="0.248" upper_limit="0.724"/>
                  <measurement group_id="O5" value="0.248" lower_limit="0.11" upper_limit="0.462"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP; Day 30 (N=58,57,57,57,53)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.248" lower_limit="0.187" upper_limit="0.486"/>
                  <measurement group_id="O2" value="0.248" lower_limit="0.17" upper_limit="0.34"/>
                  <measurement group_id="O3" value="0.248" lower_limit="0.129" upper_limit="0.486"/>
                  <measurement group_id="O4" value="0.248" lower_limit="0.2" upper_limit="0.486"/>
                  <measurement group_id="O5" value="0.248" lower_limit="0.15" upper_limit="0.486"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP; Day 30+ (N=59,57,57,59,54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.248" lower_limit="0.192" upper_limit="0.53"/>
                  <measurement group_id="O2" value="0.248" lower_limit="0.18" upper_limit="0.34"/>
                  <measurement group_id="O3" value="0.248" lower_limit="0.13" upper_limit="0.486"/>
                  <measurement group_id="O4" value="0.248" lower_limit="0.2" upper_limit="0.52"/>
                  <measurement group_id="O5" value="0.248" lower_limit="0.15" upper_limit="0.486"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP; Day 31 (N=59,56,55,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.521" lower_limit="0.87" upper_limit="2.39"/>
                  <measurement group_id="O2" value="1.047" lower_limit="0.498" upper_limit="1.518"/>
                  <measurement group_id="O3" value="0.61" lower_limit="0.248" upper_limit="1.224"/>
                  <measurement group_id="O4" value="0.486" lower_limit="0.248" upper_limit="0.724"/>
                  <measurement group_id="O5" value="0.248" lower_limit="0.129" upper_limit="0.486"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP; Day 33 (N=58,56,56,59,55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.6" lower_limit="1.438" upper_limit="4.333"/>
                  <measurement group_id="O2" value="1.2" lower_limit="0.637" upper_limit="2.186"/>
                  <measurement group_id="O3" value="0.707" lower_limit="0.46" upper_limit="1.365"/>
                  <measurement group_id="O4" value="0.486" lower_limit="0.248" upper_limit="0.962"/>
                  <measurement group_id="O5" value="0.248" lower_limit="0.129" upper_limit="0.486"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP; Day 37 (N=59,55,55,56,53)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.319" lower_limit="0.229" upper_limit="0.641"/>
                  <measurement group_id="O2" value="0.248" lower_limit="0.17" upper_limit="0.486"/>
                  <measurement group_id="O3" value="0.248" lower_limit="0.13" upper_limit="0.41"/>
                  <measurement group_id="O4" value="0.248" lower_limit="0.229" upper_limit="0.478"/>
                  <measurement group_id="O5" value="0.248" lower_limit="0.12" upper_limit="0.468"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Levels of White Blood Cells (WBC) and of Creatine Phosphokinases (CPK)</title>
        <description>Analysis of levels of CPK and WBC was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
        <time_frame>At Days 0, 30, 37 and 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 1 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. The GSK223192A vaccine antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 2 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. The GSK223192A vaccine antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 3 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. The GSK223192A vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the Fendrix Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of Fendrix™, at Days 0 and 30. The Fendrix™ vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the Engerix-B Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of Engerix-B™, at Days 0 and 30. The Engerix-B™ vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="68"/>
                  <measurement group_id="O3" value="66"/>
                  <measurement group_id="O4" value="71"/>
                  <measurement group_id="O5" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Normalized Levels of White Blood Cells (WBC) and of Creatine Phosphokinases (CPK)</title>
            <description>Analysis of levels of CPK and WBC was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
            <units>IH Center normalized ratio</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>WBC; Day 0 (N=68,68,66,71,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6627.764" lower_limit="5719.286" upper_limit="8273.819"/>
                  <measurement group_id="O2" value="6748.689" lower_limit="5403.462" upper_limit="8568.018"/>
                  <measurement group_id="O3" value="6782.414" lower_limit="5578.947" upper_limit="8350"/>
                  <measurement group_id="O4" value="7590" lower_limit="5810" upper_limit="8550"/>
                  <measurement group_id="O5" value="6810" lower_limit="5573.77" upper_limit="8020"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 30 (N=68,65,65,69,66</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6870.05" lower_limit="5643.182" upper_limit="7705"/>
                  <measurement group_id="O2" value="6454.545" lower_limit="5735.385" upper_limit="7888.889"/>
                  <measurement group_id="O3" value="6600" lower_limit="5555.556" upper_limit="7900"/>
                  <measurement group_id="O4" value="6950.82" lower_limit="5475.41" upper_limit="8777.778"/>
                  <measurement group_id="O5" value="6590" lower_limit="5720" upper_limit="8272.727"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 37 (N=65,66,61,66,63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6736.842" lower_limit="5772.308" upper_limit="7960"/>
                  <measurement group_id="O2" value="7196.579" lower_limit="6113.846" upper_limit="8454.545"/>
                  <measurement group_id="O3" value="6550" lower_limit="5672.131" upper_limit="8622.951"/>
                  <measurement group_id="O4" value="6673.182" lower_limit="5550" upper_limit="8264.615"/>
                  <measurement group_id="O5" value="6440" lower_limit="5770" upper_limit="8650"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 60 (N=68,66,60,68,65)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6738.636" lower_limit="5999.933" upper_limit="8061.393"/>
                  <measurement group_id="O2" value="6330" lower_limit="5333.333" upper_limit="8181.818"/>
                  <measurement group_id="O3" value="6625.789" lower_limit="5265" upper_limit="8110.526"/>
                  <measurement group_id="O4" value="7175.909" lower_limit="5420" upper_limit="9099.817"/>
                  <measurement group_id="O5" value="6740" lower_limit="5530" upper_limit="8090"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 0 (N=68,68,66,71,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="105.529" lower_limit="76" upper_limit="140.279"/>
                  <measurement group_id="O2" value="102.696" lower_limit="82.842" upper_limit="135.314"/>
                  <measurement group_id="O3" value="109.756" lower_limit="86.706" upper_limit="184.919"/>
                  <measurement group_id="O4" value="114" lower_limit="87" upper_limit="159.474"/>
                  <measurement group_id="O5" value="120.857" lower_limit="71.622" upper_limit="184.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 30 (N=68,65,65,68,66</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108.617" lower_limit="79.697" upper_limit="148.105"/>
                  <measurement group_id="O2" value="103.647" lower_limit="81" upper_limit="128.316"/>
                  <measurement group_id="O3" value="114" lower_limit="88.4" upper_limit="172.947"/>
                  <measurement group_id="O4" value="102.1" lower_limit="87.885" upper_limit="135.311"/>
                  <measurement group_id="O5" value="113.079" lower_limit="79" upper_limit="151.333"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 37 (N=65,66,61,66,63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="105.351" lower_limit="84.824" upper_limit="141.676"/>
                  <measurement group_id="O2" value="99.399" lower_limit="77.294" upper_limit="132.891"/>
                  <measurement group_id="O3" value="109.294" lower_limit="88.054" upper_limit="147.655"/>
                  <measurement group_id="O4" value="122.66" lower_limit="88.919" upper_limit="161.059"/>
                  <measurement group_id="O5" value="124.667" lower_limit="82" upper_limit="203.081"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK; Day 60 (N=68,66,61,68,65)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112.842" lower_limit="84.5" upper_limit="187.354"/>
                  <measurement group_id="O2" value="104" lower_limit="75.6" upper_limit="140.105"/>
                  <measurement group_id="O3" value="107.6" lower_limit="78.541" upper_limit="152.919"/>
                  <measurement group_id="O4" value="102.4" lower_limit="84.333" upper_limit="146.793"/>
                  <measurement group_id="O5" value="120.989" lower_limit="84.526" upper_limit="178"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Levels of C-reactive Protein (CRP)</title>
        <description>Analysis of levels of CRP was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
        <time_frame>At Days 0, 30 and 37.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 1 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. The GSK223192A vaccine antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 2 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. The GSK223192A vaccine antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 3 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. The GSK223192A vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the Fendrix Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of Fendrix™, at Days 0 and 30. The Fendrix™ vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the Engerix-B Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of Engerix-B™, at Days 0 and 30. The Engerix-B™ vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="66"/>
                  <measurement group_id="O3" value="64"/>
                  <measurement group_id="O4" value="69"/>
                  <measurement group_id="O5" value="66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Normalized Levels of C-reactive Protein (CRP)</title>
            <description>Analysis of levels of CRP was performed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
            <units>IH Center normalized levels</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>CRP; Day 0 (N=65,65,64,69,64)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.33" lower_limit="0.153" upper_limit="0.755"/>
                  <measurement group_id="O2" value="0.486" lower_limit="0.248" upper_limit="0.739"/>
                  <measurement group_id="O3" value="0.253" lower_limit="0.229" upper_limit="0.739"/>
                  <measurement group_id="O4" value="0.296" lower_limit="0.224" upper_limit="0.739"/>
                  <measurement group_id="O5" value="0.365" lower_limit="0.178" upper_limit="0.739"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP; Day 30 (N=65,66,64,69,66</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.248" lower_limit="0.129" upper_limit="0.724"/>
                  <measurement group_id="O2" value="0.371" lower_limit="0.208" upper_limit="0.739"/>
                  <measurement group_id="O3" value="0.38" lower_limit="0.248" upper_limit="0.739"/>
                  <measurement group_id="O4" value="0.277" lower_limit="0.19" upper_limit="0.739"/>
                  <measurement group_id="O5" value="0.319" lower_limit="0.105" upper_limit="0.739"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP; Day 37 (N=64,65,59,66,59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.486" lower_limit="0.272" upper_limit="0.807"/>
                  <measurement group_id="O2" value="0.523" lower_limit="0.248" upper_limit="1.224"/>
                  <measurement group_id="O3" value="0.486" lower_limit="0.248" upper_limit="1.152"/>
                  <measurement group_id="O4" value="0.363" lower_limit="0.229" upper_limit="0.836"/>
                  <measurement group_id="O5" value="0.248" lower_limit="0.114" upper_limit="0.739"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils</title>
        <description>Levels of white blood cells (WBC) as absolute counts, neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS) and basophils (BAS) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. This outcome measure presents the raw data collected in percent (%), expressed in IH Center normalized levels based on raw data in % (IH normalized %), and concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30, 30+ (Day 30 + 3 to 6 hours), 31, 33, 37 and 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the According-to-Protocol (ATP) cohort for innate immunogenicity to Day 60, which included all evaluable subjects with immunogenicity and innate response (=early immune response [i.e. cytokines in serum, gene expression signature, white blood cells counts]) results available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils</title>
            <description>Levels of white blood cells (WBC) as absolute counts, neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS) and basophils (BAS) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. This outcome measure presents the raw data collected in percent (%), expressed in IH Center normalized levels based on raw data in % (IH normalized %), and concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>IH normalized ratio</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>WBC; Day 0 (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.498" lower_limit="0.323" upper_limit="0.608"/>
                  <measurement group_id="O2" value="0.509" lower_limit="0.422" upper_limit="0.93"/>
                  <measurement group_id="O3" value="0.341" lower_limit="0.143" upper_limit="0.756"/>
                  <measurement group_id="O4" value="0.43" lower_limit="0.246" upper_limit="0.517"/>
                  <measurement group_id="O5" value="0.479" lower_limit="0.329" upper_limit="0.608"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 0+ (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.702" lower_limit="0.427" upper_limit="0.886"/>
                  <measurement group_id="O2" value="1.123" lower_limit="0.476" upper_limit="1.205"/>
                  <measurement group_id="O3" value="0.578" lower_limit="0.395" upper_limit="1.051"/>
                  <measurement group_id="O4" value="0.647" lower_limit="0.518" upper_limit="0.926"/>
                  <measurement group_id="O5" value="0.662" lower_limit="0.498" upper_limit="0.927"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 1 (N=20,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.76" lower_limit="0.485" upper_limit="0.969"/>
                  <measurement group_id="O2" value="0.756" lower_limit="0.459" upper_limit="0.971"/>
                  <measurement group_id="O3" value="0.54" lower_limit="0.351" upper_limit="1.154"/>
                  <measurement group_id="O4" value="0.698" lower_limit="0.593" upper_limit="0.895"/>
                  <measurement group_id="O5" value="0.607" lower_limit="0.448" upper_limit="0.84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 30 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.456" lower_limit="0.246" upper_limit="0.644"/>
                  <measurement group_id="O2" value="0.596" lower_limit="0.219" upper_limit="0.878"/>
                  <measurement group_id="O3" value="0.263" lower_limit="0.193" upper_limit="0.549"/>
                  <measurement group_id="O4" value="0.385" lower_limit="0.249" upper_limit="0.479"/>
                  <measurement group_id="O5" value="0.517" lower_limit="0.392" upper_limit="0.684"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 30+ (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.69" lower_limit="0.546" upper_limit="0.844"/>
                  <measurement group_id="O2" value="0.789" lower_limit="0.479" upper_limit="1.098"/>
                  <measurement group_id="O3" value="0.574" lower_limit="0.371" upper_limit="0.814"/>
                  <measurement group_id="O4" value="0.556" lower_limit="0.356" upper_limit="0.737"/>
                  <measurement group_id="O5" value="0.76" lower_limit="0.479" upper_limit="0.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 31 (N=21,17,12,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.79" lower_limit="0.617" upper_limit="1.018"/>
                  <measurement group_id="O2" value="0.737" lower_limit="0.46" upper_limit="0.938"/>
                  <measurement group_id="O3" value="0.629" lower_limit="0.476" upper_limit="0.763"/>
                  <measurement group_id="O4" value="0.633" lower_limit="0.562" upper_limit="0.789"/>
                  <measurement group_id="O5" value="0.536" lower_limit="0.443" upper_limit="0.772"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 33 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.441" lower_limit="0.229" upper_limit="0.662"/>
                  <measurement group_id="O2" value="0.491" lower_limit="0.222" upper_limit="0.719"/>
                  <measurement group_id="O3" value="0.404" lower_limit="0.303" upper_limit="0.646"/>
                  <measurement group_id="O4" value="0.441" lower_limit="0.299" upper_limit="0.579"/>
                  <measurement group_id="O5" value="0.537" lower_limit="0.219" upper_limit="0.772"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 37 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.379" lower_limit="0.298" upper_limit="0.646"/>
                  <measurement group_id="O2" value="0.525" lower_limit="0.335" upper_limit="0.781"/>
                  <measurement group_id="O3" value="0.468" lower_limit="0.31" upper_limit="0.544"/>
                  <measurement group_id="O4" value="0.354" lower_limit="0.263" upper_limit="0.537"/>
                  <measurement group_id="O5" value="0.49" lower_limit="0.251" upper_limit="0.983"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 60 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.41" lower_limit="0.213" upper_limit="0.634"/>
                  <measurement group_id="O2" value="0.557" lower_limit="0.244" upper_limit="0.737"/>
                  <measurement group_id="O3" value="0.271" lower_limit="0.123" upper_limit="0.584"/>
                  <measurement group_id="O4" value="0.42" lower_limit="0.21" upper_limit="0.563"/>
                  <measurement group_id="O5" value="0.446" lower_limit="0.222" upper_limit="0.665"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 0 (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.648" lower_limit="0.422" upper_limit="0.83"/>
                  <measurement group_id="O2" value="0.53" lower_limit="0.478" upper_limit="0.894"/>
                  <measurement group_id="O3" value="0.58" lower_limit="0.3" upper_limit="0.837"/>
                  <measurement group_id="O4" value="0.663" lower_limit="0.343" upper_limit="0.85"/>
                  <measurement group_id="O5" value="0.445" lower_limit="0.41" upper_limit="0.541"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 0+ (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.84" lower_limit="0.652" upper_limit="0.957"/>
                  <measurement group_id="O2" value="0.752" lower_limit="0.627" upper_limit="0.993"/>
                  <measurement group_id="O3" value="0.693" lower_limit="0.47" upper_limit="0.797"/>
                  <measurement group_id="O4" value="0.767" lower_limit="0.581" upper_limit="0.87"/>
                  <measurement group_id="O5" value="0.654" lower_limit="0.443" upper_limit="0.713"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 1 (N=20,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.93" lower_limit="0.727" upper_limit="1.15"/>
                  <measurement group_id="O2" value="0.817" lower_limit="0.653" upper_limit="0.903"/>
                  <measurement group_id="O3" value="0.727" lower_limit="0.67" upper_limit="0.927"/>
                  <measurement group_id="O4" value="0.769" lower_limit="0.635" upper_limit="0.923"/>
                  <measurement group_id="O5" value="0.654" lower_limit="0.53" upper_limit="0.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 30 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.604" lower_limit="0.46" upper_limit="0.757"/>
                  <measurement group_id="O2" value="0.6" lower_limit="0.387" upper_limit="0.791"/>
                  <measurement group_id="O3" value="0.387" lower_limit="0.322" upper_limit="0.757"/>
                  <measurement group_id="O4" value="0.578" lower_limit="0.35" upper_limit="0.719"/>
                  <measurement group_id="O5" value="0.581" lower_limit="0.46" upper_limit="0.699"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 30+ (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" lower_limit="0.497" upper_limit="1.107"/>
                  <measurement group_id="O2" value="0.717" lower_limit="0.583" upper_limit="0.887"/>
                  <measurement group_id="O3" value="0.609" lower_limit="0.377" upper_limit="0.84"/>
                  <measurement group_id="O4" value="0.663" lower_limit="0.521" upper_limit="0.95"/>
                  <measurement group_id="O5" value="0.642" lower_limit="0.465" upper_limit="0.717"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 31 (N=21,17,12,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.161" lower_limit="1.067" upper_limit="1.373"/>
                  <measurement group_id="O2" value="0.959" lower_limit="0.797" upper_limit="1.135"/>
                  <measurement group_id="O3" value="0.921" lower_limit="0.478" upper_limit="1.118"/>
                  <measurement group_id="O4" value="0.78" lower_limit="0.672" upper_limit="0.943"/>
                  <measurement group_id="O5" value="0.589" lower_limit="0.357" upper_limit="0.684"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 33 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.591" lower_limit="0.447" upper_limit="0.787"/>
                  <measurement group_id="O2" value="0.509" lower_limit="0.275" upper_limit="0.69"/>
                  <measurement group_id="O3" value="0.539" lower_limit="0.34" upper_limit="0.657"/>
                  <measurement group_id="O4" value="0.587" lower_limit="0.426" upper_limit="0.819"/>
                  <measurement group_id="O5" value="0.567" lower_limit="0.457" upper_limit="0.653"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 37 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.63" lower_limit="0.459" upper_limit="0.726"/>
                  <measurement group_id="O2" value="0.652" lower_limit="0.503" upper_limit="0.77"/>
                  <measurement group_id="O3" value="0.443" lower_limit="0.313" upper_limit="0.553"/>
                  <measurement group_id="O4" value="0.569" lower_limit="0.365" upper_limit="0.823"/>
                  <measurement group_id="O5" value="0.542" lower_limit="0.373" upper_limit="0.67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 60 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.656" lower_limit="0.537" upper_limit="0.807"/>
                  <measurement group_id="O2" value="0.543" lower_limit="0.391" upper_limit="0.667"/>
                  <measurement group_id="O3" value="0.54" lower_limit="0.375" upper_limit="0.684"/>
                  <measurement group_id="O4" value="0.61" lower_limit="0.363" upper_limit="0.843"/>
                  <measurement group_id="O5" value="0.561" lower_limit="0.422" upper_limit="0.733"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 0 (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.474" lower_limit="0.345" upper_limit="0.607"/>
                  <measurement group_id="O2" value="0.366" lower_limit="0.341" upper_limit="0.524"/>
                  <measurement group_id="O3" value="0.531" lower_limit="0.359" upper_limit="0.839"/>
                  <measurement group_id="O4" value="0.403" lower_limit="0.235" upper_limit="0.557"/>
                  <measurement group_id="O5" value="0.68" lower_limit="0.459" upper_limit="0.779"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 0+ (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.328" lower_limit="0.045" upper_limit="0.438"/>
                  <measurement group_id="O2" value="0.407" lower_limit="0.048" upper_limit="0.552"/>
                  <measurement group_id="O3" value="0.543" lower_limit="0.41" upper_limit="0.679"/>
                  <measurement group_id="O4" value="0.361" lower_limit="0.148" upper_limit="0.479"/>
                  <measurement group_id="O5" value="0.609" lower_limit="0.354" upper_limit="0.745"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 1 (N=20,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.178" lower_limit="-0.136" upper_limit="0.316"/>
                  <measurement group_id="O2" value="0.272" lower_limit="0.093" upper_limit="0.341"/>
                  <measurement group_id="O3" value="0.412" lower_limit="0.19" upper_limit="0.521"/>
                  <measurement group_id="O4" value="0.283" lower_limit="0.059" upper_limit="0.472"/>
                  <measurement group_id="O5" value="0.478" lower_limit="0.324" upper_limit="0.597"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 30 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.452" lower_limit="0.274" upper_limit="0.552"/>
                  <measurement group_id="O2" value="0.51" lower_limit="0.221" upper_limit="0.538"/>
                  <measurement group_id="O3" value="0.528" lower_limit="0.336" upper_limit="0.745"/>
                  <measurement group_id="O4" value="0.433" lower_limit="0.207" upper_limit="0.634"/>
                  <measurement group_id="O5" value="0.536" lower_limit="0.335" upper_limit="0.838"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 30+ (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" lower_limit="0.026" upper_limit="0.513"/>
                  <measurement group_id="O2" value="0.386" lower_limit="0.222" upper_limit="0.5"/>
                  <measurement group_id="O3" value="0.497" lower_limit="0.345" upper_limit="0.831"/>
                  <measurement group_id="O4" value="0.413" lower_limit="0.266" upper_limit="0.479"/>
                  <measurement group_id="O5" value="0.54" lower_limit="0.313" upper_limit="0.628"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 31 (N=21,17,12,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.086" lower_limit="-0.2" upper_limit="0"/>
                  <measurement group_id="O2" value="-0.003" lower_limit="-0.179" upper_limit="0.269"/>
                  <measurement group_id="O3" value="0.15" lower_limit="-0.11" upper_limit="0.526"/>
                  <measurement group_id="O4" value="0.302" lower_limit="0.034" upper_limit="0.372"/>
                  <measurement group_id="O5" value="0.54" lower_limit="0.348" upper_limit="0.776"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 33 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.309" lower_limit="0.231" upper_limit="0.531"/>
                  <measurement group_id="O2" value="0.407" lower_limit="0.269" upper_limit="0.683"/>
                  <measurement group_id="O3" value="0.445" lower_limit="0.31" upper_limit="0.552"/>
                  <measurement group_id="O4" value="0.405" lower_limit="0.196" upper_limit="0.552"/>
                  <measurement group_id="O5" value="0.622" lower_limit="0.314" upper_limit="0.731"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 37 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.503" lower_limit="0.279" upper_limit="0.57"/>
                  <measurement group_id="O2" value="0.357" lower_limit="0.225" upper_limit="0.561"/>
                  <measurement group_id="O3" value="0.555" lower_limit="0.493" upper_limit="0.683"/>
                  <measurement group_id="O4" value="0.423" lower_limit="0.224" upper_limit="0.593"/>
                  <measurement group_id="O5" value="0.572" lower_limit="0.27" upper_limit="0.779"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 60 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.452" lower_limit="0.257" upper_limit="0.645"/>
                  <measurement group_id="O2" value="0.376" lower_limit="0.3" upper_limit="0.63"/>
                  <measurement group_id="O3" value="0.534" lower_limit="0.441" upper_limit="0.731"/>
                  <measurement group_id="O4" value="0.402" lower_limit="0.178" upper_limit="0.579"/>
                  <measurement group_id="O5" value="0.538" lower_limit="0.4" upper_limit="0.779"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 0 (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" lower_limit="0.356" upper_limit="0.589"/>
                  <measurement group_id="O2" value="0.311" lower_limit="0.222" upper_limit="0.489"/>
                  <measurement group_id="O3" value="0.439" lower_limit="0.389" upper_limit="0.522"/>
                  <measurement group_id="O4" value="0.51" lower_limit="0.4" upper_limit="0.64"/>
                  <measurement group_id="O5" value="0.489" lower_limit="0.356" upper_limit="0.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 0+ (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.422" lower_limit="0.311" upper_limit="0.533"/>
                  <measurement group_id="O2" value="0.367" lower_limit="0.32" upper_limit="0.4"/>
                  <measurement group_id="O3" value="0.367" lower_limit="0.3" upper_limit="0.567"/>
                  <measurement group_id="O4" value="0.439" lower_limit="0.321" upper_limit="0.54"/>
                  <measurement group_id="O5" value="0.389" lower_limit="0.322" upper_limit="0.456"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 1 (N=20,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.594" lower_limit="0.367" upper_limit="0.834"/>
                  <measurement group_id="O2" value="0.522" lower_limit="0.422" upper_limit="0.622"/>
                  <measurement group_id="O3" value="0.522" lower_limit="0.44" upper_limit="0.611"/>
                  <measurement group_id="O4" value="0.477" lower_limit="0.359" upper_limit="0.622"/>
                  <measurement group_id="O5" value="0.45" lower_limit="0.333" upper_limit="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 30 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.533" lower_limit="0.411" upper_limit="0.644"/>
                  <measurement group_id="O2" value="0.411" lower_limit="0.322" upper_limit="0.522"/>
                  <measurement group_id="O3" value="0.5" lower_limit="0.344" upper_limit="0.533"/>
                  <measurement group_id="O4" value="0.472" lower_limit="0.378" upper_limit="0.551"/>
                  <measurement group_id="O5" value="0.422" lower_limit="0.289" upper_limit="0.478"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 30+ (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.456" lower_limit="0.333" upper_limit="0.533"/>
                  <measurement group_id="O2" value="0.422" lower_limit="0.302" upper_limit="0.544"/>
                  <measurement group_id="O3" value="0.433" lower_limit="0.3" upper_limit="0.478"/>
                  <measurement group_id="O4" value="0.443" lower_limit="0.367" upper_limit="0.589"/>
                  <measurement group_id="O5" value="0.363" lower_limit="0.311" upper_limit="0.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 31 (N=21,17,12,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.533" lower_limit="0.333" upper_limit="0.667"/>
                  <measurement group_id="O2" value="0.544" lower_limit="0.444" upper_limit="0.756"/>
                  <measurement group_id="O3" value="0.632" lower_limit="0.4" upper_limit="0.833"/>
                  <measurement group_id="O4" value="0.427" lower_limit="0.333" upper_limit="0.6"/>
                  <measurement group_id="O5" value="0.478" lower_limit="0.278" upper_limit="0.611"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 33 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.767" lower_limit="0.533" upper_limit="1.056"/>
                  <measurement group_id="O2" value="0.578" lower_limit="0.378" upper_limit="0.711"/>
                  <measurement group_id="O3" value="0.656" lower_limit="0.389" upper_limit="0.733"/>
                  <measurement group_id="O4" value="0.549" lower_limit="0.389" upper_limit="0.656"/>
                  <measurement group_id="O5" value="0.472" lower_limit="0.278" upper_limit="0.578"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 37 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.478" lower_limit="0.4" upper_limit="0.544"/>
                  <measurement group_id="O2" value="0.433" lower_limit="0.311" upper_limit="0.5"/>
                  <measurement group_id="O3" value="0.433" lower_limit="0.289" upper_limit="0.533"/>
                  <measurement group_id="O4" value="0.472" lower_limit="0.311" upper_limit="0.567"/>
                  <measurement group_id="O5" value="0.394" lower_limit="0.256" upper_limit="0.522"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 60 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" lower_limit="0.367" upper_limit="0.567"/>
                  <measurement group_id="O2" value="0.467" lower_limit="0.378" upper_limit="0.556"/>
                  <measurement group_id="O3" value="0.456" lower_limit="0.333" upper_limit="0.511"/>
                  <measurement group_id="O4" value="0.461" lower_limit="0.356" upper_limit="0.6"/>
                  <measurement group_id="O5" value="0.344" lower_limit="0.256" upper_limit="0.556"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 0 (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" lower_limit="0.34" upper_limit="0.594"/>
                  <measurement group_id="O2" value="0.594" lower_limit="0.475" upper_limit="0.875"/>
                  <measurement group_id="O3" value="0.37" lower_limit="0.24" upper_limit="0.54"/>
                  <measurement group_id="O4" value="0.596" lower_limit="0.4" upper_limit="1.1"/>
                  <measurement group_id="O5" value="0.495" lower_limit="0.42" upper_limit="0.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 0+ (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" lower_limit="0.225" upper_limit="0.4"/>
                  <measurement group_id="O2" value="0.429" lower_limit="0.32" upper_limit="0.575"/>
                  <measurement group_id="O3" value="0.25" lower_limit="0.125" upper_limit="0.44"/>
                  <measurement group_id="O4" value="0.423" lower_limit="0.29" upper_limit="0.58"/>
                  <measurement group_id="O5" value="0.42" lower_limit="0.375" upper_limit="0.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 1 (N=20,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.291" lower_limit="0.194" upper_limit="0.478"/>
                  <measurement group_id="O2" value="0.48" lower_limit="0.36" upper_limit="0.754"/>
                  <measurement group_id="O3" value="0.313" lower_limit="0.24" upper_limit="0.531"/>
                  <measurement group_id="O4" value="0.464" lower_limit="0.28" upper_limit="0.775"/>
                  <measurement group_id="O5" value="0.41" lower_limit="0.26" upper_limit="0.66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 30 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.45" lower_limit="0.3" upper_limit="0.6"/>
                  <measurement group_id="O2" value="0.673" lower_limit="0.362" upper_limit="0.9"/>
                  <measurement group_id="O3" value="0.42" lower_limit="0.26" upper_limit="0.878"/>
                  <measurement group_id="O4" value="0.693" lower_limit="0.42" upper_limit="1.08"/>
                  <measurement group_id="O5" value="0.53" lower_limit="0.32" upper_limit="0.75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 30+ (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.32" lower_limit="0.25" upper_limit="0.348"/>
                  <measurement group_id="O2" value="0.475" lower_limit="0.375" upper_limit="0.696"/>
                  <measurement group_id="O3" value="0.34" lower_limit="0.174" upper_limit="0.6"/>
                  <measurement group_id="O4" value="0.496" lower_limit="0.355" upper_limit="0.7"/>
                  <measurement group_id="O5" value="0.38" lower_limit="0.348" upper_limit="0.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 31 (N=21,17,12,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.145" lower_limit="0.1" upper_limit="0.275"/>
                  <measurement group_id="O2" value="0.38" lower_limit="0.3" upper_limit="0.62"/>
                  <measurement group_id="O3" value="0.25" lower_limit="0.167" upper_limit="0.493"/>
                  <measurement group_id="O4" value="0.505" lower_limit="0.26" upper_limit="0.85"/>
                  <measurement group_id="O5" value="0.43" lower_limit="0.3" upper_limit="0.525"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 33 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" lower_limit="0.36" upper_limit="0.7"/>
                  <measurement group_id="O2" value="0.667" lower_limit="0.52" upper_limit="0.825"/>
                  <measurement group_id="O3" value="0.58" lower_limit="0.26" upper_limit="1.02"/>
                  <measurement group_id="O4" value="0.645" lower_limit="0.377" upper_limit="0.825"/>
                  <measurement group_id="O5" value="0.443" lower_limit="0.36" upper_limit="0.64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 37 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.46" lower_limit="0.325" upper_limit="0.625"/>
                  <measurement group_id="O2" value="0.64" lower_limit="0.42" upper_limit="0.768"/>
                  <measurement group_id="O3" value="0.44" lower_limit="0.3" upper_limit="0.939"/>
                  <measurement group_id="O4" value="0.69" lower_limit="0.452" upper_limit="1.188"/>
                  <measurement group_id="O5" value="0.52" lower_limit="0.28" upper_limit="0.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 60 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.45" lower_limit="0.36" upper_limit="0.575"/>
                  <measurement group_id="O2" value="0.652" lower_limit="0.32" upper_limit="1.1"/>
                  <measurement group_id="O3" value="0.38" lower_limit="0.3" upper_limit="0.653"/>
                  <measurement group_id="O4" value="0.709" lower_limit="0.44" upper_limit="1.058"/>
                  <measurement group_id="O5" value="0.465" lower_limit="0.28" upper_limit="0.623"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 0 (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.25" lower_limit="0.158" upper_limit="0.35"/>
                  <measurement group_id="O2" value="0.35" lower_limit="0.143" upper_limit="0.5"/>
                  <measurement group_id="O3" value="0.325" lower_limit="0.214" upper_limit="0.421"/>
                  <measurement group_id="O4" value="0.25" lower_limit="0.15" upper_limit="0.455"/>
                  <measurement group_id="O5" value="0.375" lower_limit="0.25" upper_limit="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 0+ (N=21,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.25" lower_limit="0.2" upper_limit="0.35"/>
                  <measurement group_id="O2" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                  <measurement group_id="O3" value="0.232" lower_limit="0.158" upper_limit="0.4"/>
                  <measurement group_id="O4" value="0.25" lower_limit="0.1" upper_limit="0.3"/>
                  <measurement group_id="O5" value="0.225" lower_limit="0.15" upper_limit="0.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 1 (N=20,17,14,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.232" lower_limit="0.105" upper_limit="0.35"/>
                  <measurement group_id="O2" value="0.25" lower_limit="0.2" upper_limit="0.35"/>
                  <measurement group_id="O3" value="0.286" lower_limit="0.15" upper_limit="0.4"/>
                  <measurement group_id="O4" value="0.179" lower_limit="0.1" upper_limit="0.3"/>
                  <measurement group_id="O5" value="0.25" lower_limit="0.15" upper_limit="0.421"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 30 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" lower_limit="0.25" upper_limit="0.5"/>
                  <measurement group_id="O2" value="0.35" lower_limit="0.25" upper_limit="0.5"/>
                  <measurement group_id="O3" value="0.35" lower_limit="0.182" upper_limit="0.45"/>
                  <measurement group_id="O4" value="0.333" lower_limit="0.2" upper_limit="0.5"/>
                  <measurement group_id="O5" value="0.3" lower_limit="0.25" upper_limit="0.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 30+ (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.25" lower_limit="0.2" upper_limit="0.368"/>
                  <measurement group_id="O2" value="0.25" lower_limit="0.214" upper_limit="0.45"/>
                  <measurement group_id="O3" value="0.25" lower_limit="0.15" upper_limit="0.4"/>
                  <measurement group_id="O4" value="0.211" lower_limit="0.15" upper_limit="0.45"/>
                  <measurement group_id="O5" value="0.333" lower_limit="0.25" upper_limit="0.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 31 (N=21,17,12,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.2" lower_limit="0.15" upper_limit="0.3"/>
                  <measurement group_id="O2" value="0.3" lower_limit="0.211" upper_limit="0.4"/>
                  <measurement group_id="O3" value="0.3" lower_limit="0.146" upper_limit="0.325"/>
                  <measurement group_id="O4" value="0.25" lower_limit="0.158" upper_limit="0.364"/>
                  <measurement group_id="O5" value="0.325" lower_limit="0.211" upper_limit="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 33 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.35" lower_limit="0.3" upper_limit="0.526"/>
                  <measurement group_id="O2" value="0.4" lower_limit="0.25" upper_limit="0.65"/>
                  <measurement group_id="O3" value="0.35" lower_limit="0.2" upper_limit="0.5"/>
                  <measurement group_id="O4" value="0.3" lower_limit="0.182" upper_limit="0.5"/>
                  <measurement group_id="O5" value="0.3" lower_limit="0.263" upper_limit="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 37 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.316" lower_limit="0.25" upper_limit="0.45"/>
                  <measurement group_id="O2" value="0.421" lower_limit="0.3" upper_limit="0.55"/>
                  <measurement group_id="O3" value="0.286" lower_limit="0.2" upper_limit="0.4"/>
                  <measurement group_id="O4" value="0.286" lower_limit="0.15" upper_limit="0.5"/>
                  <measurement group_id="O5" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 60 (N=21,17,13,22,14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                  <measurement group_id="O2" value="0.4" lower_limit="0.3" upper_limit="0.6"/>
                  <measurement group_id="O3" value="0.4" lower_limit="0.182" upper_limit="0.55"/>
                  <measurement group_id="O4" value="0.25" lower_limit="0.15" upper_limit="0.421"/>
                  <measurement group_id="O5" value="0.308" lower_limit="0.25" upper_limit="0.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils</title>
        <description>Levels of white blood cells (WBC) as absolute counts, neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS) and basophils (BAS) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. This outcome measure presents the raw data collected in percent (%), expressed in IH Center normalized levels based on raw data in % (IH normalized %), and concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
        <time_frame>At Days 0, 30, 37 and 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 1 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. The GSK223192A vaccine antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 2 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. The GSK223192A vaccine antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 3 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. The GSK223192A vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the Fendrix Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of Fendrix™, at Days 0 and 30. The Fendrix™ vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the Engerix-B Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of Engerix-B™, at Days 0 and 30. The Engerix-B™ vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="47"/>
                  <measurement group_id="O3" value="42"/>
                  <measurement group_id="O4" value="43"/>
                  <measurement group_id="O5" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils</title>
            <description>Levels of white blood cells (WBC) as absolute counts, neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS) and basophils (BAS) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. This outcome measure presents the raw data collected in percent (%), expressed in IH Center normalized levels based on raw data in % (IH normalized %), and concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
            <units>IH normalized ratio</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>WBC; Day 0 (N=47,47,42,43,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.426" lower_limit="0.262" upper_limit="0.79"/>
                  <measurement group_id="O2" value="0.413" lower_limit="0.246" upper_limit="0.857"/>
                  <measurement group_id="O3" value="0.497" lower_limit="0.273" upper_limit="0.722"/>
                  <measurement group_id="O4" value="0.672" lower_limit="0.344" upper_limit="0.912"/>
                  <measurement group_id="O5" value="0.465" lower_limit="0.258" upper_limit="0.722"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 30 (N=47,47,41,41,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.492" lower_limit="0.262" upper_limit="0.618"/>
                  <measurement group_id="O2" value="0.426" lower_limit="0.289" upper_limit="0.704"/>
                  <measurement group_id="O3" value="0.428" lower_limit="0.258" upper_limit="0.697"/>
                  <measurement group_id="O4" value="0.573" lower_limit="0.221" upper_limit="0.963"/>
                  <measurement group_id="O5" value="0.455" lower_limit="0.332" upper_limit="0.786"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 37 (N=44,47,38,40,43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.455" lower_limit="0.293" upper_limit="0.644"/>
                  <measurement group_id="O2" value="0.574" lower_limit="0.328" upper_limit="0.784"/>
                  <measurement group_id="O3" value="0.405" lower_limit="0.243" upper_limit="0.77"/>
                  <measurement group_id="O4" value="0.523" lower_limit="0.284" upper_limit="0.81"/>
                  <measurement group_id="O5" value="0.426" lower_limit="0.275" upper_limit="0.826"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC; Day 60 (N=47,46,37,41,45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.44" lower_limit="0.311" upper_limit="0.718"/>
                  <measurement group_id="O2" value="0.44" lower_limit="0.222" upper_limit="0.697"/>
                  <measurement group_id="O3" value="0.439" lower_limit="0.166" upper_limit="0.754"/>
                  <measurement group_id="O4" value="0.607" lower_limit="0.426" upper_limit="0.967"/>
                  <measurement group_id="O5" value="0.478" lower_limit="0.28" upper_limit="0.832"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 0 (N=47,46,42,43,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.534" lower_limit="0.291" upper_limit="0.752"/>
                  <measurement group_id="O2" value="0.559" lower_limit="0.224" upper_limit="0.838"/>
                  <measurement group_id="O3" value="0.426" lower_limit="0.297" upper_limit="0.633"/>
                  <measurement group_id="O4" value="0.503" lower_limit="0.3" upper_limit="0.788"/>
                  <measurement group_id="O5" value="0.458" lower_limit="0.256" upper_limit="0.705"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 30 (N=47,47,41,41,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.457" lower_limit="0.17" upper_limit="0.703"/>
                  <measurement group_id="O2" value="0.524" lower_limit="0.26" upper_limit="0.686"/>
                  <measurement group_id="O3" value="0.491" lower_limit="0.075" upper_limit="0.726"/>
                  <measurement group_id="O4" value="0.5" lower_limit="0.291" upper_limit="0.714"/>
                  <measurement group_id="O5" value="0.532" lower_limit="0.326" upper_limit="0.796"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 37 (N=44,47,38,40,43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.417" lower_limit="0.225" upper_limit="0.698"/>
                  <measurement group_id="O2" value="0.5" lower_limit="0.292" upper_limit="0.703"/>
                  <measurement group_id="O3" value="0.436" lower_limit="0.125" upper_limit="0.708"/>
                  <measurement group_id="O4" value="0.458" lower_limit="0.083" upper_limit="0.603"/>
                  <measurement group_id="O5" value="0.491" lower_limit="0.334" upper_limit="0.726"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU; Day 60 (N=47,46,37,41,45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.47" lower_limit="0.333" upper_limit="0.715"/>
                  <measurement group_id="O2" value="0.496" lower_limit="0.3" upper_limit="0.772"/>
                  <measurement group_id="O3" value="0.389" lower_limit="0.167" upper_limit="0.57"/>
                  <measurement group_id="O4" value="0.471" lower_limit="0.194" upper_limit="0.671"/>
                  <measurement group_id="O5" value="0.474" lower_limit="0.294" upper_limit="0.731"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 0 (N=47,46,42,43,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.408" lower_limit="0.183" upper_limit="0.6"/>
                  <measurement group_id="O2" value="0.388" lower_limit="0.128" upper_limit="0.646"/>
                  <measurement group_id="O3" value="0.552" lower_limit="0.248" upper_limit="0.757"/>
                  <measurement group_id="O4" value="0.37" lower_limit="-0.05" upper_limit="0.613"/>
                  <measurement group_id="O5" value="0.45" lower_limit="0.15" upper_limit="0.66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 30 (N=47,47,41,41,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.45" lower_limit="0.24" upper_limit="0.7"/>
                  <measurement group_id="O2" value="0.404" lower_limit="0.26" upper_limit="0.69"/>
                  <measurement group_id="O3" value="0.55" lower_limit="0.228" upper_limit="0.893"/>
                  <measurement group_id="O4" value="0.373" lower_limit="0.15" upper_limit="0.69"/>
                  <measurement group_id="O5" value="0.43" lower_limit="0.111" upper_limit="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 37 (N=44,47,38,40,43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.514" lower_limit="0.263" upper_limit="0.713"/>
                  <measurement group_id="O2" value="0.433" lower_limit="0.183" upper_limit="0.62"/>
                  <measurement group_id="O3" value="0.605" lower_limit="0.291" upper_limit="0.791"/>
                  <measurement group_id="O4" value="0.492" lower_limit="0.334" upper_limit="0.7"/>
                  <measurement group_id="O5" value="0.43" lower_limit="0.122" upper_limit="0.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM; Day 60 (N=47,46,37,41,45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.45" lower_limit="0.177" upper_limit="0.634"/>
                  <measurement group_id="O2" value="0.388" lower_limit="0.168" upper_limit="0.65"/>
                  <measurement group_id="O3" value="0.578" lower_limit="0.38" upper_limit="0.9"/>
                  <measurement group_id="O4" value="0.426" lower_limit="0.25" upper_limit="0.683"/>
                  <measurement group_id="O5" value="0.417" lower_limit="0.233" upper_limit="0.593"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 0 (N=47,46,42,43,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.52" lower_limit="0.256" upper_limit="0.675"/>
                  <measurement group_id="O2" value="0.473" lower_limit="0.333" upper_limit="0.64"/>
                  <measurement group_id="O3" value="0.5" lower_limit="0.325" upper_limit="0.656"/>
                  <measurement group_id="O4" value="0.438" lower_limit="0.3" upper_limit="0.611"/>
                  <measurement group_id="O5" value="0.55" lower_limit="0.288" upper_limit="0.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 30 (N=47,47,41,41,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.556" lower_limit="0.367" upper_limit="0.765"/>
                  <measurement group_id="O2" value="0.471" lower_limit="0.267" upper_limit="0.783"/>
                  <measurement group_id="O3" value="0.538" lower_limit="0.311" upper_limit="0.667"/>
                  <measurement group_id="O4" value="0.431" lower_limit="0.319" upper_limit="0.733"/>
                  <measurement group_id="O5" value="0.506" lower_limit="0.3" upper_limit="0.667"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 37 (N=44,47,38,40,43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.471" lower_limit="0.298" upper_limit="0.673"/>
                  <measurement group_id="O2" value="0.456" lower_limit="0.333" upper_limit="0.738"/>
                  <measurement group_id="O3" value="0.465" lower_limit="0.233" upper_limit="0.66"/>
                  <measurement group_id="O4" value="0.465" lower_limit="0.261" upper_limit="0.744"/>
                  <measurement group_id="O5" value="0.5" lower_limit="0.349" upper_limit="0.667"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON; Day 60 (N=47,46,37,41,45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.463" lower_limit="0.333" upper_limit="0.625"/>
                  <measurement group_id="O2" value="0.41" lower_limit="0.256" upper_limit="0.8"/>
                  <measurement group_id="O3" value="0.444" lower_limit="0.222" upper_limit="0.688"/>
                  <measurement group_id="O4" value="0.456" lower_limit="0.322" upper_limit="0.733"/>
                  <measurement group_id="O5" value="0.5" lower_limit="0.363" upper_limit="0.738"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 0 (N=47,46,42,43,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.304" lower_limit="0.12" upper_limit="0.582"/>
                  <measurement group_id="O2" value="0.29" lower_limit="0.164" upper_limit="0.775"/>
                  <measurement group_id="O3" value="0.275" lower_limit="0.149" upper_limit="0.575"/>
                  <measurement group_id="O4" value="0.299" lower_limit="0.15" upper_limit="0.667"/>
                  <measurement group_id="O5" value="0.319" lower_limit="0.149" upper_limit="0.612"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 30 (N=47,47,41,41,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" lower_limit="0.16" upper_limit="0.851"/>
                  <measurement group_id="O2" value="0.4" lower_limit="0.179" upper_limit="0.806"/>
                  <measurement group_id="O3" value="0.35" lower_limit="0.225" upper_limit="0.49"/>
                  <measurement group_id="O4" value="0.375" lower_limit="0.269" upper_limit="0.716"/>
                  <measurement group_id="O5" value="0.333" lower_limit="0.174" upper_limit="0.612"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 37 (N=44,47,38,40,43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.409" lower_limit="0.239" upper_limit="0.7"/>
                  <measurement group_id="O2" value="0.35" lower_limit="0.179" upper_limit="0.667"/>
                  <measurement group_id="O3" value="0.329" lower_limit="0.225" upper_limit="0.475"/>
                  <measurement group_id="O4" value="0.496" lower_limit="0.308" upper_limit="1"/>
                  <measurement group_id="O5" value="0.522" lower_limit="0.224" upper_limit="0.716"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS; Day 60 (N=47,46,37,41,45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.429" lower_limit="0.209" upper_limit="0.696"/>
                  <measurement group_id="O2" value="0.324" lower_limit="0.164" upper_limit="0.661"/>
                  <measurement group_id="O3" value="0.299" lower_limit="0.104" upper_limit="0.44"/>
                  <measurement group_id="O4" value="0.347" lower_limit="0.209" upper_limit="0.68"/>
                  <measurement group_id="O5" value="0.388" lower_limit="0.164" upper_limit="0.625"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 0 (N=47,46,42,43,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.263" lower_limit="0.118" upper_limit="0.4"/>
                  <measurement group_id="O2" value="0.286" lower_limit="0.176" upper_limit="0.5"/>
                  <measurement group_id="O3" value="0.3" lower_limit="0.171" upper_limit="0.4"/>
                  <measurement group_id="O4" value="0.353" lower_limit="0.229" upper_limit="0.6"/>
                  <measurement group_id="O5" value="0.353" lower_limit="0.118" upper_limit="0.471"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 30 (N=47,47,41,41,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" lower_limit="0.171" upper_limit="0.471"/>
                  <measurement group_id="O2" value="0.294" lower_limit="0.171" upper_limit="0.5"/>
                  <measurement group_id="O3" value="0.316" lower_limit="0.176" upper_limit="0.4"/>
                  <measurement group_id="O4" value="0.294" lower_limit="0.2" upper_limit="0.474"/>
                  <measurement group_id="O5" value="0.316" lower_limit="0.176" upper_limit="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 37 (N=44,47,38,40,43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.351" lower_limit="0.249" upper_limit="0.536"/>
                  <measurement group_id="O2" value="0.294" lower_limit="0.114" upper_limit="0.4"/>
                  <measurement group_id="O3" value="0.377" lower_limit="0.211" upper_limit="0.6"/>
                  <measurement group_id="O4" value="0.353" lower_limit="0.174" upper_limit="0.5"/>
                  <measurement group_id="O5" value="0.3" lower_limit="0.176" upper_limit="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS; Day 60 (N=47,46,37,41,45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" lower_limit="0.143" upper_limit="0.5"/>
                  <measurement group_id="O2" value="0.2" lower_limit="0.118" upper_limit="0.4"/>
                  <measurement group_id="O3" value="0.4" lower_limit="0.176" upper_limit="0.5"/>
                  <measurement group_id="O4" value="0.343" lower_limit="0.286" upper_limit="0.5"/>
                  <measurement group_id="O5" value="0.286" lower_limit="0.171" upper_limit="0.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Levels of Red Blood Cells and Platelets</title>
        <description>Analysis of levels of red blood cells (RBC) and platelets (PLA) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure presents the raw data collected in absolute count, expressed in IH Center normalized levels based on absolute count data (IH normalized abs. count).</description>
        <time_frame>At Days 0, 30, 37 and 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="142"/>
                  <measurement group_id="O3" value="141"/>
                  <measurement group_id="O4" value="145"/>
                  <measurement group_id="O5" value="142"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Normalized Levels of Red Blood Cells and Platelets</title>
            <description>Analysis of levels of red blood cells (RBC) and platelets (PLA) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure presents the raw data collected in absolute count, expressed in IH Center normalized levels based on absolute count data (IH normalized abs. count).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>RBC; Day 0 (N=143,142,141,145,142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.45" lower_limit="4.269" upper_limit="4.618"/>
                  <measurement group_id="O2" value="4.433" lower_limit="4.265" upper_limit="4.657"/>
                  <measurement group_id="O3" value="4.464" lower_limit="4.26" upper_limit="4.662"/>
                  <measurement group_id="O4" value="4.38" lower_limit="4.243" upper_limit="4.6"/>
                  <measurement group_id="O5" value="4.456" lower_limit="4.293" upper_limit="4.65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC; Day 30 (N=141,139,138,140,139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.461" lower_limit="4.278" upper_limit="4.584"/>
                  <measurement group_id="O2" value="4.382" lower_limit="4.24" upper_limit="4.569"/>
                  <measurement group_id="O3" value="4.423" lower_limit="4.257" upper_limit="4.65"/>
                  <measurement group_id="O4" value="4.388" lower_limit="4.225" upper_limit="4.57"/>
                  <measurement group_id="O5" value="4.486" lower_limit="4.243" upper_limit="4.651"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC; Day 37 (N=128,124,120,126,121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.372" lower_limit="4.23" upper_limit="4.534"/>
                  <measurement group_id="O2" value="4.346" lower_limit="4.162" upper_limit="4.514"/>
                  <measurement group_id="O3" value="4.395" lower_limit="4.2" upper_limit="4.583"/>
                  <measurement group_id="O4" value="4.37" lower_limit="4.206" upper_limit="4.521"/>
                  <measurement group_id="O5" value="4.388" lower_limit="4.23" upper_limit="4.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC; Day 60 (N=141,140,133,137,138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.421" lower_limit="4.243" upper_limit="4.555"/>
                  <measurement group_id="O2" value="4.393" lower_limit="4.23" upper_limit="4.57"/>
                  <measurement group_id="O3" value="4.364" lower_limit="4.214" upper_limit="4.579"/>
                  <measurement group_id="O4" value="4.371" lower_limit="4.219" upper_limit="4.56"/>
                  <measurement group_id="O5" value="4.4" lower_limit="4.231" upper_limit="4.579"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA; Day 0 (N=143,142,141,145,142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="269318.18" lower_limit="237500" upper_limit="309000"/>
                  <measurement group_id="O2" value="270833.33" lower_limit="229000" upper_limit="313000"/>
                  <measurement group_id="O3" value="270000" lower_limit="223333.33" upper_limit="309000"/>
                  <measurement group_id="O4" value="267187.5" lower_limit="232000" upper_limit="325000"/>
                  <measurement group_id="O5" value="259000" lower_limit="232000" upper_limit="308333.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA; Day 30 (N=141,139,138,140,139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="261363.64" lower_limit="229166.67" upper_limit="305000"/>
                  <measurement group_id="O2" value="262000" lower_limit="228000" upper_limit="304000"/>
                  <measurement group_id="O3" value="260470.78" lower_limit="222183.1" upper_limit="317410.71"/>
                  <measurement group_id="O4" value="274431.82" lower_limit="232071.43" upper_limit="322206.9"/>
                  <measurement group_id="O5" value="258333.33" lower_limit="218661.97" upper_limit="302288.73"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA; Day 37 (N=128,124,120,126,121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="295000" lower_limit="249166.67" upper_limit="338690.14"/>
                  <measurement group_id="O2" value="274431.82" lower_limit="245596.15" upper_limit="333173.08"/>
                  <measurement group_id="O3" value="269000" lower_limit="230403.85" upper_limit="321333.33"/>
                  <measurement group_id="O4" value="282477.27" lower_limit="242500" upper_limit="335000"/>
                  <measurement group_id="O5" value="268622.45" lower_limit="228000" upper_limit="322000"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA; Day 60 (N=141,140,133,137,138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="263333.33" lower_limit="230952.38" upper_limit="307954.55"/>
                  <measurement group_id="O2" value="267045.46" lower_limit="221666.67" upper_limit="307477.27"/>
                  <measurement group_id="O3" value="259000" lower_limit="224038.46" upper_limit="309000"/>
                  <measurement group_id="O4" value="273239.44" lower_limit="243181.82" upper_limit="328409.09"/>
                  <measurement group_id="O5" value="262588.03" lower_limit="228000" upper_limit="307000"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Levels of Haemoglobin, Alanine Aminotransferase and Aspartate Aminotransferase</title>
        <description>Analysis of levels of haemoglobin (Hgb), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure presents the raw data collected in absolute count, expressed in IH Center normalized levels based on absolute count data (IH normalized abs. count).</description>
        <time_frame>At Days 0, 30, 37 and 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="142"/>
                  <measurement group_id="O3" value="141"/>
                  <measurement group_id="O4" value="145"/>
                  <measurement group_id="O5" value="142"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Normalized Levels of Haemoglobin, Alanine Aminotransferase and Aspartate Aminotransferase</title>
            <description>Analysis of levels of haemoglobin (Hgb), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure presents the raw data collected in absolute count, expressed in IH Center normalized levels based on absolute count data (IH normalized abs. count).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Hgb; Day 0 (N=143,142,141,145,142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.4" lower_limit="12.825" upper_limit="13.875"/>
                  <measurement group_id="O2" value="13.35" lower_limit="12.75" upper_limit="13.9"/>
                  <measurement group_id="O3" value="13.4" lower_limit="12.9" upper_limit="13.725"/>
                  <measurement group_id="O4" value="13.275" lower_limit="12.7" upper_limit="13.725"/>
                  <measurement group_id="O5" value="13.35" lower_limit="12.825" upper_limit="13.909"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb; Day 30 (N=141,139,138,140,139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.35" lower_limit="12.886" upper_limit="13.725"/>
                  <measurement group_id="O2" value="13.186" lower_limit="12.7" upper_limit="13.725"/>
                  <measurement group_id="O3" value="13.275" lower_limit="12.7" upper_limit="13.575"/>
                  <measurement group_id="O4" value="13.121" lower_limit="12.501" upper_limit="13.715"/>
                  <measurement group_id="O5" value="13.35" lower_limit="12.73" upper_limit="13.875"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb; Day 37 (N=128,124,120,126,121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.05" lower_limit="12.434" upper_limit="13.575"/>
                  <measurement group_id="O2" value="12.957" lower_limit="12.513" upper_limit="13.382"/>
                  <measurement group_id="O3" value="13.025" lower_limit="12.6" upper_limit="13.463"/>
                  <measurement group_id="O4" value="13.05" lower_limit="12.525" upper_limit="13.568"/>
                  <measurement group_id="O5" value="13.05" lower_limit="12.5" upper_limit="13.705"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb; Day 60 (N=141,140,133,137,138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.275" lower_limit="12.75" upper_limit="13.725"/>
                  <measurement group_id="O2" value="13.136" lower_limit="12.468" upper_limit="13.675"/>
                  <measurement group_id="O3" value="13.1" lower_limit="12.6" upper_limit="13.575"/>
                  <measurement group_id="O4" value="12.975" lower_limit="12.467" upper_limit="13.568"/>
                  <measurement group_id="O5" value="13.163" lower_limit="12.545" upper_limit="13.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT; Day 0 (N=143,142,141,145,142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.086" lower_limit="15.5" upper_limit="31.061"/>
                  <measurement group_id="O2" value="18.792" lower_limit="13.968" upper_limit="27.675"/>
                  <measurement group_id="O3" value="18.636" lower_limit="14.9" upper_limit="25.42"/>
                  <measurement group_id="O4" value="21.8" lower_limit="15.6" upper_limit="29.294"/>
                  <measurement group_id="O5" value="21.32" lower_limit="16" upper_limit="31.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT; Day 30 (N=141,139,138,140,139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.32" lower_limit="15.375" upper_limit="32.303"/>
                  <measurement group_id="O2" value="18.743" lower_limit="13.12" upper_limit="26.2"/>
                  <measurement group_id="O3" value="19.897" lower_limit="14.548" upper_limit="26.9"/>
                  <measurement group_id="O4" value="20.5" lower_limit="15.375" upper_limit="27.89"/>
                  <measurement group_id="O5" value="18.743" lower_limit="14.9" upper_limit="26.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT; Day 37 (N=128,124,120,126,121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.221" lower_limit="15.623" upper_limit="33.061"/>
                  <measurement group_id="O2" value="18.767" lower_limit="13.021" upper_limit="25.574"/>
                  <measurement group_id="O3" value="18.596" lower_limit="13.999" upper_limit="26.917"/>
                  <measurement group_id="O4" value="20.7" lower_limit="15.229" upper_limit="27.06"/>
                  <measurement group_id="O5" value="19.8" lower_limit="14.76" upper_limit="27.88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT; Day 60 (N=141,140,134,137,138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.161" lower_limit="14.909" upper_limit="29.042"/>
                  <measurement group_id="O2" value="17.447" lower_limit="13.16" upper_limit="24.848"/>
                  <measurement group_id="O3" value="18.07" lower_limit="13.146" upper_limit="27.333"/>
                  <measurement group_id="O4" value="20.541" lower_limit="15.58" upper_limit="28.576"/>
                  <measurement group_id="O5" value="18.518" lower_limit="13.94" upper_limit="28.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST; Day 0 (N=143,142,141,145,142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21" lower_limit="18" upper_limit="25.065"/>
                  <measurement group_id="O2" value="20" lower_limit="16.28" upper_limit="24.9"/>
                  <measurement group_id="O3" value="20" lower_limit="17" upper_limit="23.727"/>
                  <measurement group_id="O4" value="21" lower_limit="16.71" upper_limit="24.8"/>
                  <measurement group_id="O5" value="20.478" lower_limit="17.8" upper_limit="24.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST; Day 30 (N=141,139,138,140,139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.72" lower_limit="18" upper_limit="27"/>
                  <measurement group_id="O2" value="19.24" lower_limit="16.28" upper_limit="23.7"/>
                  <measurement group_id="O3" value="20.188" lower_limit="17.76" upper_limit="24.314"/>
                  <measurement group_id="O4" value="20" lower_limit="16.555" upper_limit="25.032"/>
                  <measurement group_id="O5" value="19.097" lower_limit="16.71" upper_limit="23.871"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST; Day 37 (N=128,124,120,126,121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.881" lower_limit="17.01" upper_limit="25.371"/>
                  <measurement group_id="O2" value="19.097" lower_limit="15.35" upper_limit="23.433"/>
                  <measurement group_id="O3" value="20.043" lower_limit="17.267" upper_limit="22.97"/>
                  <measurement group_id="O4" value="20" lower_limit="16.5" upper_limit="25.065"/>
                  <measurement group_id="O5" value="20" lower_limit="16.28" upper_limit="23.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST; Day 60 (N=141,140,134,137,138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.72" lower_limit="17.02" upper_limit="24.667"/>
                  <measurement group_id="O2" value="17.986" lower_limit="14.971" upper_limit="22.45"/>
                  <measurement group_id="O3" value="20.76" lower_limit="16.313" upper_limit="23.871"/>
                  <measurement group_id="O4" value="21" lower_limit="17" upper_limit="24.314"/>
                  <measurement group_id="O5" value="19.339" lower_limit="16.6" upper_limit="24.314"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Levels of Serum Creatinine, Urea and Lactate Dehydrogenase</title>
        <description>Analysis of levels of serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure presents the raw data collected in absolute count, expressed in IH Center normalized levels based on absolute count data (IH normalized abs. count).</description>
        <time_frame>At Days 0, 30, 37 and 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="142"/>
                  <measurement group_id="O3" value="141"/>
                  <measurement group_id="O4" value="145"/>
                  <measurement group_id="O5" value="142"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Normalized Levels of Serum Creatinine, Urea and Lactate Dehydrogenase</title>
            <description>Analysis of levels of serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) were assessed with reference to the range observed at the Immune Health (IH) Centre in La Louvière, Belgium. Levels are presented as normalized levels vs. the IH center. Normalization was performed as follows: (Raw result – lower limit normal (LLN) at the IH center) divided by (Upper Limit Normal (ULN) at the IH center minus LLN at the IH center). This outcome measure presents the raw data collected in absolute count, expressed in IH Center normalized levels based on absolute count data (IH normalized abs. count).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>S-CREA; Day 0 (N=143,142,141,145,142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.893" lower_limit="0.745" upper_limit="1.046"/>
                  <measurement group_id="O2" value="0.841" lower_limit="0.705" upper_limit="0.982"/>
                  <measurement group_id="O3" value="0.889" lower_limit="0.76" upper_limit="1.02"/>
                  <measurement group_id="O4" value="0.86" lower_limit="0.722" upper_limit="1.025"/>
                  <measurement group_id="O5" value="0.85" lower_limit="0.718" upper_limit="1.043"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA, at Day 30 (N=141,140,138,140,139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" lower_limit="0.764" upper_limit="1.044"/>
                  <measurement group_id="O2" value="0.84" lower_limit="0.7" upper_limit="0.983"/>
                  <measurement group_id="O3" value="0.874" lower_limit="0.74" upper_limit="1.03"/>
                  <measurement group_id="O4" value="0.888" lower_limit="0.718" upper_limit="1.046"/>
                  <measurement group_id="O5" value="0.87" lower_limit="0.73" upper_limit="1.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA; Day 37 (N=128,124,120,126,120)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.906" lower_limit="0.737" upper_limit="1.037"/>
                  <measurement group_id="O2" value="0.83" lower_limit="0.701" upper_limit="0.98"/>
                  <measurement group_id="O3" value="0.883" lower_limit="0.719" upper_limit="1.042"/>
                  <measurement group_id="O4" value="0.92" lower_limit="0.74" upper_limit="1.043"/>
                  <measurement group_id="O5" value="0.909" lower_limit="0.741" upper_limit="1.034"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA; Day 60 (N=141,140,134,137,138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.92" lower_limit="0.75" upper_limit="1.063"/>
                  <measurement group_id="O2" value="0.84" lower_limit="0.727" upper_limit="1.003"/>
                  <measurement group_id="O3" value="0.873" lower_limit="0.757" upper_limit="1.043"/>
                  <measurement group_id="O4" value="0.934" lower_limit="0.76" upper_limit="1.052"/>
                  <measurement group_id="O5" value="0.915" lower_limit="0.77" upper_limit="1.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA; Day 0 (N=143,142,141,145,142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.5" lower_limit="25.333" upper_limit="33.5"/>
                  <measurement group_id="O2" value="28.667" lower_limit="24.895" upper_limit="32.833"/>
                  <measurement group_id="O3" value="30.095" lower_limit="25.7" upper_limit="34.5"/>
                  <measurement group_id="O4" value="30" lower_limit="26.167" upper_limit="34.5"/>
                  <measurement group_id="O5" value="29.202" lower_limit="25.11" upper_limit="33.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA; Day 30 (N=141,140,138,140,139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.127" lower_limit="25.946" upper_limit="33.667"/>
                  <measurement group_id="O2" value="28.667" lower_limit="25.333" upper_limit="32.988"/>
                  <measurement group_id="O3" value="30.462" lower_limit="26.524" upper_limit="34.5"/>
                  <measurement group_id="O4" value="30.048" lower_limit="26.293" upper_limit="34.404"/>
                  <measurement group_id="O5" value="30.095" lower_limit="24.692" upper_limit="34.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA; Day 37 (N=128,124,120,126,121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.5" lower_limit="25.1" upper_limit="33.533"/>
                  <measurement group_id="O2" value="27.833" lower_limit="23.623" upper_limit="31.183"/>
                  <measurement group_id="O3" value="30.333" lower_limit="25.791" upper_limit="34.5"/>
                  <measurement group_id="O4" value="31" lower_limit="26.9" upper_limit="34.5"/>
                  <measurement group_id="O5" value="28.667" lower_limit="25.11" upper_limit="33.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA; Day 60 (N=141,140,134,137,138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.8" lower_limit="24.692" upper_limit="33.875"/>
                  <measurement group_id="O2" value="28.905" lower_limit="24.895" upper_limit="33.35"/>
                  <measurement group_id="O3" value="29.5" lower_limit="26" upper_limit="34.5"/>
                  <measurement group_id="O4" value="30.095" lower_limit="26.6" upper_limit="34.308"/>
                  <measurement group_id="O5" value="29.65" lower_limit="25.4" upper_limit="33.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LHD; Day 0 (N=143,141,141,145,142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="336.364" lower_limit="281.169" upper_limit="381.973"/>
                  <measurement group_id="O2" value="335.281" lower_limit="283.1" upper_limit="372"/>
                  <measurement group_id="O3" value="328.3" lower_limit="278.231" upper_limit="368.831"/>
                  <measurement group_id="O4" value="336.054" lower_limit="291.991" upper_limit="384.156"/>
                  <measurement group_id="O5" value="325.85" lower_limit="285" upper_limit="372.069"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LHD; Day 30 (N=141,139,138,140,138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="343.75" lower_limit="298.9" upper_limit="389.063"/>
                  <measurement group_id="O2" value="329.6" lower_limit="283.333" upper_limit="375"/>
                  <measurement group_id="O3" value="330.32" lower_limit="290.6" upper_limit="364.966"/>
                  <measurement group_id="O4" value="337.428" lower_limit="289.068" upper_limit="385.753"/>
                  <measurement group_id="O5" value="320.671" lower_limit="285.498" upper_limit="374.479"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LHD; Day 37 (N=128,124,120,126,121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="348.894" lower_limit="297.246" upper_limit="388.037"/>
                  <measurement group_id="O2" value="342.857" lower_limit="288.8" upper_limit="380"/>
                  <measurement group_id="O3" value="331.967" lower_limit="293.45" upper_limit="373.089"/>
                  <measurement group_id="O4" value="340.606" lower_limit="289.5" upper_limit="378"/>
                  <measurement group_id="O5" value="319.048" lower_limit="282.251" upper_limit="375"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LHD; Day 60 (N=141,140,134,137,138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="341.975" lower_limit="296.32" upper_limit="391"/>
                  <measurement group_id="O2" value="335.141" lower_limit="270.7" upper_limit="376.435"/>
                  <measurement group_id="O3" value="324.675" lower_limit="278.2" upper_limit="366.146"/>
                  <measurement group_id="O4" value="348.438" lower_limit="295.2" upper_limit="378.571"/>
                  <measurement group_id="O5" value="320.927" lower_limit="285.526" upper_limit="382.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</title>
        <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 0 baseline versus their status post vaccination (Day 60). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Day 0 and up to Day 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="74"/>
                  <measurement group_id="O3" value="75"/>
                  <measurement group_id="O4" value="74"/>
                  <measurement group_id="O5" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</title>
            <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 0 baseline versus their status post vaccination (Day 60). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>BAS Abn. Day 0 – Abn. Day 60 [N=3;2;4;5;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Abn. Day 0 – Nor. Day 60 [N=3;2;4;5;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Nor. Day 0 - Abn. Day 60 [N=72;72;71;69;71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Nor. Day 0 - Nor. Day 60 [N=72;72;71;69;71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="62"/>
                  <measurement group_id="O3" value="62"/>
                  <measurement group_id="O4" value="64"/>
                  <measurement group_id="O5" value="64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Abn. Day 0 – Abn. Day 60 [N=12;11;13;14;10]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="12"/>
                  <measurement group_id="O5" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Abn. Day 0 – Nor. Day 60 [N=12;11;13;14;10]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Nor. Day 0 - Abn. Day 60 [N=63;63;62;60;65]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="20"/>
                  <measurement group_id="O5" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Nor. Day 0 - Nor. Day 60 [N=63;63;62;60;65]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="54"/>
                  <measurement group_id="O3" value="44"/>
                  <measurement group_id="O4" value="40"/>
                  <measurement group_id="O5" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Abn. Day 0 – Abn. Day 60 [N=3;8;5;4;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Abn. Day 0 – Nor. Day 60 [N=3;8;5;4;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Nor. Day 0 - Abn. Day 60 [N=72;66;70;70;70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Nor. Day 0 - Nor. Day 60 [N=72;66;70;70;70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="48"/>
                  <measurement group_id="O4" value="56"/>
                  <measurement group_id="O5" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Abn. Day 0 – Abn. Day 60 [N=4;6;4;8;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="7"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Abn. Day 0 – Nor. Day 60 [N=4;6;4;8;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Nor. Day 0 - Abn. Day 60 [N=71;68;71;66;71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Nor. Day 0 - Nor. Day 60 [N=71;68;71;66;71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="59"/>
                  <measurement group_id="O3" value="65"/>
                  <measurement group_id="O4" value="60"/>
                  <measurement group_id="O5" value="65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Abn. Day 0 – Abn. Day 60 [N=10;6;8;7;6]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Abn. Day 0 – Nor. Day 60 [N=10;6;8;7;6]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Nor. Day 0 - Abn. Day 60 [N=65;68;67;67;69]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Nor. Day 0 - Nor. Day 60 [N=65;68;67;67;69]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="51"/>
                  <measurement group_id="O4" value="56"/>
                  <measurement group_id="O5" value="59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Abn. Day 0 – Abn. Day 60 [N=1;5;7;4;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Abn. Day 0 – Nor. Day 60 [N=1;5;7;4;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Nor. Day 0 - Abn. Day 60 [N=74;69;68;70;75]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Nor. Day 0 - Nor. Day 60 [N=74;69;68;70;75]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="54"/>
                  <measurement group_id="O3" value="56"/>
                  <measurement group_id="O4" value="62"/>
                  <measurement group_id="O5" value="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Abn. Day 0 – Abn. Day 60 [N=7;3;3;4;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Abn. Day 0 – Nor. Day 60 [N=7;3;3;4;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Nor. Day 0 - Abn. Day 60 [N=68;71;72;70;75]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="13"/>
                  <measurement group_id="O5" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Nor. Day 0 - Nor. Day 60 [N=68;71;72;70;75]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="44"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="57"/>
                  <measurement group_id="O5" value="67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Abn. Day 0 – Abn. Day 60 [N=6;6;10;3;7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Abn. Day 0 – Nor. Day 60 [N=6;6;10;3;7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Nor. Day 0 - Abn. Day 60 [N=69;68;65;71;68]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="19"/>
                  <measurement group_id="O5" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Nor. Day 0 - Nor. Day 60 [N=69;68;65;71;68]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="42"/>
                  <measurement group_id="O3" value="46"/>
                  <measurement group_id="O4" value="52"/>
                  <measurement group_id="O5" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</title>
        <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 0 baseline versus their status post vaccination (Day 60). This outcome measure concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
        <time_frame>At Day 0 and up to Day 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 1 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. The GSK223192A vaccine antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 2 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. The GSK223192A vaccine antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the GSK223192A 3 Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. The GSK223192A vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the Fendrix Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of Fendrix™, at Days 0 and 30. The Fendrix™ vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – Non-HLA Subsets Group</title>
            <description>This group consisted in the subjects in the Engerix-B Group who were not identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype. Subjects in this group were aged between, and including, 18 and 45 years at the time of first vaccination and received 2 doses of Engerix-B™, at Days 0 and 30. The Engerix-B™ vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="67"/>
                  <measurement group_id="O3" value="65"/>
                  <measurement group_id="O4" value="70"/>
                  <measurement group_id="O5" value="66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</title>
            <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 0 baseline versus their status post vaccination (Day 60). This outcome measure concerns all subjects except subjects part of the HLA Subsets 1 and 2.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>BAS Abn. Day 0 – Abn. Day 60 [N=4;4;2;6;3]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Abn. Day 0 – Nor. Day 60 [N=4;4;2;6;3]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Nor. Day 0 - Abn. Day 60 [N=64;62;63;64;63]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Nor. Day 0 - Nor. Day 60 [N=64;62;63;64;63]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="60"/>
                  <measurement group_id="O4" value="58"/>
                  <measurement group_id="O5" value="60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Abn. Day 0 – Abn. Day 60 [N=12;7;18;13;17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Abn. Day 0 – Nor. Day 60 [N=12;7;18;13;17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Nor. Day 0 - Abn. Day 60 [N=56;60;47;57;49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="12"/>
                  <measurement group_id="O5" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Nor. Day 0 - Nor. Day 60 [N=56;60;47;57;49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="38"/>
                  <measurement group_id="O4" value="45"/>
                  <measurement group_id="O5" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Abn. Day 0 – Abn. Day 60 [N=8;12;9;5;8]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Abn. Day 0 – Nor. Day 60 [N=8;12;9;5;8]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Nor. Day 0 - Abn. Day 60 [N=57;51;54;62;56]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Nor. Day 0 - Nor. Day 60 [N=57;51;54;62;56]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="42"/>
                  <measurement group_id="O3" value="45"/>
                  <measurement group_id="O4" value="58"/>
                  <measurement group_id="O5" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Abn. Day 0 – Abn. Day 60 [N=9;9;5;6;7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Abn. Day 0 – Nor. Day 60 [N=9;9;5;6;7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Nor. Day 0 - Abn. Day 60 [N=59;57;60;64;59]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Nor. Day 0 - Nor. Day 60 [N=59;57;60;64;59]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="49"/>
                  <measurement group_id="O3" value="52"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Abn. Day 0 – Abn. Day 60 [N=8;10;7;14;11]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Abn. Day 0 – Nor. Day 60 [N=8;10;7;14;11]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Nor. Day 0 - Abn. Day 60 [N=60;56;58;56;55]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Nor. Day 0 - Nor. Day 60 [N=60;56;58;56;55]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="45"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Abn. Day 0 – Abn. Day 60 [N=4;3;3;4;3]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Abn. Day 0 – Nor. Day 60 [N=4;3;3;4;3]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Nor. Day 0 - Abn. Day 60 [N=64;63;62;66;63]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Nor. Day 0 - Nor. Day 60 [N=64;63;62;66;63]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="54"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="62"/>
                  <measurement group_id="O5" value="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Abn. Day 0 – Abn. Day 60 [N=5;8;6;6;8]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Abn. Day 0 – Nor. Day 60 [N=5;8;6;6;8]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Nor. Day 0 - Abn. Day 60 [N=63;58;59;64;58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="13"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Nor. Day 0 - Nor. Day 60 [N=63;58;59;64;58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="42"/>
                  <measurement group_id="O4" value="51"/>
                  <measurement group_id="O5" value="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Abn. Day 0 – Abn. Day 60 [N=7;10;9;12;9]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Abn. Day 0 – Nor. Day 60 [N=7;10;9;12;9]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Nor. Day 0 - Abn. Day 60 [N=61;57;56;58;57]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="10"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Nor. Day 0 - Nor. Day 60 [N=61;57;56;58;57]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="50"/>
                  <measurement group_id="O3" value="49"/>
                  <measurement group_id="O4" value="48"/>
                  <measurement group_id="O5" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</title>
        <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 0 baseline versus their status post vaccination (Day 180 or 360). Day 180 or 360 results were chosen based on assessment of grading of the abnormality observed, with results for higher grading being tabulated.</description>
        <time_frame>Post vaccination (up to Day 360)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                  <measurement group_id="O2" value="140"/>
                  <measurement group_id="O3" value="131"/>
                  <measurement group_id="O4" value="133"/>
                  <measurement group_id="O5" value="135"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</title>
            <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 0 baseline versus their status post vaccination (Day 180 or 360). Day 180 or 360 results were chosen based on assessment of grading of the abnormality observed, with results for higher grading being tabulated.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>BAS Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="127"/>
                  <measurement group_id="O3" value="118"/>
                  <measurement group_id="O4" value="122"/>
                  <measurement group_id="O5" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="38"/>
                  <measurement group_id="O5" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="115"/>
                  <measurement group_id="O3" value="95"/>
                  <measurement group_id="O4" value="95"/>
                  <measurement group_id="O5" value="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="19"/>
                  <measurement group_id="O5" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="125"/>
                  <measurement group_id="O2" value="120"/>
                  <measurement group_id="O3" value="111"/>
                  <measurement group_id="O4" value="114"/>
                  <measurement group_id="O5" value="125"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="119"/>
                  <measurement group_id="O2" value="118"/>
                  <measurement group_id="O3" value="112"/>
                  <measurement group_id="O4" value="111"/>
                  <measurement group_id="O5" value="110"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="130"/>
                  <measurement group_id="O3" value="118"/>
                  <measurement group_id="O4" value="119"/>
                  <measurement group_id="O5" value="126"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="16"/>
                  <measurement group_id="O5" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124"/>
                  <measurement group_id="O2" value="122"/>
                  <measurement group_id="O3" value="107"/>
                  <measurement group_id="O4" value="117"/>
                  <measurement group_id="O5" value="120"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="118"/>
                  <measurement group_id="O2" value="122"/>
                  <measurement group_id="O3" value="106"/>
                  <measurement group_id="O4" value="119"/>
                  <measurement group_id="O5" value="115"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</title>
        <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 360 baseline versus their status post vaccination (Day 390). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 360 and 390.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Booster Total Vaccinated cohort which included all HLA Subsets 1 and 2 subjects who received the booster dose of HBsAg.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="56"/>
                  <measurement group_id="O4" value="54"/>
                  <measurement group_id="O5" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.</title>
            <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), C-reactive protein (CRP) and creatine phosphokinase (CPK) at the Day 360 baseline versus their status post vaccination (Day 390). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>BAS Abn. Day 360 - Nor. Day 390 [N=3;4;2;1;2]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Abn. Day 360 - Nor. Day 390 [N=3;4;2;1;2]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Nor. Day 360 - Abn. Day 390 [N=56;52;54;53;52]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Nor. Day 360 - Nor. Day 390 [N=56;52;54;53;52]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="50"/>
                  <measurement group_id="O4" value="52"/>
                  <measurement group_id="O5" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Abn. Day 360 - Abn. Day 390 [N=15;4;11;6;6]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Abn. Day 360 - Nor. Day 390 [N=15;4;11;6;6]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Nor. Day 360 - Abn. Day 390 [N=44;52;45;49;47]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="10"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CPK Nor. Day 360 - Nor. Day 390 [N=44;52;45;49;47]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="50"/>
                  <measurement group_id="O3" value="38"/>
                  <measurement group_id="O4" value="39"/>
                  <measurement group_id="O5" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Abn. Day 360 - Abn. Day 390 [N=2;2;2;4;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Abn. Day 360 - Nor. Day 390 [N=2;2;2;4;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Nor. Day 360 - Abn. Day 390 [N=57;54;54;50;54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Nor. Day 360 - Nor. Day 390 [N=57;54;54;50;54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Abn. Day 360 - Abn. Day 390 [N=9;5;8; 4;7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Abn. Day 360 - Nor. Day 390 [N=9;5;8; 4;7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Nor. Day 360 - Abn. Day 390 [N=50;51;48;50;47]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Nor. Day 360 - Nor. Day 390 [N=50;51;48;50;47]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="48"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="47"/>
                  <measurement group_id="O5" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Abn. Day 360 - Abn. Day 390 [N=1;1;3;3;1]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Abn. Day 360 - Nor. Day 390 [N=1;1;3;3;1]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Nor. Day 360 - Abn. Day 390 [N=58;55;53;51;53]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Nor. Day 360 - Nor. Day 390 [N=58;55;53;51;53]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="54"/>
                  <measurement group_id="O3" value="52"/>
                  <measurement group_id="O4" value="49"/>
                  <measurement group_id="O5" value="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Abn. Day 360 - Abn. Day 390 [N=8;4;5;4;3]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Abn. Day 360 - Nor. Day 390 [N=8;4;5;4;3]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Nor. Day 360 - Abn. Day 390 [N=51;52;51;50;51]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Nor. Day 360 - Nor. Day 390 [N=51;52;51;50;51]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="50"/>
                  <measurement group_id="O3" value="51"/>
                  <measurement group_id="O4" value="47"/>
                  <measurement group_id="O5" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Abn. Day 360 - Abn. Day 390 [N=9;3;8; 2;5]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Abn. Day 360 - Nor. Day 390 [N=9;3;8; 2;5]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Nor. Day 360 – Abn. Day 390 [N=50;53;48;52;49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Nor. Day 360 - Nor. Day 390 [N=50;53;48;52;49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="46"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase</title>
        <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of red blood cells (RBC), platelets (PLA), haemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) at the Day 0 baseline versus their status post vaccination (Day 60).</description>
        <time_frame>At Day 0 and up to Day 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="141"/>
                  <measurement group_id="O2" value="141"/>
                  <measurement group_id="O3" value="138"/>
                  <measurement group_id="O4" value="141"/>
                  <measurement group_id="O5" value="139"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase</title>
            <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of red blood cells (RBC), platelets (PLA), haemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) at the Day 0 baseline versus their status post vaccination (Day 60).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT Abn. Day 0 – Abn. Day 60 [N=16;14;13;13;17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Abn. Day 0 – Nor. Day 60 [N=16;14;13;13;17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="7"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Nor. Day 0 – Abn. Day 60 [N=125;127;125;128;12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Nor. Day 0 - Nor. Day 60 [N=125;127;125;128;12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="113"/>
                  <measurement group_id="O2" value="122"/>
                  <measurement group_id="O3" value="115"/>
                  <measurement group_id="O4" value="120"/>
                  <measurement group_id="O5" value="113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Abn. Day 0 – Abn. Day 60 [N=4;4;3;4;5]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Abn. Day 0 – Nor. Day 60 [N=4;4;3;4;5]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Nor. Day 0 – Abn. Day 60 [N=137;137;135;137;13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Nor. Day 0 - Nor. Day 60 [N=137;137;135;137;13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="125"/>
                  <measurement group_id="O2" value="136"/>
                  <measurement group_id="O3" value="128"/>
                  <measurement group_id="O4" value="129"/>
                  <measurement group_id="O5" value="128"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Abn. Day 0 – Abn. Day 60 [N=19;15;12;13;13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Abn. Day 0 – Nor. Day 60 [N=19;15;12;13;13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Nor. Day 0 – Abn. Day 60 [N=122;126;126;128;12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Nor. Day 0 - Nor. Day 60 [N=122;126;126;128;12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="113"/>
                  <measurement group_id="O3" value="115"/>
                  <measurement group_id="O4" value="119"/>
                  <measurement group_id="O5" value="110"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Abn. Day 0 – Abn. Day 60 [N=11;8;6;8;9]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Abn. Day 0 – Nor. Day 60 [N=11;8;6;8;9]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Nor. Day 0 – Abn. Day 60 [N=130;132;132;133;13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Nor. Day 0 - Nor. Day 60 [N=130;132;132;133;13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="119"/>
                  <measurement group_id="O2" value="123"/>
                  <measurement group_id="O3" value="126"/>
                  <measurement group_id="O4" value="124"/>
                  <measurement group_id="O5" value="121"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Abn. Day 0 – Abn. Day 60 [N=10;8;6;11;8]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Abn. Day 0 – Nor. Day 60 [N=10;8;6;11;8]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Nor. Day 0 – Abn. Day 60 [N=131;133;132;130;13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Nor. Day 0 - Nor. Day 60 [N=131;133;132;130;13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="122"/>
                  <measurement group_id="O2" value="122"/>
                  <measurement group_id="O3" value="122"/>
                  <measurement group_id="O4" value="122"/>
                  <measurement group_id="O5" value="126"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Abn. Day 0 – Abn. Day 60 [N=7;13;8;6;9]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Abn. Day 0 – Nor. Day 60 [N=7;13;8;6;9]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Nor. Day 0 – Abn. Day 60 [N=134;128;130;135;13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Nor. Day 0 - Nor. Day 60 [N=134;128;130;135;13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="116"/>
                  <measurement group_id="O3" value="113"/>
                  <measurement group_id="O4" value="121"/>
                  <measurement group_id="O5" value="124"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Abn. Day 0 – Abn. Day 60 [N=5;6;7;7;15]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Abn. Day 0 – Nor. Day 60 [N=5;6;7;7;15]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Nor. Day 0 – Abn. Day 60 [N=136;135;131;134</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="12"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Nor. Day 0 - Nor. Day 60 [N=136;135;131;134</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="127"/>
                  <measurement group_id="O3" value="124"/>
                  <measurement group_id="O4" value="122"/>
                  <measurement group_id="O5" value="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Abn. Day 0 – Abn. Day 60 [N=6;3;9;11;6]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Abn. Day 0 – Nor. Day 60 [N=6;3;9;11;6]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Nor. Day 0 – Abn. Day 60 [N=135;138;129;130;1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Nor. Day 0 - Nor. Day 60 [N=135;138;129;130;1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="117"/>
                  <measurement group_id="O2" value="127"/>
                  <measurement group_id="O3" value="113"/>
                  <measurement group_id="O4" value="116"/>
                  <measurement group_id="O5" value="125"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase</title>
        <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of red blood cells (RBC), platelets (PLA), haemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) at the Day 0 baseline versus their status post vaccination (Day 180 or 360). Day 180 or 360 results were chosen based on assessment of grading of the abnormality observed, with results for higher grading being tabulated.</description>
        <time_frame>post vaccination (up to Day 360).</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                  <measurement group_id="O2" value="140"/>
                  <measurement group_id="O3" value="131"/>
                  <measurement group_id="O4" value="133"/>
                  <measurement group_id="O5" value="135"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase</title>
            <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of red blood cells (RBC), platelets (PLA), haemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) at the Day 0 baseline versus their status post vaccination (Day 180 or 360). Day 180 or 360 results were chosen based on assessment of grading of the abnormality observed, with results for higher grading being tabulated.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="23"/>
                  <measurement group_id="O5" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="123"/>
                  <measurement group_id="O3" value="113"/>
                  <measurement group_id="O4" value="110"/>
                  <measurement group_id="O5" value="118"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="135"/>
                  <measurement group_id="O3" value="122"/>
                  <measurement group_id="O4" value="128"/>
                  <measurement group_id="O5" value="126"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="17"/>
                  <measurement group_id="O5" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="127"/>
                  <measurement group_id="O3" value="119"/>
                  <measurement group_id="O4" value="116"/>
                  <measurement group_id="O5" value="120"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="126"/>
                  <measurement group_id="O3" value="121"/>
                  <measurement group_id="O4" value="129"/>
                  <measurement group_id="O5" value="124"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="13"/>
                  <measurement group_id="O5" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="131"/>
                  <measurement group_id="O3" value="124"/>
                  <measurement group_id="O4" value="120"/>
                  <measurement group_id="O5" value="125"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="7"/>
                  <measurement group_id="O5" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="120"/>
                  <measurement group_id="O3" value="115"/>
                  <measurement group_id="O4" value="126"/>
                  <measurement group_id="O5" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="129"/>
                  <measurement group_id="O3" value="119"/>
                  <measurement group_id="O4" value="124"/>
                  <measurement group_id="O5" value="117"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Abn.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="17"/>
                  <measurement group_id="O5" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Nor.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="126"/>
                  <measurement group_id="O3" value="112"/>
                  <measurement group_id="O4" value="116"/>
                  <measurement group_id="O5" value="127"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase</title>
        <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of red blood cells (RBC), platelets (PLA), haemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) at the Day 360 baseline versus their status post vaccination (Day 390). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>At Days 360 and 390.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Booster Total Vaccinated cohort which included all HLA Subsets 1 and 2 subjects who received the booster dose of HBsAg.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="54"/>
                  <measurement group_id="O4" value="55"/>
                  <measurement group_id="O5" value="53"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase</title>
            <description>Subjects were assessed with regard to their normal (Nor.) and abnormal (Abn.) levels for the above parameters of red blood cells (RBC), platelets (PLA), haemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (S-CREA), urea and lactate dehydrogenase (LDH) at the Day 360 baseline versus their status post vaccination (Day 390). This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT Abn. Day 360 - Abn. Day 390 [N=7;3;10;5;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Abn. Day 360 - Nor. Day 390 [N=7;3;10;5;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Nor. Day 360 - Abn. Day 390 [N=52;53;46;50;49</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Nor. Day 360 - Nor. Day 390 [N=52;53;46;50;49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="46"/>
                  <measurement group_id="O4" value="45"/>
                  <measurement group_id="O5" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Abn. Day 360 - Abn. Day 390 [N=4;0;4;0;1]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Abn. Day 360 - Nor. Day 390 [N=4;0;4;0;1]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Nor. Day 360 - Abn. Day 390 [N=55;56;52;55;52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Nor. Day 360 - Nor. Day 390 [N=55;56;52;55;52]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="54"/>
                  <measurement group_id="O3" value="51"/>
                  <measurement group_id="O4" value="51"/>
                  <measurement group_id="O5" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Abn. Day 360 - Abn. Day 390 [N=4;3;2;4;5]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Abn. Day 360 - Nor. Day 390 [N=4;3;2;4;5]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Nor. Day 360 - Abn. Day 390 [N=55;53;54;50;49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HGB Nor. Day 360 - Nor. Day 390 [N=55;53;54;50;49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="53"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="48"/>
                  <measurement group_id="O5" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Abn. Day 360 - Abn. Day 390 [N=4;1;3;0;2]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Abn. Day 360 - Nor. Day 390 [N=4;1;3;0;2]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Nor. Day 360 - Abn. Day 390 [N=55;55;53;55;51]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Nor. Day 360 - Nor. Day 390 [N=55;55;53;55;51]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="55"/>
                  <measurement group_id="O3" value="51"/>
                  <measurement group_id="O4" value="52"/>
                  <measurement group_id="O5" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Abn. Day 360 - Abn. Day 390 [N=4;1;2;5;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Abn. Day 360 - Nor. Day 390 [N=4;1;2;5;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Nor. Day 360 - Abn. Day 390 [N=55;55;54;49;50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Nor. Day 360 - Nor. Day 390 [N=55;55;54;49;50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="55"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="48"/>
                  <measurement group_id="O5" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Abn. Day 360 - Abn. Day 390 [N=2;4;3;3;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Abn. Day 360 - Nor. Day 390 [N=2;4;3;3;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Nor. Day 360 – Abn. Day 390 [N=57;52;53;51;50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Nor. Day 360 - Nor. Day 390 [N=57;52;53;51;50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="50"/>
                  <measurement group_id="O4" value="48"/>
                  <measurement group_id="O5" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Abn. Day 360 - Abn. Day 390 [N=0;0;3;2;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Abn. Day 360 - Nor. Day 390 [N=0;0;3;2;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Nor. Day 360 - Abn. Day 390 [N=59;56;53;53;</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S-CREA Nor. Day 360 - Nor. Day 390 [N=59;56;53;53;</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Abn. Day 360 - Abn. Day 390 [N=3;4;7;5;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Abn. Day 360 - Nor. Day 390 [N=3;4;7;5;4]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Nor. Day 360 - Abn. Day 390 [N=56;52;49;50;49</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UREA Nor. Day 360 - Nor. Day 390 [N=56;52;49;50;49</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="48"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms Following Primary Vaccination.</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. All solicited local symptoms were considered as related to study vaccination. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling above (&gt;) 50 millimeters (mm). Occurrence of a solicited local symptoms collected post-vaccination was a priori considered as related to vaccination.</description>
        <time_frame>Within the 14-day (Days 0-13) follow up period following primary vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccines.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, with analysis performed solely on subjects with results from post-primary vaccination available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                  <measurement group_id="O2" value="140"/>
                  <measurement group_id="O3" value="138"/>
                  <measurement group_id="O4" value="143"/>
                  <measurement group_id="O5" value="139"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms Following Primary Vaccination.</title>
            <description>Solicited local symptoms assessed were pain, redness and swelling. All solicited local symptoms were considered as related to study vaccination. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling above (&gt;) 50 millimeters (mm). Occurrence of a solicited local symptoms collected post-vaccination was a priori considered as related to vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="129"/>
                  <measurement group_id="O3" value="123"/>
                  <measurement group_id="O4" value="128"/>
                  <measurement group_id="O5" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="53"/>
                  <measurement group_id="O5" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness &gt; 50 mm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="36"/>
                  <measurement group_id="O3" value="34"/>
                  <measurement group_id="O4" value="43"/>
                  <measurement group_id="O5" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling &gt; 50 mm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms Following Primary Vaccination.</title>
        <description>Solicited general symptoms assessed were Fatigue, Fever – oral temperature equal to or above (&gt;=) 37.5 degrees Celsius (°C) –, Gastrointestinal symptoms (Gastr.), Headache, Malaise and Myalgia. Any = occurrence of a general symptom regardless of its intensity grade or relationship to vaccination. Related = occurrence of a general symptom assessed by the investigator to be causally related to vaccination. Grade 3 fever = oral temperature above (&gt;) 39.0 °C. Grade 3 for Gastr., Headache, Malaise and Myalgia = occurrence of the specified solicited general symptom which prevented normal activity.</description>
        <time_frame>Within the 14-day (Days 0-13) follow up period following primary vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects, with analysis performed solely on subjects with results from post-primary vaccination available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                  <measurement group_id="O2" value="140"/>
                  <measurement group_id="O3" value="138"/>
                  <measurement group_id="O4" value="144"/>
                  <measurement group_id="O5" value="139"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms Following Primary Vaccination.</title>
            <description>Solicited general symptoms assessed were Fatigue, Fever – oral temperature equal to or above (&gt;=) 37.5 degrees Celsius (°C) –, Gastrointestinal symptoms (Gastr.), Headache, Malaise and Myalgia. Any = occurrence of a general symptom regardless of its intensity grade or relationship to vaccination. Related = occurrence of a general symptom assessed by the investigator to be causally related to vaccination. Grade 3 fever = oral temperature above (&gt;) 39.0 °C. Grade 3 for Gastr., Headache, Malaise and Myalgia = occurrence of the specified solicited general symptom which prevented normal activity.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                  <measurement group_id="O2" value="76"/>
                  <measurement group_id="O3" value="67"/>
                  <measurement group_id="O4" value="70"/>
                  <measurement group_id="O5" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="67"/>
                  <measurement group_id="O3" value="57"/>
                  <measurement group_id="O4" value="55"/>
                  <measurement group_id="O5" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="12"/>
                  <measurement group_id="O5" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastr.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="29"/>
                  <measurement group_id="O4" value="36"/>
                  <measurement group_id="O5" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastr.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastr.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="20"/>
                  <measurement group_id="O5" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="67"/>
                  <measurement group_id="O3" value="66"/>
                  <measurement group_id="O4" value="62"/>
                  <measurement group_id="O5" value="59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                  <measurement group_id="O2" value="52"/>
                  <measurement group_id="O3" value="46"/>
                  <measurement group_id="O4" value="41"/>
                  <measurement group_id="O5" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="44"/>
                  <measurement group_id="O3" value="39"/>
                  <measurement group_id="O4" value="35"/>
                  <measurement group_id="O5" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="36"/>
                  <measurement group_id="O3" value="30"/>
                  <measurement group_id="O4" value="27"/>
                  <measurement group_id="O5" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="55"/>
                  <measurement group_id="O4" value="58"/>
                  <measurement group_id="O5" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="49"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="50"/>
                  <measurement group_id="O5" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms Following Booster Vaccination.</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. All solicited local symptoms were considered as related to study vaccination. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling above (&gt;) 50 millimeters (mm). Occurrence of a solicited local symptoms collected post-vaccination was a priori considered as related to vaccination. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>Within the 7-day (Days 0-6) follow up period following booster vaccination with HBsAg antigens</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Booster Total Vaccinated cohort which included all HLA Subsets 1 and 2 subjects who received the booster dose of HBsAg, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="56"/>
                  <measurement group_id="O4" value="56"/>
                  <measurement group_id="O5" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms Following Booster Vaccination.</title>
            <description>Solicited local symptoms assessed were pain, redness and swelling. All solicited local symptoms were considered as related to study vaccination. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling above (&gt;) 50 millimeters (mm). Occurrence of a solicited local symptoms collected post-vaccination was a priori considered as related to vaccination. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="16"/>
                  <measurement group_id="O5" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness &gt; 50 mm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling &gt; 50 mm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms Following Booster Vaccination.</title>
        <description>Solicited general symptoms assessed were Fatigue, Fever – oral temperature equal to or above (&gt;=) 37.5 degrees Celsius (°C) –, Gastrointestinal symptoms (Gastr.), Headache, Malaise and Myalgia. Any = occurrence of a general symptom regardless of its intensity grade or relationship to vaccination. Related = occurrence of a general symptom assessed by the investigator to be causally related to vaccination. Grade 3 fever = oral temperature above (&gt;) 39.0 °C. Grade 3 for Gastr., Headache, Malaise and Myalgia = occurrence of the specified solicited general symptom which prevented normal activity. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>Within the 7-day (Days 0-6) follow up period following booster vaccination with HBsAg antigens</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Booster Total Vaccinated cohort which included all HLA Subsets 1 and 2 subjects who received the booster dose of HBsAg, on subjects for whom results were available for the timepoint/outcome analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="56"/>
                  <measurement group_id="O4" value="56"/>
                  <measurement group_id="O5" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms Following Booster Vaccination.</title>
            <description>Solicited general symptoms assessed were Fatigue, Fever – oral temperature equal to or above (&gt;=) 37.5 degrees Celsius (°C) –, Gastrointestinal symptoms (Gastr.), Headache, Malaise and Myalgia. Any = occurrence of a general symptom regardless of its intensity grade or relationship to vaccination. Related = occurrence of a general symptom assessed by the investigator to be causally related to vaccination. Grade 3 fever = oral temperature above (&gt;) 39.0 °C. Grade 3 for Gastr., Headache, Malaise and Myalgia = occurrence of the specified solicited general symptom which prevented normal activity. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="15"/>
                  <measurement group_id="O5" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="13"/>
                  <measurement group_id="O5" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastr.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastr.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastr.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="7"/>
                  <measurement group_id="O5" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and/or Related Unsolicited Adverse Events (AEs) Following Primary Vaccination</title>
        <description>An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination. Grade 3 = occurrence of an AE that prevented normal activity. Related = occurrence of an AE assessed by the investigators as causally related to the study vaccine.</description>
        <time_frame>Within the 31-day (Days 0-30) follow up period following primary vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="142"/>
                  <measurement group_id="O3" value="141"/>
                  <measurement group_id="O4" value="145"/>
                  <measurement group_id="O5" value="142"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and/or Related Unsolicited Adverse Events (AEs) Following Primary Vaccination</title>
            <description>An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination. Grade 3 = occurrence of an AE that prevented normal activity. Related = occurrence of an AE assessed by the investigators as causally related to the study vaccine.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Subjects with any AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="73"/>
                  <measurement group_id="O3" value="76"/>
                  <measurement group_id="O4" value="67"/>
                  <measurement group_id="O5" value="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with Grade 3 AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="19"/>
                  <measurement group_id="O5" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with related AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="27"/>
                  <measurement group_id="O4" value="21"/>
                  <measurement group_id="O5" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with Grade 3 and related AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and/or Related Unsolicited Adverse Events (AEs) Following Booster Vaccination</title>
        <description>An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination. Grade 3 = occurrence of an AE that prevented normal activity. Related = occurrence of an AE assessed by the investigators as causally related to the study vaccine. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
        <time_frame>Within the 31-day (Days 0-30) follow up period following booster vaccination with HBsAg antigens</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Booster Total Vaccinated cohort which included all HLA Subsets 1 and 2 subjects who received the booster dose of HBsAg.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 1 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 2 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the GSK223192A 3 Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Fendrix Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B – HLA Subsets Group</title>
            <description>This group consisted in the subset of subjects in the Engerix-B Group identified with a pre-defined Human Leukocytes Antigen (HLA) Class I or II subtype aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™, at Days 0 and 30, followed by one booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="56"/>
                  <measurement group_id="O4" value="56"/>
                  <measurement group_id="O5" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and/or Related Unsolicited Adverse Events (AEs) Following Booster Vaccination</title>
            <description>An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination. Grade 3 = occurrence of an AE that prevented normal activity. Related = occurrence of an AE assessed by the investigators as causally related to the study vaccine. This outcome measure concerns solely subjects part of the HLA Subsets 1 &amp; 2 who received the Day 360 booster dose of HBsAg.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Subjects with any AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with any grade 3 AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with related AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with Grade 3 and related AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Adverse Events of Specific Interest (AESIs)</title>
        <description>AESIs included Autoimmune Disease (AID), neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, and other autoimmune/inflammatory events. Any AESI(s) = occurrence of any AESI(s) in a subject regardless of assessment of relationship to study vaccination. Related AESI(s) = Occurrence of AESI(s) in a subject assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the entire study period, from Day 0 to study end, at Day 360 for subjects not in Subsets 1 &amp; 2 and at Day 390 for subjects in Subsets 1 &amp; 2.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="142"/>
                  <measurement group_id="O3" value="141"/>
                  <measurement group_id="O4" value="145"/>
                  <measurement group_id="O5" value="142"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Adverse Events of Specific Interest (AESIs)</title>
            <description>AESIs included Autoimmune Disease (AID), neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, and other autoimmune/inflammatory events. Any AESI(s) = occurrence of any AESI(s) in a subject regardless of assessment of relationship to study vaccination. Related AESI(s) = Occurrence of AESI(s) in a subject assessed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AESI(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related AESI(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Serious Adverse Events (SAEs) and SAEs Related to Study Vaccination</title>
        <description>A SAE was defined as a medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any SAE(s) = occurrence of SAE(s) in a subject regardless of assessment of relationship to study vaccination. Related SAE(s) = occurrence of occurrence of SAE(s) in a subject assessed by the investigators as causally related to the study vaccination.</description>
        <time_frame>During the entire study period, from Day 0 to study end, at Day 360 for subjects not in Subsets 1 &amp; 2 and at Day 390 for subjects in Subsets 1 &amp; 2.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the Total Vaccinated cohort which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="142"/>
                  <measurement group_id="O3" value="141"/>
                  <measurement group_id="O4" value="145"/>
                  <measurement group_id="O5" value="142"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any Serious Adverse Events (SAEs) and SAEs Related to Study Vaccination</title>
            <description>A SAE was defined as a medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any SAE(s) = occurrence of SAE(s) in a subject regardless of assessment of relationship to study vaccination. Related SAE(s) = occurrence of occurrence of SAE(s) in a subject assessed by the investigators as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any SAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="7"/>
                  <measurement group_id="O5" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gene Expression Signature Related to the Immune Response to the GSK223192A, Fendrix™ and Engerix-B™ Vaccines.</title>
        <description>Gene expression signature related to the immune response to the GSK223192A, Fendrix™ and Engerix-B™ vaccines will be measured by microarray/Polymerase Chain Reaction (PCR) array/quantitative PCR, using whole blood. This outcome will be assessed in the first 140 subjects in Subsets 1 and 2 recruited at the Immune Health (IH) Centre in La Louvière, Belgium. Results for this outcome measure will be posted when available.</description>
        <time_frame>At Days 0, 0+ (Day 0 + 3 to 6 hours), 1, 30, 30+ (Day 30 + 3 to 6 hours), 31, 33 and 37.</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2050</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
        <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Tumor Necrosis Factor (TNF), Tumor Necrosis Factor Receptor Superfamily (TNFRSF9).</description>
        <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ATP cohort for innate immunogenicity up to Day 60 included all evaluable subjects, who complied with the vaccination schedule, for whom data concerning immunogenicity outcome measures were available and for whom innate immunogenicity data were available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
            <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Tumor Necrosis Factor (TNF), Tumor Necrosis Factor Receptor Superfamily (TNFRSF9).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>TNF.mRNA, Day 0 (N=17,23,28,21,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.18" lower_limit="0.55" upper_limit="2.66"/>
                  <measurement group_id="O2" value="1.09" lower_limit="0.78" upper_limit="1.75"/>
                  <measurement group_id="O3" value="1.24" lower_limit="0.84" upper_limit="2.64"/>
                  <measurement group_id="O4" value="1.18" lower_limit="0.78" upper_limit="3.18"/>
                  <measurement group_id="O5" value="1.18" lower_limit="0.76" upper_limit="2.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF.mRNA, Day 1 (N=17,23,27,21,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.33" lower_limit="0.71" upper_limit="2.48"/>
                  <measurement group_id="O2" value="1.08" lower_limit="0.44" upper_limit="3.01"/>
                  <measurement group_id="O3" value="1.1" lower_limit="0.4" upper_limit="2.58"/>
                  <measurement group_id="O4" value="1" lower_limit="0.56" upper_limit="2.39"/>
                  <measurement group_id="O5" value="1.06" lower_limit="0.63" upper_limit="2.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF.mRNA, Day 14 (N=16,23,27,21,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.95" lower_limit="0.63" upper_limit="2.14"/>
                  <measurement group_id="O2" value="1.07" lower_limit="0.57" upper_limit="1.8"/>
                  <measurement group_id="O3" value="1" lower_limit="0.63" upper_limit="2.96"/>
                  <measurement group_id="O4" value="1.03" lower_limit="0.62" upper_limit="1.58"/>
                  <measurement group_id="O5" value="1.13" lower_limit="0.52" upper_limit="1.67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF.mRNA, Day 30 (N=17,22,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.03" lower_limit="0.74" upper_limit="1.63"/>
                  <measurement group_id="O2" value="1.21" lower_limit="0.55" upper_limit="2.56"/>
                  <measurement group_id="O3" value="1.25" lower_limit="0.58" upper_limit="2.89"/>
                  <measurement group_id="O4" value="1.19" lower_limit="0.64" upper_limit="2"/>
                  <measurement group_id="O5" value="1.09" lower_limit="0.48" upper_limit="2.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF.mRNA, Day 31 (N=16,22,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.31" lower_limit="0.66" upper_limit="2.2"/>
                  <measurement group_id="O2" value="1.26" lower_limit="0.58" upper_limit="2.13"/>
                  <measurement group_id="O3" value="1.41" lower_limit="0.5" upper_limit="3.42"/>
                  <measurement group_id="O4" value="1.15" lower_limit="0.46" upper_limit="2.59"/>
                  <measurement group_id="O5" value="1.1" lower_limit="0.49" upper_limit="2.24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF.mRNA, Day 33 (N=17,21,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.99" lower_limit="0.44" upper_limit="2.47"/>
                  <measurement group_id="O2" value="1.04" lower_limit="0.67" upper_limit="2.1"/>
                  <measurement group_id="O3" value="1.12" lower_limit="0.54" upper_limit="2.99"/>
                  <measurement group_id="O4" value="1.18" lower_limit="0.47" upper_limit="2.27"/>
                  <measurement group_id="O5" value="0.97" lower_limit="0.57" upper_limit="2.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNF.mRNA, Day 37 (N=17,21,28,17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.82" lower_limit="0.36" upper_limit="1.56"/>
                  <measurement group_id="O2" value="1.04" lower_limit="0.32" upper_limit="1.69"/>
                  <measurement group_id="O3" value="1" lower_limit="0.39" upper_limit="2.39"/>
                  <measurement group_id="O4" value="1.07" lower_limit="0.42" upper_limit="1.99"/>
                  <measurement group_id="O5" value="1.06" lower_limit="0.38" upper_limit="3.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNFRSF9.mRNA, Day 0 (N=17,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.04" lower_limit="0.81" upper_limit="2.17"/>
                  <measurement group_id="O2" value="1.11" lower_limit="0.74" upper_limit="1.52"/>
                  <measurement group_id="O3" value="1.14" lower_limit="0.7" upper_limit="2.64"/>
                  <measurement group_id="O4" value="1.14" lower_limit="0.86" upper_limit="2.11"/>
                  <measurement group_id="O5" value="1.11" lower_limit="0.8" upper_limit="1.98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNFRSF9.mRNA, Day 1 (N=18,23,27,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.14" lower_limit="0.74" upper_limit="1.67"/>
                  <measurement group_id="O2" value="1.14" lower_limit="0.59" upper_limit="2.5"/>
                  <measurement group_id="O3" value="1.24" lower_limit="0.72" upper_limit="2.13"/>
                  <measurement group_id="O4" value="1.24" lower_limit="0.73" upper_limit="3.19"/>
                  <measurement group_id="O5" value="1.01" lower_limit="0.55" upper_limit="1.53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNFRSF9.mRNA, Day 14 (N=18,23,28,21,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.98" lower_limit="0.52" upper_limit="1.74"/>
                  <measurement group_id="O2" value="1.02" lower_limit="0.52" upper_limit="1.97"/>
                  <measurement group_id="O3" value="1.19" lower_limit="0.63" upper_limit="3.31"/>
                  <measurement group_id="O4" value="1.15" lower_limit="0.59" upper_limit="2.13"/>
                  <measurement group_id="O5" value="1.02" lower_limit="0.46" upper_limit="1.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNFRSF9.mRNA, Day 30 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.06" lower_limit="0.67" upper_limit="1.51"/>
                  <measurement group_id="O2" value="1.02" lower_limit="0.73" upper_limit="1.61"/>
                  <measurement group_id="O3" value="1.08" lower_limit="0.78" upper_limit="1.89"/>
                  <measurement group_id="O4" value="1.03" lower_limit="0.72" upper_limit="1.42"/>
                  <measurement group_id="O5" value="1.14" lower_limit="0.66" upper_limit="1.65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNFRSF9.mRNA, Day 31 (N=18,23,28,19,20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.14" lower_limit="0.8" upper_limit="1.98"/>
                  <measurement group_id="O2" value="1.09" lower_limit="0.55" upper_limit="1.49"/>
                  <measurement group_id="O3" value="1" lower_limit="0.57" upper_limit="1.8"/>
                  <measurement group_id="O4" value="0.97" lower_limit="0.73" upper_limit="2.01"/>
                  <measurement group_id="O5" value="1.07" lower_limit="0.68" upper_limit="1.75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNFRSF9.mRNA, Day 33 (N=18,22,28,19,20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.67" lower_limit="0.46" upper_limit="2.76"/>
                  <measurement group_id="O2" value="0.7" lower_limit="0.32" upper_limit="1.45"/>
                  <measurement group_id="O3" value="0.73" lower_limit="0.49" upper_limit="1.7"/>
                  <measurement group_id="O4" value="1.12" lower_limit="0.84" upper_limit="1.95"/>
                  <measurement group_id="O5" value="1.07" lower_limit="0.67" upper_limit="1.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TNFRSF9.mRNA, Day 37 (N=18,22,28,17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.77" lower_limit="0.41" upper_limit="3.06"/>
                  <measurement group_id="O2" value="1.01" lower_limit="0.6" upper_limit="1.61"/>
                  <measurement group_id="O3" value="0.91" lower_limit="0.55" upper_limit="3.2"/>
                  <measurement group_id="O4" value="1.01" lower_limit="0.59" upper_limit="1.78"/>
                  <measurement group_id="O5" value="1.14" lower_limit="0.55" upper_limit="2.01"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
        <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Fas associated factor 1 (FAF1), Signal Transducer And Activator Of Transcription 1(STAT1).</description>
        <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ATP cohort for innate immunogenicity up to Day 60 included all evaluable subjects, who complied with the vaccination schedule, for whom data concerning immunogenicity outcome measures were available and for whom innate immunogenicity data were available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
            <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Fas associated factor 1 (FAF1), Signal Transducer And Activator Of Transcription 1(STAT1).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>FAF1.mRNA, Day 0 (N=18,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.08" lower_limit="0.66" upper_limit="1.54"/>
                  <measurement group_id="O2" value="1.02" lower_limit="0.74" upper_limit="1.34"/>
                  <measurement group_id="O3" value="1.06" lower_limit="0.72" upper_limit="1.39"/>
                  <measurement group_id="O4" value="1.06" lower_limit="0.68" upper_limit="1.61"/>
                  <measurement group_id="O5" value="1.07" lower_limit="0.85" upper_limit="1.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FAF1.mRNA, Day 1 (N=18,23,27,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.83" lower_limit="0.66" upper_limit="1.04"/>
                  <measurement group_id="O2" value="0.88" lower_limit="0.62" upper_limit="1.63"/>
                  <measurement group_id="O3" value="0.89" lower_limit="0.57" upper_limit="1.28"/>
                  <measurement group_id="O4" value="0.93" lower_limit="0.71" upper_limit="1.29"/>
                  <measurement group_id="O5" value="1.08" lower_limit="0.72" upper_limit="1.44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FAF1.mRNA, Day 14 (N=18,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.05" lower_limit="0.69" upper_limit="1.32"/>
                  <measurement group_id="O2" value="1.06" lower_limit="0.7" upper_limit="1.68"/>
                  <measurement group_id="O3" value="0.97" lower_limit="0.7" upper_limit="1.48"/>
                  <measurement group_id="O4" value="1" lower_limit="0.65" upper_limit="1.26"/>
                  <measurement group_id="O5" value="1.01" lower_limit="0.75" upper_limit="1.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FAF1.mRNA, Day 30 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.93" lower_limit="0.73" upper_limit="1.29"/>
                  <measurement group_id="O2" value="1.03" lower_limit="0.77" upper_limit="1.79"/>
                  <measurement group_id="O3" value="1.03" lower_limit="0.77" upper_limit="1.58"/>
                  <measurement group_id="O4" value="0.99" lower_limit="0.8" upper_limit="1.25"/>
                  <measurement group_id="O5" value="1.02" lower_limit="0.7" upper_limit="1.54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FAF1.mRNA, Day 31 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" lower_limit="0.46" upper_limit="1.09"/>
                  <measurement group_id="O2" value="0.67" lower_limit="0.49" upper_limit="1.35"/>
                  <measurement group_id="O3" value="0.83" lower_limit="0.4" upper_limit="1.43"/>
                  <measurement group_id="O4" value="0.9" lower_limit="0.66" upper_limit="1.46"/>
                  <measurement group_id="O5" value="1.02" lower_limit="0.79" upper_limit="1.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FAF1.mRNA, Day 33 (N=18,22,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.85" lower_limit="0.65" upper_limit="1.37"/>
                  <measurement group_id="O2" value="0.95" lower_limit="0.72" upper_limit="1.23"/>
                  <measurement group_id="O3" value="0.94" lower_limit="0.71" upper_limit="1.38"/>
                  <measurement group_id="O4" value="1.01" lower_limit="0.7" upper_limit="1.34"/>
                  <measurement group_id="O5" value="0.98" lower_limit="0.54" upper_limit="1.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FAF1.mRNA, Day 37 (N=18,22,28,17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.93" lower_limit="0.63" upper_limit="1.38"/>
                  <measurement group_id="O2" value="0.97" lower_limit="0.79" upper_limit="1.73"/>
                  <measurement group_id="O3" value="0.97" lower_limit="0.77" upper_limit="1.65"/>
                  <measurement group_id="O4" value="0.97" lower_limit="0.73" upper_limit="1.54"/>
                  <measurement group_id="O5" value="1.07" lower_limit="0.71" upper_limit="1.95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>STAT1.mRNA, Day 0 (N=18,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.92" lower_limit="0.7" upper_limit="1.21"/>
                  <measurement group_id="O2" value="0.99" lower_limit="0.79" upper_limit="1.3"/>
                  <measurement group_id="O3" value="0.97" lower_limit="0.77" upper_limit="1.41"/>
                  <measurement group_id="O4" value="0.96" lower_limit="0.6" upper_limit="1.25"/>
                  <measurement group_id="O5" value="0.95" lower_limit="0.8" upper_limit="1.19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>STAT1.mRNA, Day 1 (N=18,23,27, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.31" lower_limit="0.71" upper_limit="5.23"/>
                  <measurement group_id="O2" value="2.88" lower_limit="0.24" upper_limit="6.32"/>
                  <measurement group_id="O3" value="1.31" lower_limit="0.54" upper_limit="6.66"/>
                  <measurement group_id="O4" value="0.92" lower_limit="0.66" upper_limit="1.36"/>
                  <measurement group_id="O5" value="0.95" lower_limit="0.56" upper_limit="1.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>STAT1.mRNA, Day 14 (N=18,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.02" lower_limit="0.15" upper_limit="2.84"/>
                  <measurement group_id="O2" value="0.96" lower_limit="0.18" upper_limit="1.93"/>
                  <measurement group_id="O3" value="0.98" lower_limit="0.2" upper_limit="2.41"/>
                  <measurement group_id="O4" value="1.04" lower_limit="0.74" upper_limit="5.74"/>
                  <measurement group_id="O5" value="0.96" lower_limit="0.42" upper_limit="2.44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>STAT1.mRNA, Day 30 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.96" lower_limit="0.63" upper_limit="1.2"/>
                  <measurement group_id="O2" value="0.88" lower_limit="0.6" upper_limit="1.17"/>
                  <measurement group_id="O3" value="0.96" lower_limit="0.73" upper_limit="1.45"/>
                  <measurement group_id="O4" value="0.89" lower_limit="0.6" upper_limit="1.22"/>
                  <measurement group_id="O5" value="0.96" lower_limit="0.71" upper_limit="1.21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>STAT1.mRNA, Day 31 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.95" lower_limit="1.5" upper_limit="7.8"/>
                  <measurement group_id="O2" value="3.83" lower_limit="1.61" upper_limit="7.2"/>
                  <measurement group_id="O3" value="3.13" lower_limit="1.06" upper_limit="7.93"/>
                  <measurement group_id="O4" value="0.88" lower_limit="0.26" upper_limit="1.29"/>
                  <measurement group_id="O5" value="0.96" lower_limit="0.19" upper_limit="1.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>STAT1.mRNA, Day 33 (N=18,22,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.03" lower_limit="0.82" upper_limit="4.86"/>
                  <measurement group_id="O2" value="1.25" lower_limit="0.49" upper_limit="4.19"/>
                  <measurement group_id="O3" value="1.12" lower_limit="0.42" upper_limit="2.95"/>
                  <measurement group_id="O4" value="1.01" lower_limit="0.21" upper_limit="1.55"/>
                  <measurement group_id="O5" value="1" lower_limit="0.25" upper_limit="1.54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>STAT1.mRNA, Day 37 (N=18,22,28, 17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.87" lower_limit="0.63" upper_limit="1.45"/>
                  <measurement group_id="O2" value="0.89" lower_limit="0.35" upper_limit="1.45"/>
                  <measurement group_id="O3" value="0.86" lower_limit="0.23" upper_limit="1.37"/>
                  <measurement group_id="O4" value="0.95" lower_limit="0.16" upper_limit="1.43"/>
                  <measurement group_id="O5" value="1.02" lower_limit="0.19" upper_limit="1.81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
        <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Interferon Regulatory Factor 1 (IRF1), MX Dynamin-Like GTPase 1(MX1).</description>
        <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ATP cohort for innate immunogenicity up to Day 60 included all evaluable subjects, who complied with the vaccination schedule, for whom data concerning immunogenicity outcome measures were available and for whom innate immunogenicity data were available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
            <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Interferon Regulatory Factor 1 (IRF1), MX Dynamin-Like GTPase 1(MX1).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>IRF1.mRNA, Day 0 (N=18,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.96" lower_limit="0.61" upper_limit="1.53"/>
                  <measurement group_id="O2" value="0.99" lower_limit="0.65" upper_limit="1.83"/>
                  <measurement group_id="O3" value="0.95" lower_limit="0.65" upper_limit="1.42"/>
                  <measurement group_id="O4" value="1.03" lower_limit="0.84" upper_limit="1.69"/>
                  <measurement group_id="O5" value="1" lower_limit="0.87" upper_limit="1.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IRF1.mRNA, Day 1 (N=18,23,27,22,20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.51" lower_limit="0.8" upper_limit="2.98"/>
                  <measurement group_id="O2" value="1.59" lower_limit="0.44" upper_limit="3.23"/>
                  <measurement group_id="O3" value="1.24" lower_limit="0.54" upper_limit="2.81"/>
                  <measurement group_id="O4" value="1.08" lower_limit="0.76" upper_limit="1.45"/>
                  <measurement group_id="O5" value="0.95" lower_limit="0.7" upper_limit="1.34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IRF1.mRNA, Day 14 (N=18,23,28,21,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.02" lower_limit="0.25" upper_limit="1.79"/>
                  <measurement group_id="O2" value="1.01" lower_limit="0.49" upper_limit="1.93"/>
                  <measurement group_id="O3" value="1.02" lower_limit="0.4" upper_limit="1.87"/>
                  <measurement group_id="O4" value="1.14" lower_limit="0.82" upper_limit="4.12"/>
                  <measurement group_id="O5" value="0.97" lower_limit="0.6" upper_limit="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IRF1.mRNA, Day 30 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.59" upper_limit="1.82"/>
                  <measurement group_id="O2" value="0.93" lower_limit="0.69" upper_limit="1.62"/>
                  <measurement group_id="O3" value="0.92" lower_limit="0.71" upper_limit="1.45"/>
                  <measurement group_id="O4" value="0.96" lower_limit="0.71" upper_limit="1.2"/>
                  <measurement group_id="O5" value="0.99" lower_limit="0.65" upper_limit="1.67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IRF1.mRNA, Day 31 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.14" lower_limit="1.12" upper_limit="8.06"/>
                  <measurement group_id="O2" value="2.63" lower_limit="1.32" upper_limit="3.95"/>
                  <measurement group_id="O3" value="1.73" lower_limit="0.8" upper_limit="5.63"/>
                  <measurement group_id="O4" value="1.05" lower_limit="0.35" upper_limit="1.5"/>
                  <measurement group_id="O5" value="0.99" lower_limit="0.45" upper_limit="1.47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IRF1.mRNA, Day 33 (N=18,22,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.33" lower_limit="0.78" upper_limit="2.63"/>
                  <measurement group_id="O2" value="1.03" lower_limit="0.62" upper_limit="1.72"/>
                  <measurement group_id="O3" value="0.9" lower_limit="0.54" upper_limit="1.6"/>
                  <measurement group_id="O4" value="1.11" lower_limit="0.43" upper_limit="1.59"/>
                  <measurement group_id="O5" value="1.05" lower_limit="0.52" upper_limit="1.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IRF1.mRNA, Day 37 (N=18,22,28,17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.99" lower_limit="0.42" upper_limit="2.24"/>
                  <measurement group_id="O2" value="0.93" lower_limit="0.59" upper_limit="1.3"/>
                  <measurement group_id="O3" value="0.9" lower_limit="0.35" upper_limit="1.63"/>
                  <measurement group_id="O4" value="0.97" lower_limit="0.27" upper_limit="1.38"/>
                  <measurement group_id="O5" value="1" lower_limit="0.54" upper_limit="1.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MX1.mRNA, Day 0 (N=18,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.77" upper_limit="1.21"/>
                  <measurement group_id="O2" value="1.01" lower_limit="0.77" upper_limit="1.38"/>
                  <measurement group_id="O3" value="0.98" lower_limit="0.7" upper_limit="1.32"/>
                  <measurement group_id="O4" value="1.01" lower_limit="0.82" upper_limit="2.02"/>
                  <measurement group_id="O5" value="0.98" lower_limit="0.66" upper_limit="1.29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MX1.mRNA, Day 1 (N=18,23,27, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.61" lower_limit="0.96" upper_limit="3.42"/>
                  <measurement group_id="O2" value="1.59" lower_limit="0.14" upper_limit="3.29"/>
                  <measurement group_id="O3" value="1.18" lower_limit="0.45" upper_limit="4.98"/>
                  <measurement group_id="O4" value="1.01" lower_limit="0.48" upper_limit="1.4"/>
                  <measurement group_id="O5" value="0.9" lower_limit="0.58" upper_limit="1.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MX1.mRNA, Day 14 (N=18,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.95" lower_limit="0.05" upper_limit="8.35"/>
                  <measurement group_id="O2" value="1.03" lower_limit="0.08" upper_limit="4.12"/>
                  <measurement group_id="O3" value="0.91" lower_limit="0.06" upper_limit="5.32"/>
                  <measurement group_id="O4" value="1.11" lower_limit="0.4" upper_limit="9.7"/>
                  <measurement group_id="O5" value="1.08" lower_limit="0.26" upper_limit="3.54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MX1.mRNA, Day 30 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.96" lower_limit="0.41" upper_limit="1.46"/>
                  <measurement group_id="O2" value="0.92" lower_limit="0.74" upper_limit="2.02"/>
                  <measurement group_id="O3" value="0.92" lower_limit="0.69" upper_limit="1.51"/>
                  <measurement group_id="O4" value="0.96" lower_limit="0.55" upper_limit="1.26"/>
                  <measurement group_id="O5" value="0.94" lower_limit="0.58" upper_limit="1.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MX1.mRNA, Day 31 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.06" lower_limit="0.69" upper_limit="6.38"/>
                  <measurement group_id="O2" value="2.19" lower_limit="1.18" upper_limit="9.95"/>
                  <measurement group_id="O3" value="2.06" lower_limit="0.84" upper_limit="6.64"/>
                  <measurement group_id="O4" value="0.96" lower_limit="0.28" upper_limit="1.22"/>
                  <measurement group_id="O5" value="0.92" lower_limit="0.17" upper_limit="1.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MX1.mRNA, Day 33 (N=18,22,27, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.92" lower_limit="0.6" upper_limit="8.49"/>
                  <measurement group_id="O2" value="1.83" lower_limit="0.32" upper_limit="7.39"/>
                  <measurement group_id="O3" value="1.87" lower_limit="0.38" upper_limit="5.45"/>
                  <measurement group_id="O4" value="1.07" lower_limit="0.16" upper_limit="1.35"/>
                  <measurement group_id="O5" value="0.98" lower_limit="0.12" upper_limit="1.54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MX1.mRNA, Day 37 (N=18,22,28, 17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.93" lower_limit="0.63" upper_limit="5.86"/>
                  <measurement group_id="O2" value="0.9" lower_limit="0.19" upper_limit="1.75"/>
                  <measurement group_id="O3" value="0.86" lower_limit="0.1" upper_limit="1.74"/>
                  <measurement group_id="O4" value="1.07" lower_limit="0.06" upper_limit="2.17"/>
                  <measurement group_id="O5" value="1.08" lower_limit="0.08" upper_limit="4.66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
        <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Interleukin-12A (IL-12A), Marker Of Proliferation Ki-67 (MKI67).</description>
        <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ATP cohort for innate immunogenicity up to Day 60 included all evaluable subjects, who complied with the vaccination schedule, for whom data concerning immunogenicity outcome measures were available and for whom innate immunogenicity data were available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
            <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Interleukin-12A (IL-12A), Marker Of Proliferation Ki-67 (MKI67).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>IL-12A.mRNA, Day 0 (N=18,23,28,21,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.01" lower_limit="0.53" upper_limit="2.3"/>
                  <measurement group_id="O2" value="0.97" lower_limit="0.54" upper_limit="1.36"/>
                  <measurement group_id="O3" value="0.95" lower_limit="0.53" upper_limit="1.88"/>
                  <measurement group_id="O4" value="0.9" lower_limit="0.31" upper_limit="1.73"/>
                  <measurement group_id="O5" value="1.07" lower_limit="0.55" upper_limit="1.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-12A.mRNA, Day 1 (N=18,23,27,21,20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.04" lower_limit="0.5" upper_limit="2.68"/>
                  <measurement group_id="O2" value="1.01" lower_limit="0.56" upper_limit="2.97"/>
                  <measurement group_id="O3" value="1.04" lower_limit="0.45" upper_limit="2.23"/>
                  <measurement group_id="O4" value="0.94" lower_limit="0.39" upper_limit="1.71"/>
                  <measurement group_id="O5" value="1.06" lower_limit="0.44" upper_limit="2.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-12A.mRNA, Day 14 (N=18,23,28,21,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.97" lower_limit="0.6" upper_limit="1.73"/>
                  <measurement group_id="O2" value="0.97" lower_limit="0.42" upper_limit="2.64"/>
                  <measurement group_id="O3" value="1.09" lower_limit="0.36" upper_limit="2.06"/>
                  <measurement group_id="O4" value="0.77" lower_limit="0.57" upper_limit="1.72"/>
                  <measurement group_id="O5" value="0.96" lower_limit="0.5" upper_limit="2.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-12A.mRNA, Day 30 (N=18,23,28,18,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.01" lower_limit="0.5" upper_limit="1.61"/>
                  <measurement group_id="O2" value="1" lower_limit="0.44" upper_limit="5.85"/>
                  <measurement group_id="O3" value="0.87" lower_limit="0.46" upper_limit="1.8"/>
                  <measurement group_id="O4" value="1.1" lower_limit="0.39" upper_limit="2.52"/>
                  <measurement group_id="O5" value="1.03" lower_limit="0.38" upper_limit="1.76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-12A.mRNA, Day 31 (N=18,22,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.32" lower_limit="0.68" upper_limit="3.55"/>
                  <measurement group_id="O2" value="1.2" lower_limit="0.61" upper_limit="2.61"/>
                  <measurement group_id="O3" value="1.04" lower_limit="0.47" upper_limit="2.35"/>
                  <measurement group_id="O4" value="0.9" lower_limit="0.36" upper_limit="1.41"/>
                  <measurement group_id="O5" value="1.01" lower_limit="0.43" upper_limit="2.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-12A.mRNA, Day 33 (N=18,21,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.94" lower_limit="0.61" upper_limit="2.92"/>
                  <measurement group_id="O2" value="0.85" lower_limit="0.44" upper_limit="1.64"/>
                  <measurement group_id="O3" value="0.86" lower_limit="0.41" upper_limit="1.78"/>
                  <measurement group_id="O4" value="0.89" lower_limit="0.46" upper_limit="1.52"/>
                  <measurement group_id="O5" value="1.05" lower_limit="0.37" upper_limit="2.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-12A.mRNA, Day 37 (N=18,22,27,17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.14" lower_limit="0.56" upper_limit="1.73"/>
                  <measurement group_id="O2" value="1.08" lower_limit="0.42" upper_limit="2.75"/>
                  <measurement group_id="O3" value="0.95" lower_limit="0.47" upper_limit="2.45"/>
                  <measurement group_id="O4" value="1.09" lower_limit="0.33" upper_limit="3.13"/>
                  <measurement group_id="O5" value="1.22" lower_limit="0.61" upper_limit="1.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MKI67.mRNA, Day 0 (N=18,23,28, 22,20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.91" lower_limit="0.23" upper_limit="1.63"/>
                  <measurement group_id="O2" value="0.89" lower_limit="0.45" upper_limit="2.72"/>
                  <measurement group_id="O3" value="0.98" lower_limit="0.45" upper_limit="1.74"/>
                  <measurement group_id="O4" value="0.83" lower_limit="0.51" upper_limit="2.12"/>
                  <measurement group_id="O5" value="1.03" lower_limit="0.61" upper_limit="2.51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MKI67.mRNA, Day 1 (N=18,23,27, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.89" lower_limit="0.33" upper_limit="1.7"/>
                  <measurement group_id="O2" value="0.9" lower_limit="0.46" upper_limit="2.63"/>
                  <measurement group_id="O3" value="0.99" lower_limit="0.55" upper_limit="1.48"/>
                  <measurement group_id="O4" value="0.94" lower_limit="0.37" upper_limit="1.85"/>
                  <measurement group_id="O5" value="1.03" lower_limit="0.48" upper_limit="1.79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MKI67.mRNA, Day 14 (N=18,23,27, 21,20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.06" lower_limit="0.57" upper_limit="2.83"/>
                  <measurement group_id="O2" value="1.14" lower_limit="0.39" upper_limit="3.17"/>
                  <measurement group_id="O3" value="1.18" lower_limit="0.32" upper_limit="2.74"/>
                  <measurement group_id="O4" value="0.99" lower_limit="0.6" upper_limit="2.75"/>
                  <measurement group_id="O5" value="1.07" lower_limit="0.4" upper_limit="3.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MKI67.mRNA, Day 30 (N=18,23,27, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.56" upper_limit="1.61"/>
                  <measurement group_id="O2" value="0.92" lower_limit="0.68" upper_limit="1.56"/>
                  <measurement group_id="O3" value="1.1" lower_limit="0.48" upper_limit="1.77"/>
                  <measurement group_id="O4" value="0.98" lower_limit="0.42" upper_limit="1.8"/>
                  <measurement group_id="O5" value="0.97" lower_limit="0.5" upper_limit="1.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MKI67.mRNA, Day 31 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.84" lower_limit="0.45" upper_limit="1.57"/>
                  <measurement group_id="O2" value="0.83" lower_limit="0.5" upper_limit="1.87"/>
                  <measurement group_id="O3" value="0.97" lower_limit="0.42" upper_limit="2.44"/>
                  <measurement group_id="O4" value="0.95" lower_limit="0.3" upper_limit="1.52"/>
                  <measurement group_id="O5" value="1.12" lower_limit="0.52" upper_limit="4.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MKI67.mRNA, Day 33 (N=18,22,28, 18,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.96" lower_limit="0.44" upper_limit="2.13"/>
                  <measurement group_id="O2" value="1.02" lower_limit="0.5" upper_limit="2.72"/>
                  <measurement group_id="O3" value="1.14" lower_limit="0.38" upper_limit="2.52"/>
                  <measurement group_id="O4" value="0.89" lower_limit="0.28" upper_limit="1.42"/>
                  <measurement group_id="O5" value="1.03" lower_limit="0.55" upper_limit="8.12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MKI67.mRNA, Day 37 (N=18,22,28, 17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.52" lower_limit="0.38" upper_limit="3.28"/>
                  <measurement group_id="O2" value="1.56" lower_limit="0.58" upper_limit="4.01"/>
                  <measurement group_id="O3" value="1.38" lower_limit="0.37" upper_limit="3.94"/>
                  <measurement group_id="O4" value="1.06" lower_limit="0.58" upper_limit="2.01"/>
                  <measurement group_id="O5" value="1.08" lower_limit="0.35" upper_limit="1.76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
        <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Chemokine Ligand 10 (CXCL10), Interleukin-1B (IL-1B).</description>
        <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ATP cohort for innate immunogenicity up to Day 60 included all evaluable subjects, who complied with the vaccination schedule, for whom data concerning immunogenicity outcome measures were available and for whom innate immunogenicity data were available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
            <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Chemokine Ligand 10 (CXCL10), Interleukin-1B (IL-1B).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>IL-1B.mRNA, Day 0 (N=18,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.04" lower_limit="0.41" upper_limit="1.54"/>
                  <measurement group_id="O2" value="1.12" lower_limit="0.6" upper_limit="2.33"/>
                  <measurement group_id="O3" value="1.02" lower_limit="0.51" upper_limit="2.24"/>
                  <measurement group_id="O4" value="1.04" lower_limit="0.59" upper_limit="2.21"/>
                  <measurement group_id="O5" value="0.96" lower_limit="0.53" upper_limit="1.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B.mRNA, Day 1 (N=18,23,27,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.56" lower_limit="0.56" upper_limit="2.8"/>
                  <measurement group_id="O2" value="1.31" lower_limit="0.67" upper_limit="2.1"/>
                  <measurement group_id="O3" value="1.21" lower_limit="0.55" upper_limit="2.58"/>
                  <measurement group_id="O4" value="1.24" lower_limit="0.82" upper_limit="2.68"/>
                  <measurement group_id="O5" value="0.92" lower_limit="0.4" upper_limit="1.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B.mRNA, Day 14 (N=18,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.94" lower_limit="0.24" upper_limit="1.95"/>
                  <measurement group_id="O2" value="0.93" lower_limit="0.43" upper_limit="3.61"/>
                  <measurement group_id="O3" value="0.97" lower_limit="0.34" upper_limit="2.24"/>
                  <measurement group_id="O4" value="1.23" lower_limit="0.72" upper_limit="3.1"/>
                  <measurement group_id="O5" value="1" lower_limit="0.52" upper_limit="1.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B.mRNA, Day 30 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" lower_limit="0.43" upper_limit="2.08"/>
                  <measurement group_id="O2" value="0.98" lower_limit="0.55" upper_limit="1.51"/>
                  <measurement group_id="O3" value="1.04" lower_limit="0.68" upper_limit="1.51"/>
                  <measurement group_id="O4" value="0.94" lower_limit="0.58" upper_limit="1.48"/>
                  <measurement group_id="O5" value="1.05" lower_limit="0.57" upper_limit="1.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B.mRNA, Day 31 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.02" lower_limit="1.38" upper_limit="5.6"/>
                  <measurement group_id="O2" value="1.47" lower_limit="0.78" upper_limit="2.2"/>
                  <measurement group_id="O3" value="1.23" lower_limit="0.64" upper_limit="2.87"/>
                  <measurement group_id="O4" value="1.14" lower_limit="0.47" upper_limit="1.92"/>
                  <measurement group_id="O5" value="1.06" lower_limit="0.44" upper_limit="1.54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B.mRNA, Day 33 (N=18,22,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.31" lower_limit="0.81" upper_limit="6.05"/>
                  <measurement group_id="O2" value="1.07" lower_limit="0.54" upper_limit="1.76"/>
                  <measurement group_id="O3" value="0.93" lower_limit="0.58" upper_limit="1.59"/>
                  <measurement group_id="O4" value="1.02" lower_limit="0.72" upper_limit="1.95"/>
                  <measurement group_id="O5" value="1.01" lower_limit="0.49" upper_limit="2.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-1B.mRNA, Day 37 (N=18,22,28,17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.97" lower_limit="0.38" upper_limit="2.6"/>
                  <measurement group_id="O2" value="0.87" lower_limit="0.36" upper_limit="1.83"/>
                  <measurement group_id="O3" value="0.85" lower_limit="0.29" upper_limit="1.8"/>
                  <measurement group_id="O4" value="0.83" lower_limit="0.35" upper_limit="1.52"/>
                  <measurement group_id="O5" value="1.01" lower_limit="0.45" upper_limit="2.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CXCL10.mRNA, Day 0 (N=17,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.92" lower_limit="0.55" upper_limit="1.36"/>
                  <measurement group_id="O2" value="0.97" lower_limit="0.52" upper_limit="1.79"/>
                  <measurement group_id="O3" value="0.92" lower_limit="0.37" upper_limit="1.97"/>
                  <measurement group_id="O4" value="0.97" lower_limit="0.31" upper_limit="1.73"/>
                  <measurement group_id="O5" value="1.07" lower_limit="0.55" upper_limit="1.99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CXCL10.mRNA, Day 1 (N=18,23,27, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.96" lower_limit="0.28" upper_limit="4.43"/>
                  <measurement group_id="O2" value="1.14" lower_limit="0.27" upper_limit="9.62"/>
                  <measurement group_id="O3" value="1.06" lower_limit="0.12" upper_limit="12.97"/>
                  <measurement group_id="O4" value="0.97" lower_limit="0.39" upper_limit="1.91"/>
                  <measurement group_id="O5" value="0.96" lower_limit="0.44" upper_limit="2.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CXCL10.mRNA, Day 14 (N=18,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.88" lower_limit="0.16" upper_limit="1.99"/>
                  <measurement group_id="O2" value="0.95" lower_limit="0.13" upper_limit="2.64"/>
                  <measurement group_id="O3" value="1.06" lower_limit="0.06" upper_limit="2.92"/>
                  <measurement group_id="O4" value="0.9" lower_limit="0.39" upper_limit="48.74"/>
                  <measurement group_id="O5" value="0.97" lower_limit="0.6" upper_limit="3.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CXCL10.mRNA, Day 30 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.08" lower_limit="0.64" upper_limit="2.04"/>
                  <measurement group_id="O2" value="1.03" lower_limit="0.61" upper_limit="5.85"/>
                  <measurement group_id="O3" value="0.88" lower_limit="0.46" upper_limit="2.62"/>
                  <measurement group_id="O4" value="1.1" lower_limit="0.33" upper_limit="1.81"/>
                  <measurement group_id="O5" value="0.92" lower_limit="0.43" upper_limit="1.76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CXCL10.mRNA, Day 31 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.25" lower_limit="0.68" upper_limit="32.91"/>
                  <measurement group_id="O2" value="2.93" lower_limit="0.75" upper_limit="16.09"/>
                  <measurement group_id="O3" value="1.59" lower_limit="0.47" upper_limit="16.85"/>
                  <measurement group_id="O4" value="0.95" lower_limit="0.04" upper_limit="1.44"/>
                  <measurement group_id="O5" value="1.18" lower_limit="0.29" upper_limit="1.54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CXCL10.mRNA, Day 33 (N=18,22,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.35" lower_limit="0.61" upper_limit="5.9"/>
                  <measurement group_id="O2" value="1.06" lower_limit="0.6" upper_limit="2.73"/>
                  <measurement group_id="O3" value="0.86" lower_limit="0.38" upper_limit="2.6"/>
                  <measurement group_id="O4" value="1.13" lower_limit="0.02" upper_limit="1.94"/>
                  <measurement group_id="O5" value="1.05" lower_limit="0.31" upper_limit="2.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CXCL10.mRNA, Day 37 (N=18,22,28, 17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.91" lower_limit="0.51" upper_limit="5.33"/>
                  <measurement group_id="O2" value="1.02" lower_limit="0.53" upper_limit="2.75"/>
                  <measurement group_id="O3" value="0.94" lower_limit="0.35" upper_limit="2.45"/>
                  <measurement group_id="O4" value="1.03" lower_limit="0.02" upper_limit="2.06"/>
                  <measurement group_id="O5" value="1.09" lower_limit="0.51" upper_limit="2.37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
        <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Prostaglandin-Endoperoxide Synthase 2 (PTGS2), Dual Specificity Phosphatase 1 (DUSP1).</description>
        <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ATP cohort for innate immunogenicity up to Day 60 included all evaluable subjects, who complied with the vaccination schedule, for whom data concerning immunogenicity outcome measures were available and for whom innate immunogenicity data were available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
            <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Prostaglandin-Endoperoxide Synthase 2 (PTGS2), Dual Specificity Phosphatase 1 (DUSP1).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>PTGS2.mRNA, Day 0 (N=18,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.06" lower_limit="0.63" upper_limit="1.59"/>
                  <measurement group_id="O2" value="1.01" lower_limit="0.67" upper_limit="1.66"/>
                  <measurement group_id="O3" value="1.07" lower_limit="0.64" upper_limit="1.73"/>
                  <measurement group_id="O4" value="1.06" lower_limit="0.77" upper_limit="1.76"/>
                  <measurement group_id="O5" value="1.04" lower_limit="0.63" upper_limit="1.28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PTGS2.mRNA, Day 1 (N=18,23,27,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.25" lower_limit="0.74" upper_limit="1.74"/>
                  <measurement group_id="O2" value="1.15" lower_limit="0.69" upper_limit="2.55"/>
                  <measurement group_id="O3" value="1.16" lower_limit="0.77" upper_limit="2.13"/>
                  <measurement group_id="O4" value="1.05" lower_limit="0.73" upper_limit="1.47"/>
                  <measurement group_id="O5" value="0.95" lower_limit="0.71" upper_limit="1.32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PTGS2.mRNA, Day 14 (N=18,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.07" lower_limit="0.65" upper_limit="1.69"/>
                  <measurement group_id="O2" value="0.92" lower_limit="0.7" upper_limit="1.66"/>
                  <measurement group_id="O3" value="1.01" lower_limit="0.4" upper_limit="2.08"/>
                  <measurement group_id="O4" value="1.06" lower_limit="0.67" upper_limit="2.4"/>
                  <measurement group_id="O5" value="1.13" lower_limit="0.49" upper_limit="1.29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PTGS2.mRNA, Day 30 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.14" lower_limit="0.58" upper_limit="1.5"/>
                  <measurement group_id="O2" value="0.94" lower_limit="0.67" upper_limit="1.38"/>
                  <measurement group_id="O3" value="1.02" lower_limit="0.69" upper_limit="1.51"/>
                  <measurement group_id="O4" value="0.98" lower_limit="0.58" upper_limit="1.22"/>
                  <measurement group_id="O5" value="1.09" lower_limit="0.67" upper_limit="1.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PTGS2.mRNA, Day 31 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.66" lower_limit="1.17" upper_limit="2.83"/>
                  <measurement group_id="O2" value="1.33" lower_limit="0.97" upper_limit="2.4"/>
                  <measurement group_id="O3" value="1.11" lower_limit="0.74" upper_limit="1.99"/>
                  <measurement group_id="O4" value="1.08" lower_limit="0.72" upper_limit="1.63"/>
                  <measurement group_id="O5" value="1.04" lower_limit="0.63" upper_limit="1.43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PTGS2.mRNA, Day 33 (N=18,22,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.97" lower_limit="0.66" upper_limit="3.53"/>
                  <measurement group_id="O2" value="0.85" lower_limit="0.52" upper_limit="1.22"/>
                  <measurement group_id="O3" value="0.82" lower_limit="0.57" upper_limit="1.64"/>
                  <measurement group_id="O4" value="1.07" lower_limit="0.77" upper_limit="2.73"/>
                  <measurement group_id="O5" value="1.01" lower_limit="0.6" upper_limit="2.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PTGS2.mRNA, Day 37 (N=18,22,28,17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.87" lower_limit="0.33" upper_limit="3.76"/>
                  <measurement group_id="O2" value="0.94" lower_limit="0.59" upper_limit="1.65"/>
                  <measurement group_id="O3" value="0.91" lower_limit="0.57" upper_limit="2.15"/>
                  <measurement group_id="O4" value="0.96" lower_limit="0.62" upper_limit="1.35"/>
                  <measurement group_id="O5" value="1.15" lower_limit="0.55" upper_limit="1.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DUSP1.mRNA, Day 0 (N=18,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.84" lower_limit="0.45" upper_limit="1.52"/>
                  <measurement group_id="O2" value="0.96" lower_limit="0.52" upper_limit="1.8"/>
                  <measurement group_id="O3" value="1.02" lower_limit="0.58" upper_limit="2.27"/>
                  <measurement group_id="O4" value="0.89" lower_limit="0.55" upper_limit="1.96"/>
                  <measurement group_id="O5" value="0.9" lower_limit="0.5" upper_limit="1.27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DUSP1.mRNA, Day 1 (N=18,23,27, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.09" lower_limit="0.67" upper_limit="1.95"/>
                  <measurement group_id="O2" value="1.1" lower_limit="0.52" upper_limit="2.03"/>
                  <measurement group_id="O3" value="1.12" lower_limit="0.68" upper_limit="2.46"/>
                  <measurement group_id="O4" value="1.14" lower_limit="0.6" upper_limit="1.99"/>
                  <measurement group_id="O5" value="0.85" lower_limit="0.53" upper_limit="1.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DUSP1.mRNA, Day 14 (N=18,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.95" lower_limit="0.6" upper_limit="1.81"/>
                  <measurement group_id="O2" value="0.85" lower_limit="0.63" upper_limit="1.91"/>
                  <measurement group_id="O3" value="1.2" lower_limit="0.32" upper_limit="2.45"/>
                  <measurement group_id="O4" value="1.07" lower_limit="0.81" upper_limit="1.86"/>
                  <measurement group_id="O5" value="1" lower_limit="0.45" upper_limit="1.55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DUSP1.mRNA, Day 30 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.03" lower_limit="0.44" upper_limit="2.14"/>
                  <measurement group_id="O2" value="0.81" lower_limit="0.48" upper_limit="1.46"/>
                  <measurement group_id="O3" value="0.92" lower_limit="0.55" upper_limit="2.04"/>
                  <measurement group_id="O4" value="0.86" lower_limit="0.63" upper_limit="1.28"/>
                  <measurement group_id="O5" value="0.96" lower_limit="0.53" upper_limit="1.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DUSP1.mRNA, Day 31 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.34" lower_limit="0.8" upper_limit="3.56"/>
                  <measurement group_id="O2" value="1.3" lower_limit="0.64" upper_limit="1.95"/>
                  <measurement group_id="O3" value="1.05" lower_limit="0.63" upper_limit="1.67"/>
                  <measurement group_id="O4" value="1.31" lower_limit="0.76" upper_limit="1.97"/>
                  <measurement group_id="O5" value="0.94" lower_limit="0.57" upper_limit="1.85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DUSP1.mRNA, Day 33 (N=18,22,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.97" lower_limit="0.58" upper_limit="5.29"/>
                  <measurement group_id="O2" value="0.84" lower_limit="0.43" upper_limit="1.42"/>
                  <measurement group_id="O3" value="0.81" lower_limit="0.52" upper_limit="1.56"/>
                  <measurement group_id="O4" value="1.18" lower_limit="0.78" upper_limit="2.69"/>
                  <measurement group_id="O5" value="0.99" lower_limit="0.42" upper_limit="1.91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DUSP1.mRNA, Day 37 (N=18,22,28, 17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.91" lower_limit="0.27" upper_limit="4.05"/>
                  <measurement group_id="O2" value="0.94" lower_limit="0.34" upper_limit="1.57"/>
                  <measurement group_id="O3" value="0.95" lower_limit="0.51" upper_limit="1.61"/>
                  <measurement group_id="O4" value="0.94" lower_limit="0.68" upper_limit="1.53"/>
                  <measurement group_id="O5" value="1" lower_limit="0.45" upper_limit="2.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
        <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Nuclear Factor Of Activated T-Cells, Cytoplasmic, Calcineurin-Dependent 2 (NFATC2) and Interferon-gamma (IFN-γ).</description>
        <time_frame>At Days 0, 1, 14, 30, 31, 33 and 37</time_frame>
        <safety_issue>No</safety_issue>
        <population>The ATP cohort for innate immunogenicity up to Day 60 included all evaluable subjects, who complied with the vaccination schedule, for whom data concerning immunogenicity outcome measures were available and for whom innate immunogenicity data were available for at least one post-vaccination time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK223192A 1 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK223192A 2 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK223192A 3 Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fendrix Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Engerix-B Group</title>
            <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Levels of Messenger Ribonucleic Acid (mRNA) as Measured by Quantitative Polymerase Chain Reaction (qPCR)</title>
            <description>The analysis of the mRNA levels of 14 target genes was performed using whole blood, in the first 140 subjects from the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium, by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR. Among the target genes were Nuclear Factor Of Activated T-Cells, Cytoplasmic, Calcineurin-Dependent 2 (NFATC2) and Interferon-gamma (IFN-γ).</description>
            <units>cells/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>NFATC2.mRNA, Day 0 (N=18,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.98" lower_limit="0.52" upper_limit="1.25"/>
                  <measurement group_id="O2" value="0.94" lower_limit="0.64" upper_limit="1.64"/>
                  <measurement group_id="O3" value="1.03" lower_limit="0.74" upper_limit="1.91"/>
                  <measurement group_id="O4" value="0.93" lower_limit="0.51" upper_limit="1.56"/>
                  <measurement group_id="O5" value="1.11" lower_limit="0.64" upper_limit="1.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NFATC2.mRNA, Day 1 (N=18,23,27,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.66" lower_limit="0.48" upper_limit="1.06"/>
                  <measurement group_id="O2" value="0.73" lower_limit="0.43" upper_limit="2.55"/>
                  <measurement group_id="O3" value="0.83" lower_limit="0.47" upper_limit="1.56"/>
                  <measurement group_id="O4" value="0.83" lower_limit="0.6" upper_limit="1.23"/>
                  <measurement group_id="O5" value="1.04" lower_limit="0.73" upper_limit="1.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NFATC2.mRNA, Day 14 (N=18,23,28,22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.48" upper_limit="1.69"/>
                  <measurement group_id="O2" value="0.98" lower_limit="0.42" upper_limit="2.12"/>
                  <measurement group_id="O3" value="1.09" lower_limit="0.61" upper_limit="1.78"/>
                  <measurement group_id="O4" value="0.89" lower_limit="0.53" upper_limit="1.39"/>
                  <measurement group_id="O5" value="1.1" lower_limit="0.64" upper_limit="1.59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NFATC2.mRNA, Day 30 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.92" lower_limit="0.7" upper_limit="1.64"/>
                  <measurement group_id="O2" value="0.99" lower_limit="0.72" upper_limit="1.37"/>
                  <measurement group_id="O3" value="1" lower_limit="0.78" upper_limit="1.57"/>
                  <measurement group_id="O4" value="1.05" lower_limit="0.82" upper_limit="1.5"/>
                  <measurement group_id="O5" value="1.08" lower_limit="0.79" upper_limit="1.44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NFATC2.mRNA, Day 31 (N=18,23,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.46" lower_limit="0.32" upper_limit="1.06"/>
                  <measurement group_id="O2" value="0.58" lower_limit="0.34" upper_limit="1.15"/>
                  <measurement group_id="O3" value="0.78" lower_limit="0.33" upper_limit="1.46"/>
                  <measurement group_id="O4" value="0.87" lower_limit="0.69" upper_limit="1.78"/>
                  <measurement group_id="O5" value="1.1" lower_limit="0.83" upper_limit="1.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NFATC2.mRNA, Day 33 (N=18,22,28,19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.79" lower_limit="0.59" upper_limit="1.36"/>
                  <measurement group_id="O2" value="0.9" lower_limit="0.56" upper_limit="1.79"/>
                  <measurement group_id="O3" value="0.87" lower_limit="0.63" upper_limit="1.55"/>
                  <measurement group_id="O4" value="1.05" lower_limit="0.63" upper_limit="1.43"/>
                  <measurement group_id="O5" value="1.05" lower_limit="0.75" upper_limit="1.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NFATC2.mRNA, Day 37 (N=18,22,28,17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.03" lower_limit="0.74" upper_limit="1.22"/>
                  <measurement group_id="O2" value="1.03" lower_limit="0.66" upper_limit="1.59"/>
                  <measurement group_id="O3" value="0.98" lower_limit="0.72" upper_limit="1.99"/>
                  <measurement group_id="O4" value="1.16" lower_limit="0.83" upper_limit="1.56"/>
                  <measurement group_id="O5" value="1.11" lower_limit="0.69" upper_limit="1.91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-γ.mRNA, Day 0 (N=18,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.97" lower_limit="0.55" upper_limit="1.36"/>
                  <measurement group_id="O2" value="0.97" lower_limit="0.54" upper_limit="1.79"/>
                  <measurement group_id="O3" value="0.94" lower_limit="0.59" upper_limit="1.97"/>
                  <measurement group_id="O4" value="0.97" lower_limit="0.31" upper_limit="1.73"/>
                  <measurement group_id="O5" value="1.07" lower_limit="0.55" upper_limit="1.99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-γ.mRNA, Day 1 (N=18,23,27, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.89" lower_limit="0.5" upper_limit="1.74"/>
                  <measurement group_id="O2" value="1.01" lower_limit="0.6" upper_limit="2.97"/>
                  <measurement group_id="O3" value="1.03" lower_limit="0.45" upper_limit="1.94"/>
                  <measurement group_id="O4" value="0.97" lower_limit="0.39" upper_limit="1.91"/>
                  <measurement group_id="O5" value="0.96" lower_limit="0.44" upper_limit="2.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-γ.mRNA, Day 14 (N=18,23,28, 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.88" lower_limit="0.55" upper_limit="1.99"/>
                  <measurement group_id="O2" value="0.97" lower_limit="0.44" upper_limit="2.64"/>
                  <measurement group_id="O3" value="1.11" lower_limit="0.48" upper_limit="2.08"/>
                  <measurement group_id="O4" value="0.82" lower_limit="0.39" upper_limit="1.72"/>
                  <measurement group_id="O5" value="0.96" lower_limit="0.6" upper_limit="2.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-γ.mRNA, Day 30 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.08" lower_limit="0.64" upper_limit="2.04"/>
                  <measurement group_id="O2" value="1.03" lower_limit="0.61" upper_limit="5.85"/>
                  <measurement group_id="O3" value="0.88" lower_limit="0.46" upper_limit="3.19"/>
                  <measurement group_id="O4" value="1.13" lower_limit="0.47" upper_limit="1.81"/>
                  <measurement group_id="O5" value="0.92" lower_limit="0.48" upper_limit="1.76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-γ.mRNA, Day 31 (N=18,23,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.91" lower_limit="0.61" upper_limit="2.46"/>
                  <measurement group_id="O2" value="0.86" lower_limit="0.44" upper_limit="2.61"/>
                  <measurement group_id="O3" value="0.89" lower_limit="0.4" upper_limit="1.53"/>
                  <measurement group_id="O4" value="0.96" lower_limit="0.41" upper_limit="1.89"/>
                  <measurement group_id="O5" value="1.18" lower_limit="0.45" upper_limit="1.54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-γ.mRNA, Day 33 (N=18,22,28, 19,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" lower_limit="0.61" upper_limit="4.25"/>
                  <measurement group_id="O2" value="0.92" lower_limit="0.6" upper_limit="2.04"/>
                  <measurement group_id="O3" value="0.83" lower_limit="0.38" upper_limit="2.6"/>
                  <measurement group_id="O4" value="1.13" lower_limit="0.47" upper_limit="1.94"/>
                  <measurement group_id="O5" value="1.05" lower_limit="0.53" upper_limit="2.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IFN-γ.mRNA, Day 37 (N=18,22,28, 17,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.89" lower_limit="0.51" upper_limit="5.33"/>
                  <measurement group_id="O2" value="1.02" lower_limit="0.53" upper_limit="2.75"/>
                  <measurement group_id="O3" value="0.94" lower_limit="0.47" upper_limit="2.45"/>
                  <measurement group_id="O4" value="1.09" lower_limit="0.6" upper_limit="2.06"/>
                  <measurement group_id="O5" value="1.09" lower_limit="0.71" upper_limit="2.37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms post primary/booster vaccination: 14/7-day follow-up period after vaccination; Unsolicited adverse events (AEs): 31-day follow-up period after vaccination; Serious AEs: From Day 0 to Day 360 (non-Subsets 1 &amp; 2)/390 (Subsets 1 &amp; 2)</time_frame>
      <desc>Solicited symptoms data below result from analyses on the Total Vaccinated cohort, inclusive of all vaccinated subjects, and on the Booster Total Vaccinated cohort, inclusive of all vaccinated subjects from Subsets 1and 2 vaccinated with HBsAg antigens at Day 360, performed solely on subjects from whose symptom sheets were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK223192A 1 Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK223192A 2 Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>GSK223192A 3 Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>Fendrix Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="E5">
          <title>Engerix-B Group</title>
          <description>Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group – subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) – additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Somatisation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="128" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Solicited symptom reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="128" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>Solicited symptom reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Solicited symptom reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Solicited symptom reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>Solicited symptom reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Solicited symptom reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Solicited symptom reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Fever (Oral temperature &gt;= 37.5°C)</sub_title>
                <description>Solicited symptom reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <description>Solicited symptom reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Solicited symptom reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Solicited symptom reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Solicited symptom reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Solicited symptom reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Fever (Oral temperature &gt; = 37.5°C)</sub_title>
                <description>Solicited symptom reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <description>Solicited symptom reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Solicited symptom reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Solicited symptom reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Solicited symptom reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unsolicited AE reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unsolicited AE reported post vaccination with HBsAg antigens.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unsolicited AE reported post vaccination with the GSK223192A, Fendrix™ or Engerix-B™ vaccine.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
